





<p>(86) Date de dépôt PCT/PCT Filing Date: 2010/12/28</p> <p>(87) Date publication PCT/PCT Publication Date: 2011/07/28</p> <p>(45) Date de délivrance/Issue Date: 2018/05/01</p> <p>(85) Entrée phase nationale/National Entry: 2012/06/26</p> <p>(86) N° demande PCT/PCT Application No.: US 2010/062209</p> <p>(87) N° publication PCT/PCT Publication No.: 2011/090708</p> <p>(30) Priorité/Priority: 2009/12/28 (US61/290,297)</p>	<p>(51) Cl.Int./Int.Cl. <i>A61K 39/17</i> (2006.01), <i>C12N 1/13</i> (2006.01), <i>C12N 15/45</i> (2006.01), <i>C12N 15/82</i> (2006.01)</p> <p>(72) Inventeurs/Inventors: GUO, XUAN, US; TROUPE, KAROLYN MARIE, US; FEILMEIER, BRADLEY J., US; PRITCHARD, JOYCE ANITA, US; CRUZ-COY, JULIO SERGIO, US</p> <p>(73) Propriétaire/Owner: MERIAL, INC., US</p> <p>(74) Agent: SMART & BIGGAR</p>
---	--

(54) Titre : ANTIGENE RECOMBINANT DU NDV, ET SES UTILISATIONS

(54) Title: RECOMBINANT NDV ANTIGEN AND USES THEREOF



(57) **Abrégé/Abstract:**
The present invention encompasses NDV vaccines. The vaccine may be a subunit vaccine based on HN of NDV. The NDV HN may be expressed in plants or algae including microalgae. The invention also encompasses recombinant vectors encoding and expressing NDV antigens, epitopes or immunogens which can be used to protect animals against NDV. It encompasses also a vaccination regime compatible with the DIVA strategy, including a prime-boost scheme using viral vector or inactivated vaccines and subunit vaccines.

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau(43) International Publication Date
28 July 2011 (28.07.2011)(10) International Publication Number
WO 2011/090708 A3

(51) International Patent Classification:

A61K 39/17 (2006.01) *C12N 15/45* (2006.01)
C12N 15/82 (2006.01) *C12N 1/13* (2006.01)

(21) International Application Number:

PCT/US2010/062209

(22) International Filing Date:

28 December 2010 (28.12.2010)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

61/290,297 28 December 2009 (28.12.2009) US

(71) Applicant (for all designated States except US): **MERIAL LIMITED** [US/US]; 3239 Satellite Blvd., Duluth, GA 30096 (US).

(72) Inventors; and

(75) Inventors/Applicants (for US only): **GUO, Xuan** [CN/US]; 233 Reynoldston Way, Suwanee, GA 30024 (US). **TROUPE, Karolyn Marie** [US/US]; 166 Jamigan Drive, Athens, GA 30605 (US). **FEILMEIER, Bradley J.** [US/US]; 1170 Windy Creek Drive, Watkinsville, GA 30677 (US). **PRITCHARD, Joyce Anita** [US/US]; 3804 Princeton Court, Gainesville, GA 60504 (US). **CRUZ-COY, Julio Sergio** [US/US]; 749 Hillside Drive, Gainesville, GA 30501 (US).(74) Agent: **JARECKI-BLACK, Judy**; 3239 Satellite Blvd, Duluth, GA 30096 (US).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PE, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:

- with international search report (Art. 21(3))
- before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))
- with sequence listing part of description (Rule 5.2(a))

(88) Date of publication of the international search report:

15 December 2011

(54) Title: RECOMBINANT NDV ANTIGEN AND USES THEREOF

Figure 3A





Figure 3B



(57) Abstract: The present invention encompasses NDV vaccines. The vaccine may be a subunit vaccine based on HN of NDV. The NDV HN may be expressed in plants or algae including microalgae. The invention also encompasses recombinant vectors encoding and expressing NDV antigens, epitopes or immunogens which can be used to protect animals against NDV. It encompasses also a vaccination regime compatible with the DIVA strategy, including a prime-boost scheme using viral vector or inactivated vaccines and subunit vaccines.

WO 2011/090708 A3

RECOMBINANT NDV ANTIGEN AND USES THEREOF

CROSS-REFERENCE TO RELATED APPLICATIONS

[0001] This application claims benefit of US provisional application Serial No. 61/290,297 filed December 28, 2009.

FIELD OF THE INVENTION

[0002] The present invention encompasses pharmaceutical compositions comprising an NDV antigen, in particular pharmaceutical compositions comprising NDV HN antigen.

BACKGROUND OF THE INVENTION

[0003] The virus family *Paramyxoviridae* includes both human (measles, mumps, paraNDV and respiratory syncytial virus) and animal pathogens (Newcastle disease virus and rinderpest virus) that cause significant impact on public health as well as the global economy (Lamb et al., 2007, *Paramyxoviridae: The viruses and Their Replication*, p. 1449-1496). Members of this virus family are defined by having a monopartite, negative sense, single-stranded RNA genome. The *Paramyxoviridae* family consists of two subfamilies namely *Paramyxovirinae* and *Pneumovirinae*. Owing to recent reclassification, the subfamily *Paramyxovirinae* includes five genera, i.e. *Morbillivirus*, *Henipavirus*, *Rubulavirus*, *Respirovirus* and *Avulavirus* while *Pneumovirinae* includes *Pneumovirus* and *Metapneumovirus* (Mayo, 2002, Arch Virol 147:1655-63). Avian paramyxoviruses (APMV) are classified in the genus *Avulavirus* and comprise nine antigenically distinct serotypes that have been defined using hemagglutination inhibition (HI) tests (Alexander, 1988, Newcastle disease, p. x, 378 p). Of the nine serotypes, isolates belonging to the APMV-1 subtype can cause a devastating disease in commercial poultry and are classified as velogenic Newcastle disease virus (NDV). Milder forms of NDV are designated as mesogenic and lentogenic isolates, wherein the latter form is mostly asymptomatic in domestic poultry. The genomic RNA of NDV contains genes encoding six proteins: HN (hemagglutinin-neuraminidase), NP (nucleocapsid protein), P (phosphoprotein), M (matrix protein), F (fusion protein), and L (RNA-dependent RNA polymerase).

[0004] Viral vector vaccines represent one of the most rapidly growing areas in vaccine development. Many vaccines in clinical development for major global infectious diseases, HIV, tuberculosis and malaria, are viral vectors. The disadvantage of currently used viral

vectors is the existence of maternally derived antibodies or antibodies acquired due to a past infection.

[0005] Recently, plants and algae have been investigated as a source for the production of therapeutic agents such as vaccines, antibodies, and biopharmaceuticals. These plant and algae expression systems provide several advantages. For example, deriving vaccines from plant or algae expression products can eliminate the risk of contamination with animal pathogens, provide a heat-stable environment, and would avoid injection-related hazards if administered as an edible agent (Thanavala et al., Expert Rev. Vaccines 2006, 5, 249-260). In addition, plants or algae can be grown on a large scale and can utilize existing cultivation, harvest, and storage facilities. Furthermore, there is a lower cost of production and processing to derive therapeutic agents from plants (Giddings et al., Nature Biotech. 2000, 18, 1151-1155) or algae. The F and HN proteins of NDV were expressed in potato plants for developing edible vaccine against NDV (Berinstein A., et al., 2005, Vaccine 23: 5583-6689). WO2004/098533 discloses the expression of the NDV HN antigen and the Avian Influenza Virus HA antigen in tobacco plants. US patent application publication No. US2010/0189731 discloses the expression of Avian Influenza Virus HA antigen in duckweed plants.

[0006] Development of vaccines, antibodies, proteins, and biopharmaceuticals from plants or algae is far from a remedial process, and there are numerous obstacles that are commonly associated with such vaccine production. Limitations to successfully producing plant vaccines include low yield of the bioproduct or expressed antigen (Chargelegue et al., Trends in Plant Science 2001, 6, 495-496), protein instability, inconsistencies in product quality (Schillberg et al., Vaccine 2005, 23, 1764-1769), and insufficient capacity to produce viral-like products of expected size and immunogenicity (Arntzen et al., Vaccine 2005, 23, 1753-1756). In order to address these problems, codon optimization, careful approaches to harvesting and purifying plant or algae products, use of plant parts such as chloroplasts to increase uptake of the material, and improved subcellular targeting are all being considered as potential strategies (Koprowski, Vaccine 2005, 23, 1757-1763).

[0007] Considering the potential effect of animal pathogens, such as NDV on public health and the economy, methods of preventing infection and protecting animals are needed. Moreover, there is a need for an effective vaccine against the pathogens and a suitable method for making the vaccine.

SUMMARY OF THE INVENTION

[0008] Compositions comprising NDV (Newcastle Disease Virus) antigens and fragments and variants thereof are provided. The NDV antigens and fragments and variants thereof possess immunogenic and protective properties. Preferably, the NDV antigens comprise an NDV HN (hemagglutinin-neuraminidase) antigen or fragment or variant thereof. The NDV antigens may be produced in plants or algae.

[0009] The NDV antigens and fragments and variants thereof can be formulated into vaccines and/or pharmaceutical compositions. Such vaccines or compositions can be used to vaccinate an animal and provide protection against at least one form of NDV.

[0010] Methods of the invention include methods for making the NDV antigens and fragments and variants thereof in plants or algae. The methods also include methods of use including administering to an animal an effective amount of NDV antigenic polypeptide(s) and fragments and variants thereof to elicit a protective immunogenic response. After production in plants or algae, the NDV antigenic polypeptides and fragments and variants thereof can be partially or substantially purified for use as a vaccine or composition.

[0011] Kits comprising at least one NDV antigenic polypeptide or fragment or variant thereof and instructions for use are also provided.

[0011a] In another embodiment, the invention provides a composition comprising an NDV (Newcastle Disease Virus) HN (Hemagglutinin-Neuraminidase) polypeptide or antigen and a pharmaceutical or veterinarily acceptable carrier, excipient, vehicle or adjuvant; wherein the NDV HN polypeptide or antigen is obtained by expression in *Schizochytrium*, wherein the NDV HN polypeptide or antigen comprises an amino acid sequence having at least 90% sequence identity to the full length of the sequence as set forth in SEQ ID NO: 3, 5, 7, 9, 15, 17, 19, or 20, and wherein the NDV HN polypeptide or antigen is glycosylated and contains high-mannose type glycans.

[0011b] In another embodiment, the invention provides use, for the vaccination of an animal susceptible to NDV, of the composition as described herein.

[0011c] In another embodiment, the invention provides a substantially purified NDV polypeptide or antigen wherein the NDV polypeptide or antigen is obtained by expression in *Schizochytrium*, wherein the NDV HN polypeptide or antigen comprises an amino acid sequence having at least 90% sequence identity to the full length of the sequence as set forth

in SEQ ID NO: 3, 5, 7, 9, 15, 17, 19, or 20, and wherein the NDV HN polypeptide or antigen is glycosylated and contains high-mannose type glycans.

[0011d] In another embodiment, the invention provides *Schizochytrium* culture stably transformed with a gene for expressing an NDV HN polypeptide or antigen comprising an amino acid sequence having at least 90% sequence identity to the full length of the sequence as set forth in SEQ ID NO: 3, 5, 7, 9, 15, 17, 19, or 20.

[0011e] In another embodiment, the invention provides a method of producing an NDV HN polypeptide or antigen, comprising: (a) culturing a *Schizochytrium* culture within a *Schizochytrium* culture medium, wherein the *Schizochytrium* culture is stably transformed to express the NDV HN polypeptide, and wherein the NDV HN polypeptide is expressed from a nucleotide sequence comprising a coding sequence for the NDV HN polypeptide and an operably linked coding sequence for a signal peptide that directs secretion of the polypeptide into said culture medium and the NDV HN polypeptide or antigen comprises an amino acid sequence having at least 90% sequence identity to the full length of the sequence as set forth in SEQ ID NO: 3, 5, 7, 9, 15, 17, 19, or 20; and (b) collecting the NDV HN polypeptide or antigen from the culture medium.

[0011f] In another embodiment, the invention provides a plasmid comprising a DNA fragment encoding a signal peptide having a sequence as set forth in SEQ ID NO: 13, or 21 wherein the DNA fragment is operably linked to a polynucleotide encoding an NDV HN polypeptide or antigen comprising an amino acid sequence having at least 90% sequence identity to the full length of the sequence as set forth in SEQ ID NO: 3, 5, 7, 9, 15, 17, 19, or 20, wherein the plasmid is for *Schizochytrium* transformation.

BRIEF DESCRIPTION OF THE DRAWINGS

[0012] The following detailed description, given by way of example, but not intended to limit the invention solely to the specific embodiments described, may best be understood in conjunction with the accompanying drawings, in which:

[0013] Figure 1 provides a table showing the SEQ ID NO assigned to the polynucleotide and protein sequence.

[0014] Figure 2 provides DNA and protein sequences of NDV HN genes and the glycosylation sites.

[0015] Figure 3 shows the HA analysis in 96 well plate format.

[0016] Figure 4 shows the SDS-PAGE and Western blot analysis of the expressed NDV HN gene.

[0017] Figure 5 shows the pictures of coomassie stain, periodic acid staining, immunoblot for glycosylation analysis and glycosylation site analysis.

[0018] Figures 6a and 6b provide the protein sequence alignments of NDV HN from different strains and mature protein sequence (without signal peptide).

[0019] Figures 7a provides the sequence alignment of DNA from different NDV strains. Fig. 7b shows the DNA sequence alignment between wildtype and codon-optimized

(microalgae-preferred) DNA coding for NDV HN and wildtype and codon-optimized (duckweed-preferred) DNA coding for NDV HN. Figure 7c depicts the plasmid maps for duckweed plant transformation.

[0020] Figure 8 provides the sequence alignment of NDV HN proteins to show the HN linear epitope region.

[0021] Figure 9 provides a table showing the location and presence of glycosylation sites in NDV HN of different strains.

[0022] Figure 10 provides a graphical feature map of the glycosylation sites and the HN linear epitope region of NDV HN CA/02 Protein (SEQ ID NO:3).

[0023] Figure 11 provides peptide sequence analysis of expressed NDV HN (SEQ ID NO:3) in algae.

[0024] Figure 12 provides the HI titer test result and motility test result.

DETAILED DESCRIPTION

[0025] Compositions comprising an NDV (Newcastle Disease Virus) antigen and fragments and variants thereof that elicit an immunogenic response in an animal are provided. The NDV antigen or fragments or variants thereof may be produced in algae. The NDV antigen or fragments or variants may be formulated into vaccines or pharmaceutical compositions and used to elicit or stimulate a protective response in an animal. In one embodiment the NDV antigen is an NDV hemagglutinin-neuraminidase (HN) polypeptide or active fragment or variant thereof.

[0026] It is recognized that the antigenic polypeptides of the invention may be full length polypeptides or active fragments or variants thereof. By “active fragments” or “active variants” is intended that the fragments or variants retain the antigenic nature of the polypeptide. Thus, the present invention encompasses any NDV polypeptide, antigen, epitope or immunogen that elicits an immunogenic response in an animal. The NDV polypeptide, antigen, epitope or immunogen may be any NDV polypeptide, antigen, epitope or immunogen that elicits, induces or stimulates a response in an animal.

[0027] A particular antigenic polypeptide of interest is hemagglutinin-neuraminidase (HN). The glycoprotein, hemagglutinin-neuraminidase (HN) has the transmembrane region located in the amino-terminal region making it a type II integral membrane protein that is involved with viral attachment to cells via sialic acid receptors. The HN protein protrudes from the envelope allowing the virus to contain both hemagglutinin and neuraminidase activities (Yusoff K, Tan WS, 2001, Avian Pathol 30:439-455).

[0028] However, there are different antigens, any of which can be used in the practice of the invention. It is further recognized that precursors of any of these antigens can be used.

[0029] The antigenic polypeptides of the invention are capable of protecting against NDV. That is, they are capable of stimulating an immune response in an animal. By “antigen” or “immunogen” means a substance that induces a specific immune response in a host animal. The antigen may comprise a whole organism, killed, attenuated or live; a portion of an organism; a recombinant vector containing an insert with immunogenic properties; a piece or fragment of DNA capable of inducing an immune response upon presentation to a host animal; a polypeptide, an epitope, a hapten, or any combination thereof. Alternately, the immunogen or antigen may comprise a toxin or antitoxin.

[0030] The terms “protein”, “peptide”, “polypeptide” and “polypeptide fragment” are used interchangeably herein to refer to polymers of amino acid residues of any length. The polymer can be linear or branched, it may comprise modified amino acids or amino acid analogs, and it may be interrupted by chemical moieties other than amino acids. The terms also encompass an amino acid polymer that has been modified naturally or by intervention; for example disulfide bond formation, glycosylation, lipidation, acetylation, phosphorylation, or any other manipulation or modification, such as conjugation with a labeling or bioactive component.

[0031] The term “immunogenic or antigenic polypeptide” as used herein includes polypeptides that are immunologically active in the sense that once administered to the host, it is able to evoke an immune response of the humoral and/or cellular type directed against the protein. Preferably the protein fragment is such that it has substantially the same immunological activity as the total protein. Thus, a protein fragment according to the invention comprises or consists essentially of or consists of at least one epitope or antigenic determinant. An “immunogenic” protein or polypeptide, as used herein, includes the full-length sequence of the protein, analogs thereof, or immunogenic fragments thereof. By “immunogenic fragment” is meant a fragment of a protein which includes one or more epitopes and thus elicits the immunological response described above. Such fragments can be identified using any number of epitope mapping techniques well known in the art. See, e.g., Epitope Mapping Protocols in Methods in Molecular Biology, Vol. 66 (Glenn E. Morris, Ed., 1996). For example, linear epitopes may be determined by e.g., concurrently synthesizing large numbers of peptides on solid supports, the peptides corresponding to portions of the protein molecule, and reacting the peptides with antibodies while the peptides are still attached to the supports. Such techniques are known in the art and described in, e.g.,

U.S. Pat. No. 4,708,871. Similarly, conformational epitopes are readily identified by determining spatial conformation of amino acids such as by, e.g., x-ray crystallography and 2-dimensional nuclear magnetic resonance. See, e.g., Epitope Mapping Protocols, supra.

[0032] As discussed herein, the invention encompasses active fragments and variants of the antigenic polypeptide. Thus, the term "immunogenic or antigenic polypeptide" further contemplates deletions, additions and substitutions to the sequence, so long as the polypeptide functions to produce an immunological response as defined herein. The term "conservative variation" denotes the replacement of an amino acid residue by another biologically similar residue, or the replacement of a nucleotide in a nucleic acid sequence such that the encoded amino acid residue does not change or is another biologically similar residue. In this regard, particularly preferred substitutions will generally be conservative in nature, i.e., those substitutions that take place within a family of amino acids. For example, amino acids are generally divided into four families: (1) acidic--aspartate and glutamate; (2) basic--lysine, arginine, histidine; (3) non-polar--alanine, valine, leucine, isoleucine, proline, phenylalanine, methionine, tryptophan; and (4) uncharged polar--glycine, asparagine, glutamine, cysteine, serine, threonine, tyrosine. Phenylalanine, tryptophan, and tyrosine are sometimes classified as aromatic amino acids. Examples of conservative variations include the substitution of one hydrophobic residue such as isoleucine, valine, leucine or methionine for another hydrophobic residue, or the substitution of one polar residue for another polar residue, such as the substitution of arginine for lysine, glutamic acid for aspartic acid, or glutamine for asparagine, and the like; or a similar conservative replacement of an amino acid with a structurally related amino acid that will not have a major effect on the biological activity. Proteins having substantially the same amino acid sequence as the reference molecule but possessing minor amino acid substitutions that do not substantially affect the immunogenicity of the protein are, therefore, within the definition of the reference polypeptide. All of the polypeptides produced by these modifications are included herein. The term "conservative variation" also includes the use of a substituted amino acid in place of an unsubstituted parent amino acid provided that antibodies raised to the substituted polypeptide also immunoreact with the unsubstituted polypeptide.

[0033] The term "epitope" refers to the site on an antigen or hapten to which specific B cells and/or T cells respond. The term is also used interchangeably with "antigenic determinant" or "antigenic determinant site". Antibodies that recognize the same epitope can be identified in a simple immunoassay showing the ability of one antibody to block the binding of another antibody to a target antigen.

[0034] An "immunological response" to a composition or vaccine is the development in the host of a cellular and/or antibody-mediated immune response to a composition or vaccine of interest. Usually, an "immunological response" includes but is not limited to one or more of the following effects: the production of antibodies, B cells, helper T cells, and/or cytotoxic T cells, directed specifically to an antigen or antigens included in the composition or vaccine of interest. Preferably, the host will display either a therapeutic or protective immunological response such that resistance to new infection will be enhanced and/or the clinical severity of the disease reduced. Such protection will be demonstrated by either a reduction or lack of symptoms normally displayed by an infected host, a quicker recovery time and/or a lowered viral titer in the infected host.

[0035] By "animal" is intended mammals, birds, and the like. Animal or host as used herein includes mammals and human. The animal may be selected from the group consisting of equine (e.g., horse), canine (e.g., dogs, wolves, foxes, coyotes, jackals), feline (e.g., lions, tigers, domestic cats, wild cats, other big cats, and other felines including cheetahs and lynx), ovine (e.g., sheep), bovine (e.g., cattle), porcine (e.g., pig), avian (e.g., chicken, duck, goose, turkey, quail, pheasant, parrot, finches, hawk, crow, ostrich, emu and cassowary), primate (e.g., prosimian, tarsier, monkey, gibbon, ape), and fish. The term "animal" also includes an individual animal in all stages of development, including embryonic and fetal stages.

[0036] The term "plants" as used herein includes both dicotyledonous (dicot) plants and monocotyledonous (monocot) plant. Dicot plants include, but are not limited to, legumes such as pea, alfalfa and soybean, carrot, celery, tomato, potato, tobacco, pepper, oilseed rape, beet, cabbage, cauliflower, broccoli, lettuce, peanut, and the like. Monocot plants include, but are not limited to, cereals such as wheat, barley, sorghum and millet, rye, triticale, maize, rice or oats, sugarcane, duckweed, grasses, and the like. The term "plant" also include non-flowering plants including, but not limited to, ferns, horsetails, club mosses, mosses, liverworts, hornworts, algae. The terms "algae" and "alga" as used herein include any strain of algae capable of producing a polypeptide or fragment or variant thereof. The algae may include, for example, red, brown, and green algae, gametophytes, and the like. The algae may be microalgae. The microalgae may be *Thraustochytriaceae*, for example, *Schizochytrium*, *Thraustochytrium*, *Labyrinthuloides*, and *Japonochytrium*.

[0037] Unless otherwise explained, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this disclosure belongs. The singular terms "a", "an", and "the" include plural referents unless

51440-197

context clearly indicates otherwise. Similarly, the word “or” is intended to include “and” unless the context clearly indicates otherwise.

[0038] It is noted that in this disclosure and particularly in the claims and/or paragraphs, terms such as “comprises”, “comprised”, “comprising” and the like can mean “includes”, “included”, “including”, and the like; and that terms such as “consisting essentially of” and “consists essentially of” allow for elements not explicitly recited, but exclude elements that are found in the prior art or that affect a basic or novel characteristic of the invention.

Compositions

[0039] The present invention relates to an NDV vaccine or composition which may comprise an effective amount of a recombinant NDV polypeptide or antigen and a pharmaceutically or veterinarily acceptable carrier, excipient, or vehicle. The NDV polypeptide, antigen, epitope or immunogen may be any NDV polypeptide, antigen, epitope or immunogen that elicits, induces or stimulates a response in an animal. In one embodiment, the NDV polypeptide, antigen, epitope or immunogen is a hemagglutinin-neuramidase (HN), RNA polymerase, Fusion protein (F), matrix protein, phosphoprotein and a nucleoprotein. In another embodiment, the NDV antigen may be a hemagglutinin-neuramidase (HN).

[0040] The invention is based, in part, on Applicants’ surprising discovery that a recombinant NDV HN gene expressed in a plant or algal protein expression system was highly immunogenic and protected animals against challenge from homologous and heterologous NDV strains.

[0041] The present invention relates to an NDV vaccine or composition which may comprise an effective amount of a recombinant NDV HN polypeptide or antigen and a pharmaceutically or veterinarily acceptable carrier, excipient, or vehicle. In one embodiment, the recombinant NDV HN antigen is expressed in algae. In yet another embodiment, the algae are selected from *Schizochytrium*. In one embodiment, the recombinant NDV HN antigen may be expressed in a *Schizochytrium* protein expression system, as described, for example, in US 7,001,772, US 2008/0022422, US 2006/0275904, US 2006/0286650.

[0042] In an embodiment, the subject matter disclosed herein is directed to a composition comprising a recombinant NDV HN polypeptide or antigen produced by a duckweed expression system and plant material from duckweed, including the genus *Lemna*, and a pharmaceutical or veterinarily acceptable carrier, excipient or vehicle. In another

embodiment, the subject matter disclosed herein is directed to an optionally aglycosylated protein produced by a duckweed expression system comprising an NDV HN polypeptide or antigen. The recombinant NDV HN polypeptide or antigen may be expressed in a *Lemna minor* protein expression system, such as Biolex's LEX systemSM.

[0043] In one embodiment, the pharmaceutically or veterinarily acceptable carrier, excipient, or vehicle may be a water-in-oil emulsion. In another embodiment, the water-in-oil emulsion may be a water/oil/water (W/O/W) triple emulsion. In yet another embodiment, the pharmaceutically or veterinarily acceptable carrier, excipient, or vehicle may be an oil-in-water emulsion.

[0044] In an embodiment, the composition or vaccine comprises a recombinant vector and a pharmaceutical or veterinary acceptable excipient, carrier or vehicle. The recombinant vector is plant or algae expression vector which may comprise a polynucleotide encoding an NDV polypeptide, antigen, epitope or immunogen. In one embodiment, the NDV polypeptide, antigen, epitope or immunogen may be derived from an avian infected with NDV or an avian NDV strain.

[0045] In an embodiment, the NDV polypeptide or antigen or fragment or variant thereof comprises an NDV HN polypeptide or fragment or variant thereof. In an aspect of this embodiment, the HN polypeptide or fragment or variant thereof is a recombinant polypeptide produced by an NDV HN gene. In another aspect of this embodiment, the NDV HN gene has at least 70% identity to the sequence as set forth in SEQ ID NO: 1, 2, 4, 6, 8, 12, 14, 16, 18, 22 or 23. In another aspect of this embodiment, the NDV HN polypeptide or fragment or variant thereof has at least 80% identity to the sequence as set forth in SEQ ID NO: 3, 5, 7, 9, 10, 11, 13, 15, 17, 19, 20, 21, or 28. In another aspect of this embodiment, the HN polypeptide or fragment or variant thereof comprises an HN linear epitope region. In another aspect of this embodiment, the epitope region has at least 80% identity to the sequence as set forth in SEQ ID NO: 10, 11, or 28.

[0046] In an embodiment, the NDV antigen is partially purified; or, in another embodiment, the NDV antigen is substantially purified. In yet another embodiment, the NDV antigen is present in the microalgae harvested in whole. In yet another embodiment, the NDV antigen is present in the low-speed supernatant.

[0047] Synthetic antigens are also included within the definition, for example, polyepitopes, flanking epitopes, and other recombinant or synthetically derived antigens. See, e.g., Bergmann et al., 1993; Bergmann et al., 1996; Suhrbier, 1997; Gardner et al., 1998. Immunogenic fragments, for purposes of the present invention, will usually include at least

about 3 amino acids, at least about 5 amino acids, at least about 10-15 amino acids, or about 15-25 amino acids or more amino acids, of the molecule. There is no critical upper limit to the length of the fragment, which could comprise nearly the full-length of the protein sequence, or even a fusion protein comprising at least one epitope of the protein.

[0048] Accordingly, a minimum structure of a polynucleotide expressing an epitope is that it comprises or consists essentially of or consists of nucleotides encoding an epitope or antigenic determinant of an NDV polypeptide. A polynucleotide encoding a fragment of an NDV polypeptide may comprise or consist essentially of or consist of a minimum of 15 nucleotides, about 30-45 nucleotides, about 45-75, or at least 57, 87 or 150 consecutive or contiguous nucleotides of the sequence encoding the polypeptide. Epitope determination procedures, such as, generating overlapping peptide libraries (Hemmer et al., 1998), Pepscan (Geysen et al., 1984; Geysen et al., 1985; Van der Zee R. et al., 1989; Geysen, 1990; Multipin.RTM. Peptide Synthesis Kits de Chiron) and algorithms (De Groot et al., 1999; PCT/US2004/022605) can be used in the practice of the invention.

[0049] Glycosylation of a protein may have multiple effects on the immunogenicity of a protein. In the case of NDV, it appears glycosylation is required for the proper folding of the protein and conformational epitope formation (McGinnes, L. W., and T. G. Morrison. 1995, *Virology* 212:398-410.). According to McGinnes, *et al.*, glycosylation of the HN protein at glycosylation sites 433 and 481 (see Figures 8-10) are required for protein binding activity and conformational epitope formation. Proper glycosylation of the HN protein may be required for the protein function and the immune response of the host to the composition of the invention.

[0050] Conformational epitopes and a primary linear epitope of the HN protein are described in Gotoh, BT, et al., 1988, *Virology* 163:174-82, Iorio, R. M., J. B. et al., 1986, *J Gen Virol* 67:1393-403, Iorio, RM, et al., 1989, *Virus Res* 13:245-61. It appears that variations in the linear epitope may be the cause of vaccine evasion by emerging strains (Cho, SH, et al., 2008, *J Clin Microbiol* 46:1541-4). Figure 8 provides an alignment of the HN proteins from four NDV strains to show the level of variation in the linear epitope region.

[0051] The term “nucleic acid” and “polynucleotide” refers to RNA or DNA that is linear or branched, single or double stranded, or a hybrid thereof. The term also encompasses RNA/DNA hybrids. The following are non-limiting examples of polynucleotides: a gene or gene fragment, exons, introns, mRNA, tRNA, rRNA, ribozymes, cDNA, recombinant polynucleotides, branched polynucleotides, plasmids, vectors, isolated DNA of any sequence, isolated RNA of any sequence, nucleic acid probes and primers. A polynucleotide may

comprise modified nucleotides, such as methylated nucleotides and nucleotide analogs, uracyl, other sugars and linking groups such as fluororibose and thiolate, and nucleotide branches. The sequence of nucleotides may be further modified after polymerization, such as by conjugation, with a labeling component. Other types of modifications included in this definition are caps, substitution of one or more of the naturally occurring nucleotides with an analog, and introduction of means for attaching the polynucleotide to proteins, metal ions, labeling components, other polynucleotides or solid support. The polynucleotides can be obtained by chemical synthesis or derived from a microorganism.

[0052] The term “gene” is used broadly to refer to any segment of polynucleotide associated with a biological function. Thus, genes include introns and exons as in genomic sequence, or just the coding sequences as in cDNAs and/or the regulatory sequences required for their expression. For example, gene also refers to a nucleic acid fragment that expresses mRNA or functional RNA, or encodes a specific protein, and which includes regulatory sequences.

[0053] The invention further comprises a complementary strand to a polynucleotide encoding an NDV antigen, epitope or immunogen. The complementary strand can be polymeric and of any length, and can contain deoxyribonucleotides, ribonucleotides, and analogs in any combination.

[0054] An “isolated” biological component (such as a nucleic acid or protein or organelle) refers to a component that has been substantially separated or purified away from other biological components in the cell of the organism in which the component naturally occurs, for instance, other chromosomal and extra-chromosomal DNA and RNA, proteins, and organelles. Nucleic acids and proteins that have been “isolated” include nucleic acids and proteins purified by standard purification methods. The term also embraces nucleic acids and proteins prepared by recombinant technology as well as chemical synthesis.

[0055] The term “purified” as used herein does not require absolute purity; rather, it is intended as a relative term. Thus, for example, a partially purified polypeptide preparation is one in which the polypeptide is more enriched than the polypeptide is in its natural environment. That is the polypeptide is separated from cellular components. By “substantially purified” is intended that such that at least 60%, at least 70%, at least 80%, at least 90%, at least 95%, or at least 98%, or more of the cellular components or materials have been removed. Likewise, a polypeptide may be partially purified. By “partially purified” is intended that less than 60% of the cellular components or material is removed. The same

applies to polynucleotides. The polypeptides disclosed herein can be purified by any of the means known in the art.

[0056] In one aspect, the present invention provides NDV HN polypeptides. In another aspect, the present invention provides an NDV HN polypeptide having a sequence as set forth in SEQ ID NO: 3, 5, 7, 9, 10, 11, 13, 15, 17, 19, 20, 21, or 28 and variant or fragment thereof.

[0057] Moreover, homologs of NDV HN polypeptides are intended to be within the scope of the present invention. As used herein, the term “homologs” includes orthologs, analogs and paralog. The term “analog” refers to two polynucleotides or polypeptides that have the same or similar function, but that have evolved separately in unrelated organisms. The term “orthologs” refers to two polynucleotides or polypeptides from different species, but that have evolved from a common ancestral gene by speciation. Normally, orthologs encode polypeptides having the same or similar functions. The term “paralog” refers to two polynucleotides or polypeptides that are related by duplication within a genome. Paralog usually have different functions, but these functions may be related. Analog, ortholog, and paralog of a wild-type NDV polypeptide can differ from the wild-type NDV polypeptide by post-translational modifications, by amino acid sequence differences, or by both. In particular, homologs of the invention will generally exhibit at least 80-85%, 85-90%, 90-95%, or 95%, 96%, 97%, 98%, 99% sequence identity, with all or part of the wild-type NDV polypeptide or polynucleotide sequences, and will exhibit a similar function.

[0058] In another aspect, the present invention provides a polypeptide having at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, 96%, 97%, 98% or 99% sequence identity to an NDV HN polypeptide having a sequence as set forth in SEQ ID NO: 3, 5, 7, 9, 10, 11, 13, 15, 17, 19, 20, 21, or 28. In yet another aspect, the present invention provides an NDV HN polypeptide comprising an immunogenic fragment having a sequence as set forth in SEQ ID NO:10, SEQ ID NO:11, or SEQ ID NO:28, and wherein the polypeptide has at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, 96%, 97%, 98% or 99% sequence identity to a polypeptide having a sequence as set forth in SEQ ID NO: 3, 5, 7, 9, 15, 17, 19, or 20.

[0059] In yet another aspect, the present invention provides fragments and variants of the NDV HN polypeptides identified above (SEQ ID NO: 3, 5, 7, 9, 10, 11, 13, 15, 17, 19, 20, 21, or 28) which may readily be prepared by one of skill in the art using well-known molecular biology techniques.

[0060] Variants are homologous polypeptides having an amino acid sequence at least 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% identity to the amino acid sequence as set forth in SEQ ID NO: 3, 5, 7, 9, 10, 11, 13, 15, 17, 19, 20, 21, or 28.

[0061] Variants include allelic variants. The term "allelic variant" refers to a polynucleotide or a polypeptide containing polymorphisms that lead to changes in the amino acid sequences of a protein and that exist within a natural population (e.g., a virus species or variety). Such natural allelic variations can typically result in 1- 5% variance in a polynucleotide or a polypeptide. Allelic variants can be identified by sequencing the nucleic acid sequence of interest in a number of different species, which can be readily carried out by using hybridization probes to identify the same genetic locus in those species. Any and all such nucleic acid variations and resulting amino acid polymorphisms or variations that are the result of natural allelic variation and that do not alter the functional activity of gene of interest, are intended to be within the scope of the invention.

[0062] As used herein, the term "derivative" or "variant" refers to a polypeptide, or a nucleic acid encoding a polypeptide, that has one or more conservative amino acid variations or other minor modifications such that (1) the corresponding polypeptide has substantially equivalent function when compared to the wild type polypeptide or (2) an antibody raised against the polypeptide is immunoreactive with the wild-type polypeptide. These variants or derivatives include polypeptides having minor modifications of the NDV polypeptide primary amino acid sequences that may result in peptides which have substantially equivalent activity as compared to the unmodified counterpart polypeptide. Such modifications may be deliberate, as by site-directed mutagenesis, or may be spontaneous. The term "variant" further contemplates deletions, additions and substitutions to the sequence, so long as the polypeptide functions to produce an immunological response as defined herein.

[0063] The term "conservative variation" denotes the replacement of an amino acid residue by another biologically similar residue, or the replacement of a nucleotide in a nucleic acid sequence such that the encoded amino acid residue does not change or is another biologically similar residue. In this regard, particularly preferred substitutions will generally be conservative in nature, as described above.

[0064] An immunogenic fragment of an NDV HN polypeptide includes at least 8, 10, 13, 14, 15, or 20 consecutive amino acids, at least 21 amino acids, at least 23 amino acids, at least 25 amino acids, or at least 30 amino acids of an NDV HN polypeptide having a sequence as set forth in SEQ ID NO: 3, 5, 7, 9, 10, 11, 13, 15, 17, 19, 20, 21, or 28, or variants thereof. In another embodiment, a fragment of an NDV HN polypeptide includes a

specific antigenic epitope found on a full-length NDV HN polypeptide. An immunogenic fragment may comprise a fragment containing the NDV HN linear epitope region. In one embodiment, the immunogenic fragment comprises the polypeptide having a sequence as set forth in SEQ ID NO:10, SEQ ID NO:11, or SEQ ID NO:28.

[0065] In another aspect, the present invention provides a polynucleotide encoding an NDV HN polypeptide, such as a polynucleotide encoding an NDV HN polypeptide having a sequence as set forth in SEQ ID NO: 3, 5, 7, 9, 10, 11, 13, 15, 17, 19, 20, 21, or 28. In yet another aspect, the present invention provides a polynucleotide encoding an NDV HN polypeptide having at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, 96%, 97%, 98% or 99% sequence identity to a polypeptide having a sequence as set forth in SEQ ID NO: 3, 5, 7, 9, 10, 11, 13, 15, 17, 19, 20, 21, or 28, or a conservative variant, an allelic variant, a homolog or an immunogenic fragment comprising at least eight or at least ten consecutive amino acids of one of these polypeptides, or a combination of these polypeptides. In yet another aspect, the present invention provides a polynucleotide encoding an NDV HN polypeptide comprising an immunogenic fragment having a sequence as set forth in SEQ ID NO:10, SEQ ID NO:11, or SEQ ID NO:28, and wherein the polypeptide has at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, 96%, 97%, 98% or 99% sequence identity to a polypeptide having a sequence as set forth in SEQ ID NO: 3, 5, 7, 9, 15, 17, 19, or 20.

[0066] In another aspect, the present invention provides a polynucleotide having a nucleotide sequence as set forth in SEQ ID NO: 1, 2, 4, 6, 8, 12, 14, 16, 18, 22, or 23, or a variant thereof. In yet another aspect, the present invention provides a polynucleotide having at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 95%, 96%, 97%, 98% or 99% sequence identity to one of a polynucleotide having a sequence as set forth in SEQ ID NO: 1, 2, 4, 6, 8, 12, 14, 16, 18, 22, or 23, or a variant thereof.

[0067] The polynucleotides of the disclosure include sequences that are degenerate as a result of the genetic code, e.g., optimized codon usage for a specific host. As used herein, “optimized” refers to a polynucleotide that is genetically engineered to increase its expression in a given species. To provide optimized polynucleotides coding for NDV polypeptides, the DNA sequence of the NDV protein gene can be modified to 1) comprise codons preferred by highly expressed genes in a particular species; 2) comprise an A+T or G+C content in nucleotide base composition to that substantially found in said species; 3) form an initiation sequence of said species; or 4) eliminate sequences that cause destabilization, inappropriate polyadenylation, degradation and termination of RNA, or that form secondary structure

hairpins or RNA splice sites. Increased expression of NDV protein in said species can be achieved by utilizing the distribution frequency of codon usage in eukaryotes and prokaryotes, or in a particular species. The term “frequency of preferred codon usage” refers to the preference exhibited by a specific host cell in usage of nucleotide codons to specify a given amino acid. There are 20 natural amino acids, most of which are specified by more than one codon. Therefore, all degenerate nucleotide sequences are included in the disclosure as long as the amino acid sequence of the NDV HN polypeptide encoded by the nucleotide sequence is functionally unchanged.

[0068] The sequence identity between two amino acid sequences may be established by the NCBI (National Center for Biotechnology Information) pairwise blast and the blosum62 matrix, using the standard parameters (see, e.g., the BLAST or BLASTX algorithm available on the "National Center for Biotechnology Information" (NCBI, Bethesda, Md., USA) server).

[0069] The “identity” with respect to sequences can refer to the number of positions with identical nucleotides or amino acids divided by the number of nucleotides or amino acids in the shorter of the two sequences wherein alignment of the two sequences can be determined in accordance with the Wilbur and Lipman algorithm (Wilbur and Lipman), for instance, using a window size of 20 nucleotides, a word length of 4 nucleotides, and a gap penalty of 4, and computer-assisted analysis and interpretation of the sequence data including alignment can be conveniently performed using commercially available programs (e.g., Intelligenetics™ Suite, Intelligenetics Inc. CA). When RNA sequences are said to be similar, or have a degree of sequence identity or homology with DNA sequences, thymine (T) in the DNA sequence is considered equal to uracil (U) in the RNA sequence. Thus, RNA sequences are within the scope of the invention and can be derived from DNA sequences, by thymine (T) in the DNA sequence being considered equal to uracil (U) in RNA sequences.

[0070] The sequence identity or sequence similarity of two amino acid sequences, or the sequence identity between two nucleotide sequences can be determined using Vector NTI software package (Invitrogen, 1600 Faraday Ave., Carlsbad, CA).

[0071] Hybridization reactions can be performed under conditions of different stringency. Conditions that increase stringency of a hybridization reaction are well known. See for example, “Molecular Cloning: A Laboratory Manual”, second edition (Sambrook et al., 1989).

[0072] The invention further encompasses the NDV polynucleotides contained in a vector molecule or an expression vector and operably linked to a promoter element.

[0073] A “vector” refers to a recombinant DNA or RNA plasmid or virus that comprises a heterologous polynucleotide to be delivered to a target cell, either *in vitro* or *in vivo*. The heterologous polynucleotide may comprise a sequence of interest for purposes of prevention or therapy, and may optionally be in the form of an expression cassette. As used herein, a vector needs not be capable of replication in the ultimate target cell or subject. The term includes cloning vectors and viral vectors.

[0074] The term “recombinant” means a polynucleotide with semisynthetic, or synthetic origin which either does not occur in nature or is linked to another polynucleotide in an arrangement not found in nature.

[0075] “Heterologous” means derived from a genetically distinct entity from the rest of the entity to which it is being compared. For example, a polynucleotide may be placed by genetic engineering techniques into a plasmid or vector derived from a different source, and is a heterologous polynucleotide. A promoter removed from its native coding sequence and operatively linked to a coding sequence other than the native sequence is a heterologous promoter.

[0076] The polynucleotides of the invention may comprise additional sequences, such as additional encoding sequences within the same transcription unit, controlling elements such as promoters, ribosome binding sites, 5'UTR, 3'UTR, transcription terminators, polyadenylation sites, additional transcription units under control of the same or a different promoter, sequences that permit cloning, expression, homologous recombination, and transformation of a host cell, and any such construct as may be desirable to provide embodiments of this invention.

[0077] Elements for the expression of an NDV polypeptide, antigen, epitope or immunogen are advantageously present in an inventive vector. In minimum manner, this comprises an initiation codon (ATG), a stop codon and a promoter, and optionally also a polyadenylation sequence for certain vectors such as plasmid and certain viral vectors, e.g., viral vectors other than poxviruses. When the polynucleotide encodes a polypeptide fragment, e.g. an NDV peptide, advantageously, in the vector, an ATG is placed at 5' of the reading frame and a stop codon is placed at 3'. Other elements for controlling expression may be present, such as enhancer sequences, stabilizing sequences, such as intron and signal sequences permitting the secretion of the protein.

[0078] The present invention also relates to compositions comprising vectors, such as expression vectors. The compositions can comprise one or more vectors, e.g., expression vectors, such as *in vivo* expression vectors, comprising and expressing one or more NDV

polypeptides, antigens, epitopes or immunogens. In one embodiment, the vector comprises a polynucleotide coding for and/or expressing an NDV polypeptide, antigen, epitope or immunogen, in a pharmaceutically or veterinarily acceptable carrier, excipient or vehicle.

[0079] According to another embodiment of the invention, the expression vector is a plasmid vector, in particular an *in vivo* expression vector. In a specific, non-limiting example, the pVR1020 or 1012 plasmid (VICAL Inc.; Luke et al., 1997; Hartikka et al., 1996, see, e.g., U.S. Patent Nos. 5,846,946 and 6,451,769) can be utilized as a vector for the insertion of a polynucleotide sequence. The pVR1020 plasmid is derived from pVR1012 and contains the human tPA signal sequence. In one embodiment the human tPA signal comprises from amino acid M(1) to amino acid S(23) of GenBank accession number HUMTPA14. In another specific, non-limiting example, the plasmid utilized as a vector for the insertion of a polynucleotide sequence can contain the signal peptide sequence of equine IGF1 from amino acid M(24) to amino acid A(48) of GenBank accession number U28070. Additional information on DNA plasmids which may be consulted or employed in the practice are found, for example, in U.S. Patent Nos. 6,852,705; 6,818,628; 6,586,412; 6,576,243; 6,558,674; 6,464,984; 6,451,770; 6,376,473 and 6,221,362.

[0080] The term plasmid covers any DNA transcription unit comprising a polynucleotide according to the invention and the elements necessary for its *in vivo* expression in a cell or cells of the desired host or target; and, in this regard, it is noted that a supercoiled or non-supercoiled, circular plasmid, as well as a linear form, are intended to be within the scope of the invention.

[0081] Each plasmid comprises a polynucleotide encoding an NDV polypeptide, antigen, epitope or immunogen operably linked to a promoter or under the control of a promoter or dependent upon a promoter. In general, it is advantageous to employ a strong promoter functional in eukaryotic cells. The strong promoter may be, but not limited to, the immediate early cytomegalovirus promoter (CMV-IE) of human or murine origin, or optionally having another origin such as the rat or guinea pig.

[0082] In more general terms, the promoter has a viral, a plant, or a cellular origin. A strong viral promoter other than CMV-IE that may be usefully employed in the practice of the invention is the early/late promoter of the SV40 virus or the LTR promoter of the Rous sarcoma virus. A strong cellular promoter that may be usefully employed in the practice of the invention is the promoter of a gene of the cytoskeleton, such as e.g. the desmin promoter (Kwissa et al., 2000), or the actin promoter (Miyazaki et al., 1989).

[0083] The plasmids may comprise other expression control elements. It is particularly advantageous to incorporate stabilizing sequence(s), e.g., intron sequence(s), for example, maize alcohol dehydrogenase intron (maize ADHI intron), the first intron of the hCMV-IE (WO1989/01036), the intron II of the rabbit β -globin gene (van Ooyen et al., 1979). In another embodiment, the plasmids may comprise 3' UTR. The 3' UTR may be, but not limited to, agrobacterium nopaline synthase (Nos) 3' UTR. The plasmids may further comprise the OrfC terminator (also known as the PFA3 terminator).

[0084] As to the polyadenylation signal (polyA) for the plasmids and viral vectors other than poxviruses, use can be made of the poly(A) signal of the bovine growth hormone (bGH) gene (see U.S. 5,122,458), or the poly(A) signal of the rabbit β -globin gene or the poly(A) signal of the SV40 virus.

[0085] A "host cell" denotes a prokaryotic or eukaryotic cell that has been genetically altered, or is capable of being genetically altered by administration of an exogenous polynucleotide, such as a recombinant plasmid or vector. When referring to genetically altered cells, the term refers both to the originally altered cell and to the progeny thereof.

[0086] In one embodiment, the recombinant NDV HN antigen is expressed in a transgenic plant. In another embodiment, the recombinant NDV HN antigen is expressed in transgenic algae. In yet another embodiment, the transgenic algae are *Schizochytrium*. Details of the algae protein expression system may be found, for example, in US 7,001,772, US 2008/0022422. The NDV HN polypeptide or antigen in the embodiments may be any polypeptide disclosed herein, or a polypeptide encoded by any polynucleotide disclosed herein.

Methods for Expressing NDV polypeptides in Microalgae or Duckweed

[0087] In some embodiments of the invention, NDV HN polypeptides, or fragments or variants thereof, are expressed in microalgae or duckweed. These methods comprise the use of expression cassettes that are introduced into algae or plants using any suitable transformation method known in the art. Polynucleotides within these expression cassettes can be modified for enhanced expression of the antigenic NDV HN polypeptide, or fragment or variant thereof, in microalgae or duckweed, as follows.

Cassettes for Microalgae or duckweed Expression of Antigenic NDV Polypeptides

[0088] Transgenic microalgae or duckweed expressing an NDV HN polypeptide, or fragment or variant thereof are obtained by transformation of microalgae or duckweed with

an expression cassette comprising a polynucleotide encoding the NDV HN polypeptide, or fragment or variant thereof. In this manner, a polynucleotide encoding the NDV HN polypeptide, or fragment or variant thereof, is constructed within an expression cassette and introduced into microalgae or duckweed by any suitable transformation method known in the art.

[0089] In some embodiments, the microalgae or duckweed that are transformed with an expression cassette comprising a polynucleotide encoding the NDV HN polypeptide, or fragment or variant thereof, have also been transformed with an expression cassette that provides for expression of another heterologous polypeptide of interest, for example, another NDV polypeptide, fragment, or variant thereof. The expression cassette providing for expression of another heterologous polypeptide of interest can be provided on the same polynucleotide (for example, on the same transformation vector) for introduction into microalgae or duckweed, or on a different polynucleotide (for example, on different transformation vectors) for introduction into the microalgae or duckweed at the same time or at different times, by the same or by different methods of introduction, for example, by the same or different transformation methods.

[0090] The expression cassettes for use in transformation of microalgae or duckweed comprise expression control elements that at least comprise a transcriptional initiation region (e.g., a promoter) operably linked to the polynucleotide of interest, i.e., a polynucleotide encoding an NDV HN polypeptide, fragment, or variant thereof. “Operably linked” as used herein in reference to nucleotide sequences refers to multiple nucleotide sequences that are placed in a functional relationship with each other. Generally, operably linked DNA sequences are contiguous and, where necessary to join two protein coding regions, in reading frame. Such an expression cassette is provided with a plurality of restriction sites for insertion of the polynucleotide or polynucleotides of interest (e.g., one polynucleotide of interest, two polynucleotides of interest, etc.) to be under the transcriptional regulation of the promoter and other expression control elements. In particular embodiments of the invention, the polynucleotide to be transferred contains two or more expression cassettes, each of which contains at least one polynucleotide of interest.

[0091] By “expression control element” is intended a regulatory region of DNA, usually comprising a TATA box, capable of directing RNA polymerase II, or in some embodiments, RNA polymerase III, to initiate RNA synthesis at the appropriate transcription initiation site for a particular coding sequence. An expression control element may additionally comprise other recognition sequences generally positioned upstream or 5' to the TATA box, which

influence (e.g., enhance) the transcription initiation rate. Furthermore, an expression control element may additionally comprise sequences generally positioned downstream or 3' to the TATA box, which influence (e.g., enhance) the transcription initiation rate.

[0092] The transcriptional initiation region (e.g., a promoter) may be native or homologous or foreign or heterologous to the microalgal host or duckweed plant, or could be the natural sequence or a synthetic sequence. By foreign, it is intended that the transcriptional initiation region is not found in the wild-type microalgal host or duckweed plant into which the transcriptional initiation region is introduced. By “functional promoter” is intended the promoter, when operably linked to a sequence encoding an NDV HN polypeptide, or fragment or variant thereof, is capable of driving expression (i.e., transcription and translation) of the encoded polypeptide, fragment, or variant. The promoters can be selected based on the desired outcome. Thus the expression cassettes of the invention can comprise constitutive, inducible, tissue-preferred, or other promoters for expression in microalgae or duckweed.

[0093] Any suitable promoter known in the art can be employed in the expression cassettes according to the present invention, including bacterial, yeast, fungal, insect, mammalian, algae, and plant promoters. For example, plant or algae promoters, including microalgae promoters, may be used. Exemplary promoters include, but are not limited to, the Cauliflower Mosaic Virus 35S promoter, the opine synthetase promoters (e.g., nos, mas, ocs, etc.), the ubiquitin promoter, the actin promoter, the ribulose biphosphate (RubP) carboxylase small subunit promoter, and the alcohol dehydrogenase promoter. U.S. patent No. 7,001,772 disclosed nucleic acid and amino acid sequences for an acetolactate synthase, an acetolactate synthase promoter and terminator region, an α -tubulin promoter, a promoter from a *Thraustochytriales* polyketide synthase (PKS) system, and a fatty acid desaturase promoter, each from a *Thraustochytriales* microorganism. U.S. patent application publications US2006/0275904 and US2006/0286650 disclose the sequences for promoters and terminators for each of *Schizochytrium* actin, elongation factor 1 alpha and glyceraldehyde 3-phosphate dehydrogenase as well as their use in vectors for expressing genes in *Schizochytrium* host cells. The microalgae RubP carboxylase small subunit promoter is known in the art (Silverthorne *et al.* (1990) *Plant Mol. Biol.* 15:49). Other promoters from viruses that infect plants or algae are also suitable including, but not limited to, promoters isolated from Dasheen mosaic virus, Chlorella virus (e.g., the Chlorella virus adenine methyltransferase promoter; Mitra *et al.* (1994) *Plant Mol. Biol.* 26:85), tomato spotted wilt virus, tobacco rattle virus, tobacco necrosis virus, tobacco ring spot virus, tomato

ring spot virus, cucumber mosaic virus, peanut stunt virus, alfalfa mosaic virus, sugarcane bacilliform badnavirus and the like.

[0094] Expression control elements, including promoters, can be chosen to give a desired level of regulation. For example, in some instances, it may be advantageous to use a promoter that confers constitutive expression (e.g., the mannopine synthase promoter from *Agrobacterium tumefaciens*). Alternatively, in other situations, it may be advantageous to use promoters that are activated in response to specific environmental stimuli (e.g., heat shock gene promoters, drought-inducible gene promoters, pathogen-inducible gene promoters, wound-inducible gene promoters, and light/dark-inducible gene promoters) or plant growth regulators (e.g., promoters from genes induced by abscissic acid, auxins, cytokinins, and gibberellic acid). As a further alternative, promoters can be chosen that give tissue-specific expression (e.g., root, leaf, and floral-specific promoters).

[0095] The overall strength of a given promoter can be influenced by the combination and spatial organization of cis-acting nucleotide sequences such as upstream activating sequences. For example, activating nucleotide sequences derived from the *Agrobacterium tumefaciens* octopine synthase gene can enhance transcription from the *Agrobacterium tumefaciens* mannopine synthase promoter (see U.S. Patent 5,955,646). In the present invention, the expression cassette can contain activating nucleotide sequences inserted upstream of the promoter sequence to enhance the expression of the antigenic NDV polypeptide of interest, or fragment or variant thereof. In one embodiment, the expression cassette includes three upstream activating sequences derived from the *Agrobacterium tumefaciens* octopine synthase gene operably linked to a promoter derived from an *Agrobacterium tumefaciens* mannopine synthase gene (see U.S. Patent 5,955,646).

[0096] The expression cassette thus includes in the 5'-3' direction of transcription, an expression control element comprising a transcriptional and translational initiation region, a polynucleotide of encoding an NDV HN polypeptide (or fragment or variant thereof), and a transcriptional and translational termination region functional in plants or algae. Any suitable termination sequence known in the art may be used in accordance with the present invention. The termination region may be native with the transcriptional initiation region, may be native with the coding sequence of interest, or may be derived from another source. Convenient termination regions are available from the Ti-plasmid of *A. tumefaciens*, such as the octopine synthetase and nopaline synthetase termination regions. See also Guerineau *et al.* (1991) *Mol. Gen. Genet.* 262:141; Proudfoot (1991) *Cell* 64:671; Sanfacon *et al.* (1991) *Genes Dev.* 5:141; Mogen *et al.* (1990) *Plant Cell* 2:1261; Munroe *et al.* (1990) *Gene* 91:151; Ballas *et*

al. (1989) *Nucleic Acids Res.* 17:7891; and Joshi *et al.* (1987) *Nucleic Acids Res.* 15:9627.

Additional exemplary termination sequences are the pea RubP carboxylase small subunit termination sequence and the Cauliflower Mosaic Virus 35S termination sequence.

[0097] Generally, the expression cassette will comprise a selectable marker gene for the selection of transformed microalgae cells or tissues. Selectable marker genes include genes encoding antibiotic resistance, such as those encoding neomycin phosphotransferase II (NEO) and hygromycin phosphotransferase (HPT), as well as genes conferring resistance to herbicidal compounds. Herbicide resistance genes generally code for a modified target protein insensitive to the herbicide or for an enzyme that degrades or detoxifies the herbicide in the plant before it can act. See DeBlock *et al.* (1987) *EMBO J.* 6:2513; DeBlock *et al.* (1989) *Plant Physiol.* 91:691; Fromm *et al.* (1990) *BioTechnology* 8:833; Gordon-Kamm *et al.* (1990) *Plant Cell* 2:603. For example, resistance to glyphosphate or sulfonylurea herbicides has been obtained using genes coding for the mutant target enzymes, 5-enolpyruvylshikimate-3-phosphate synthase (EPSPS) and acetolactate synthase (ALS). Resistance to glufosinate ammonium, boromoxynil, and 2,4-dichlorophenoxyacetate (2,4-D) has been obtained by using bacterial genes encoding phosphinothricin acetyltransferase, a nitrilase, or a 2,4-dichlorophenoxyacetate monooxygenase, which detoxify the respective herbicides.

[0098] For purpose of the present invention, selectable marker genes include, but are not limited to, genes encoding neomycin phosphotransferase II (Fraley *et al.* (1986) *CRC Critical Reviews in Plant Science* 4:1); cyanamide hydratase (Maier-Greiner *et al.* (1991) *Proc. Natl. Acad. Sci. USA* 88:4250); acetolactate synthase (ALS, Li, *et al.* (1992) *Plant Physiol.* 100:662-668); aspartate kinase; dihydrodipicolinate synthase (Perl *et al.* (1993) *BioTechnology* 11:715); bar gene (Toki *et al.* (1992) *Plant Physiol.* 100:1503; Meagher *et al.* (1996) *Crop Sci.* 36:1367); tryptophan decarboxylase (Goddijn *et al.* (1993) *Plant Mol. Biol.* 22:907); neomycin phosphotransferase (NEO; Southern *et al.* (1982) *J. Mol. Appl. Gen.* 1:327); hygromycin phosphotransferase (HPT or HYG; Shimizu *et al.* (1986) *Mol. Cell. Biol.* 6:1074); dihydrofolate reductase (DHFR; Kwok *et al.* (1986) *Proc. Natl. Acad. Sci. USA* 83:4552); phosphinothricin acetyltransferase (DeBlock *et al.* (1987) *EMBO J.* 6:2513); 2,2-dichloropropionic acid dehalogenase (Buchanan-Wollaston *et al.* (1989) *J. Cell. Biochem.* 33:330); acetohydroxyacid synthase (U.S. Pat. No. 4,761,373; Haughn *et al.* (1988) *Mol. Gen. Genet.* 221:266); 5-enolpyruvyl-shikimate-phosphate synthase (*aroA*; Comai *et al.* (1985) *Nature* 317:741); haloarylnitrilase (WO 87/04181); acetyl-coenzyme A carboxylase (Parker *et al.* (1990) *Plant Physiol.* 92:1220); dihydropteroate synthase (*sulI*; Guerineau *et al.*

(1990) *Plant Mol. Biol.* 15:127); and 32 kDa photosystem II polypeptide (psbA; Hirschberg *et al.* (1983) *Science* 222:1346 (1983).

[0099] Also included are genes encoding resistance to: gentamycin (*e.g.*, aacC1, Wohlleben *et al.* (1989) *Mol. Gen. Genet.* 217:202-208); chloramphenicol (Herrera-Estrella *et al.* (1983) *EMBO J.* 2:987); methotrexate (Herrera-Estrella *et al.* (1983) *Nature* 303:209; Meijer *et al.* (1991) *Plant Mol. Biol.* 16:807); hygromycin (Waldron *et al.* (1985) *Plant Mol. Biol.* 5:103; Zhijian *et al.* (1995) *Plant Science* 108:219; Meijer *et al.* (1991) *Plant Mol. Bio.* 16:807); streptomycin (Jones *et al.* (1987) *Mol. Gen. Genet.* 210:86); spectinomycin (Bretagne-Sagnard *et al.* (1996) *Transgenic Res.* 5:131); bleomycin (Hille *et al.* (1986) *Plant Mol. Biol.* 7:171); sulfonamide (Guerineau *et al.* (1990) *Plant Mol. Bio.* 15:127); bromoxynil (Stalker *et al.* (1988) *Science* 242:419); 2,4-D (Streber *et al.* (1989) *BioTechnology* 7:811); phosphinothricin (DeBlock *et al.* (1987) *EMBO J.* 6:2513); spectinomycin (Bretagne-Sagnard and Chupeau, *Transgenic Research* 5:131).

[0100] The bar gene confers herbicide resistance to glufosinate-type herbicides, such as phosphinothricin (PPT) or bialaphos, and the like. As noted above, other selectable markers that could be used in the vector constructs include, but are not limited to, the pat gene, also for bialaphos and phosphinothricin resistance, the ALS gene for imidazolinone resistance, the HPH or HYG gene for hygromycin resistance, the EPSP synthase gene for glyphosate resistance, the Hm1 gene for resistance to the Hc-toxin, and other selective agents used routinely and known to one of ordinary skill in the art. See Yarranton (1992) *Curr. Opin. Biotech.* 3:506; Christopherson *et al.* (1992) *PNAS USA* 89:6314; Yao *et al.* (1992) *Cell* 71:63; Reznikoff (1992) *Mol. Microbiol.* 6:2419; Barkley *et al.* (1980) *The Operon* 177-220; Hu *et al.* (1987) *Cell* 48:555; Brown *et al.* (1987) *Cell* 49:603; Figge *et al.* (1988) *Cell* 52:713; Deuschle *et al.* (1989) *PNAS USA* 86:5400; Fuerst *et al.* (1989) *PNAS USA* 86:2549; Deuschle *et al.* (1990) *Science* 248:480; Labow *et al.* (1990) *Mol. Cell. Biol.* 10:3343; Zambretti *et al.* (1992) *PNAS USA* 89:3952; Baim *et al.* (1991) *PNAS USA* 88:5072; Wyborski *et al.* (1991) *Nuc. Acids Res.* 19:4647; Hillenand-Wissman (1989) *Topics in Mol. And Struc. Biol.* 10:143; Degenkolb *et al.* (1991) *Antimicrob. Agents Chemother.* 35:1591; Kleinschmidt *et al.* (1988) *Biochemistry* 27:1094; Gatz *et al.* (1992) *Plant J.* 2:397; Gossen *et al.* (1992) *PNAS USA* 89:5547; Oliva *et al.* (1992) *Antimicrob. Agents Chemother.* 36:913; Hlavka *et al.* (1985) *Handbook of Experimental Pharmacology* 78; and Gill *et al.* (1988) *Nature* 334:721.

[0101] The above list of selectable marker genes is not meant to be limiting. Any selectable marker gene can be used in the present invention.

Modification of Nucleotide Sequences for Enhanced Expression in a Microalgal Host or Duckweed Plant

[0102] Where the NDV HN polypeptide or fragment or variant thereof is expressed within microalgae or duckweed, the expressed polynucleotide sequence encoding the NDV HN polypeptide or fragment or variant thereof can be modified to enhance its expression in microalgae. One such modification is the synthesis of the polynucleotide using plant- or algae-preferred codons, particularly microalgae-preferred codons. Methods are available in the art for synthesizing nucleotide sequences with plant- or algae-preferred codons. See, e.g., U.S. Patent Nos. 5,380,831 and 5,436,391; EP 0 359 472; EP 0 385 962; WO 91/16432; Perlak *et al.* (1991) *PNAS USA* 15:3324; Iannacome *et al.* (1997) *Plant Mol. Biol.* 34:485; and Murray *et al.* (1989) *Nucleic Acids. Res.* 17:477. Synthesis can be accomplished using any method known to one of skill in the art. The preferred codons may be determined from the codons of highest frequency in the proteins expressed in microalgae. For example, the frequency of codon usage for microalgae is found in Table A.

Table A *Schizochytrium sp. ATCC_20888* [gbpln]: 3 CDS's (6473 codons)

fields: [triplet] [frequency: per thousand] ([number])							
UUU	12.2 (79)	UCU	7.0 (45)	UAU	1.1 (7)	UGU	0.8 (5)
UUC	19.9 (129)	UCC	23.8 (154)	UAC	21.5 (139)	UGC	15.3 (99)
UUA	0.0 (0)	UCA	0.5 (3)	UAA	0.5 (3)	UGA	0.0 (0)
UUG	0.6 (4)	UCG	18.8 (122)	UAG	0.0 (0)	UGG	8.3 (54)
CUU	12.7 (82)	CCU	11.7 (76)	CAU	2.3 (15)	CGU	7.1 (46)
CUC	61.2 (396)	CCC	23.8 (154)	CAC	12.8 (83)	CGC	42.9 (278)
CUA	0.0 (0)	CCA	1.5 (10)	CAA	2.3 (15)	CGA	0.3 (2)
CUG	7.4 (48)	CCG	16.2 (105)	CAG	27.7 (179)	CGG	0.8 (5)
AUU	13.9 (90)	ACU	9.1 (59)	AAU	1.9 (12)	AGU	1.5 (10)
AUC	33.5 (217)	ACC	29.2 (189)	AAC	32.4 (210)	AGC	15.6 (101)
AUA	0.0 (0)	ACA	1.5 (10)	AAA	2.2 (14)	AGA	0.2 (1)
AUG	27.8 (180)	ACG	9.6 (62)	AAG	54.5 (353)	AGG	0.0 (0)
GUU	8.3 (54)	GCU	24.4 (158)	GAU	13.4 (87)	GGU	13.0 (84)
GUC	53.0 (343)	GCC	86.0 (557)	GAC	45.0 (291)	GGC	54.5 (353)
GUA	0.2 (1)	GCA	4.0 (26)	GAA	7.3 (47)	GGA	3.9 (25)
GUG	14.4 (93)	GCG	15.9 (103)	GAG	62.3 (403)	GGG	0.5 (3)

[0103] For purposes of the present invention, “microalgae-preferred codons” refers to codons that have a frequency of codon usage in microalgae of greater than 17%. The term “microalgae-preferred codons” as used herein refers to codons that have a frequency of codon usage in the family *Thraustochytriaceae* of greater than 17%. “*Schizochytrium*-preferred codons” as used herein refers to codons that have a frequency of codon usage in *schizochytrium* of greater than 17% where the frequency of codon usage in *schizochytrium* is obtained from the Codon Usage Database (GenBank Release 160.0, June 15, 2007).

[0104] The frequency of codon usage for *Lemna minor* is found in Table B, the frequency of codon usage for *Schizochytrium* is found in Table C.

Table B. *Lemna minor* [gbpln]: 4 CDS's (1597 codons)

fields: [triplet] [frequency: per thousand] ([number])							
UUU	17.5 (28)	UCU	13.8 (22)	UAU	8.8 (14)	UGU	5.0 (8)
UUC	36.3 (58)	UCC	17.5 (28)	UAC	15.7 (25)	UGC	14.4 (23)
UUA	5.6 (9)	UCA	14.4 (23)	UAA	0.0 (0)	UGA	1.9 (3)
UUG	13.8 (22)	UCG	13.8 (22)	UAG	0.6 (1)	UGG	16.3 (26)
CUU	15.7 (25)	CCU	11.9 (19)	CAU	6.9 (11)	CGU	4.4 (7)
CUC	25.7 (41)	CCC	15.7 (25)	CAC	16.9 (27)	CGC	18.2 (29)
CUA	5.0 (8)	CCA	11.3 (18)	CAA	10.0 (16)	CGA	6.3 (10)
CUG	21.3 (34)	CCG	14.4 (23)	CAG	22.5 (36)	CGG	10.6 (17)
AUU	18.8 (30)	ACU	9.4 (15)	AAU	13.8 (22)	AGU	10.0 (16)
AUC	19.4 (31)	ACC	17.5 (28)	AAC	21.9 (35)	AGC	15.0 (24)
AUA	1.9 (3)	ACA	5.0 (8)	AAA	15.7 (25)	AGA	20.7 (33)
AUG	20.7 (33)	ACG	10.0 (16)	AAG	35.7 (57)	AGG	17.5 (28)
GUU	15.0 (24)	GCU	25.0 (40)	GAU	20.0 (32)	GGU	8.1 (13)
GUC	25.0 (40)	GCC	22.5 (36)	GAC	26.3 (42)	GGC	21.9 (35)
GUA	6.3 (10)	GCA	14.4 (23)	GAA	26.3 (42)	GGA	16.9 (27)
GUG	30.7 (49)	GCG	18.2 (29)	GAG	40.1 (64)	GGG	18.2 (29)

Table C *Schizochytrium* sp. ATCC_20888 [gbpln]: 3 CDS's (6473 codons)

fields: [triplet] [frequency: per thousand] ([number])							
UUU	12.2 (79)	UCU	7.0 (45)	UAU	1.1 (7)	UGU	0.8 (5)
UUC	19.9 (129)	UCC	23.8 (154)	UAC	21.5 (139)	UGC	15.3 (99)
UUA	0.0 (0)	UCA	0.5 (3)	UAA	0.5 (3)	UGA	0.0 (0)
UUG	0.6 (4)	UCG	18.8 (122)	UAG	0.0 (0)	UGG	8.3 (54)

CUU 12.7 (82)	CCU 11.7 (76)	CAU 2.3 (15)	CGU 7.1 (46)
CUC 61.2 (396)	CCC 23.8 (154)	CAC 12.8 (83)	CGC 42.9 (278)
CUA 0.0 (0)	CCA 1.5 (10)	CAA 2.3 (15)	CGA 0.3 (2)
CUG 7.4 (48)	CCG 16.2 (105)	CAG 27.7 (179)	CGG 0.8 (5)
AUU 13.9 (90)	ACU 9.1 (59)	AAU 1.9 (12)	AGU 1.5 (10)
AUC 33.5 (217)	ACC 29.2 (189)	AAC 32.4 (210)	AGC 15.6 (101)
AUA 0.0 (0)	ACA 1.5 (10)	AAA 2.2 (14)	AGA 0.2 (1)
AUG 27.8 (180)	ACG 9.6 (62)	AAG 54.5 (353)	AGG 0.0 (0)
GUU 8.3 (54)	GCU 24.4 (158)	GAU 13.4 (87)	GGU 13.0 (84)
GUC 53.0 (343)	GCC 86.0 (557)	GAC 45.0 (291)	GGC 54.5 (353)
GUA 0.2 (1)	GCA 4.0 (26)	GAA 7.3 (47)	GGA 3.9 (25)
GUG 14.4 (93)	GCG 15.9 (103)	GAG 62.3 (403)	GGG 0.5 (3)

[0105] For purposes of the present invention, “duckweed-preferred codons” refers to codons that have a frequency of codon usage in duckweed of greater than 17%. “*Lemna*-preferred codons” as used herein refers to codons that have a frequency of codon usage in the genus *Lemna* of greater than 17%. “*Lemna minor*-preferred codons” as used herein refers to codons that have a frequency of codon usage in *Lemna minor* of greater than 17% where the frequency of codon usage in *Lemna minor* is obtained from the Codon Usage Database (GenBank Release 160.0, June 15, 2007).

[0106] It is further recognized that all or any part of the polynucleotide encoding the antigenic NDV polypeptide of interest, or fragment or variant thereof, may be optimized or synthetic. In other words, fully optimized or partially optimized sequences may also be used. For example, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 87%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% of the codons may be microalgae-preferred or duckweed-preferred codons. In one embodiment, between 90% and 96 % of the codons are microalgae-preferred or duckweed-preferred codons. In one embodiment, the NDV polypeptide is an NDV HN polypeptide, for example, the NDV HN polypeptide as set forth in SEQ ID NO:3 or 15, and the expression cassette comprises an optimized coding sequence for this NDV HN polypeptide, wherein the coding sequence comprises microalgae-preferred codons, for example, *Thraustochytriaceae* -preferred or *Schizochytrium* -preferred codons. In one such embodiment, the expression cassette comprises SEQ ID NO:1 or 14, which contains *Schizochytrium* -preferred codons encoding the HN polypeptide set forth in

SEQ ID NO:3 or 15. In another such embodiment, the expression cassette comprises SEQ ID NO:22 or 23, which contains *Schizochytrium*-preferred codons encoding the HN polypeptide set forth in SEQ ID NO: 17, or 20.

[0107] Other modifications can also be made to the polynucleotide encoding the antigenic NDV polypeptide of interest, or fragment or variant thereof, to enhance its expression in microalgae. These modifications include, but are not limited to, elimination of sequences encoding spurious polyadenylation signals, exon-intron splice site signals, transposon-like repeats, and other such well characterized sequences that may be deleterious to gene expression. When possible, the polynucleotide encoding the heterologous polypeptide of interest may be modified to avoid predicted hairpin secondary mRNA structures.

[0108] There are known differences between the optimal translation initiation context nucleotide sequences for translation initiation codons in animals and plants. "Translation initiation context nucleotide sequence" as used herein refers to the identity of the three nucleotides directly 5' of the translation initiation codon. "Translation initiation codon" refers to the codon that initiates the translation of the mRNA transcribed from the nucleotide sequence of interest. The composition of these translation initiation context nucleotide sequences can influence the efficiency of translation initiation. See, for example, Lukaszewicz *et al.* (2000) *Plant Science* 154:89-98; and Joshi *et al.* (1997); *Plant Mol. Biol.* 35:993-1001. In the present invention, the translation initiation context nucleotide sequence for the translation initiation codon of the polynucleotide encoding the antigenic NDV polypeptide of interest, or fragment or variant thereof, may be modified to enhance expression in microalgae. In one embodiment, the nucleotide sequence is modified such that the three nucleotides directly upstream of the translation initiation codon are "ACC." In a second embodiment, these nucleotides are "ACA."

[0109] Expression of an antigenic NDV polypeptide in microalgae or duckweed can also be enhanced by the use of 5' leader sequences. Such leader sequences can act to enhance translation. Translation leaders are known in the art and include, but are not limited to, picornavirus leaders, e.g., EMCV leader (Encephalomyocarditis 5' noncoding region; Elroy-Stein *et al.* (1989) *PNAS USA* 86:6126); potyvirus leaders, e.g., TEV leader (Tobacco Etch Virus; Allison *et al.* (1986) *Virology* 154:9); human immunoglobulin heavy-chain binding protein (BiP; Macajak and Sarnow (1991) *Nature* 353:90); untranslated leader from the coat protein mRNA of alfalfa mosaic virus (AMV RNA 4; Jobling and Gehrke (1987) *Nature* 325:622); tobacco mosaic virus leader (TMV; Gallie (1989) *Molecular Biology of RNA*,

23:56); potato etch virus leader (Tomashevskaya *et al.* (1993) *J. Gen. Virol.* 74:2717-2724); Fed-1 5' untranslated region (Dickey (1992) *EMBO J.* 11:2311-2317); RbcS 5' untranslated region (Silverthorne *et al.* (1990) *J. Plant. Mol. Biol.* 15:49-58); and maize chlorotic mottle virus leader (MCMV; Lommel *et al.* (1991) *Virology* 81:382). See also, Della-Cioppa *et al.* (1987) *Plant Physiology* 84:965. Leader sequence comprising plant intron sequence, including intron sequence from the maize alcohol dehydrogenase 1 (ADH1) gene, the castor bean catalase gene, or the *Arabidopsis* tryptophan pathway gene PAT1 has also been shown to increase translational efficiency in plants (Callis *et al.* (1987) *Genes Dev.* 1:1183-1200; Mascarenhas *et al.* (1990) *Plant Mol. Biol.* 15:913-920).

[0110] In some embodiments of the present invention, nucleotide sequence corresponding to nucleotides 1222-1775 of the maize alcohol dehydrogenase 1 gene (ADH1; GenBank Accession Number X04049) is inserted upstream of the polynucleotide encoding the NDV HN polypeptide, or fragment or variant thereof, to enhance the efficiency of its translation. In another embodiment, the expression cassette contains the leader from the *Lemna gibba* ribulose-bis-phosphate carboxylase small subunit 5B gene (RbcS leader; see Buzby *et al.* (1990) *Plant Cell* 2:805-814).

[0111] It is recognized that any of the expression-enhancing nucleotide sequence modifications described above can be used in the present invention, including any single modification or any possible combination of modifications. The phrase “modified for enhanced expression” in microalgae or duckweed, as used herein, refers to a polynucleotide sequence that contains any one or any combination of these modifications.

Signal Peptide.

[0112] The NDV polypeptide of interest can be normally or advantageously expressed as a secreted protein. Secreted proteins are usually translated from precursor polypeptides that include a “signal peptide” that interacts with a receptor protein on the membrane of the endoplasmic reticulum (ER) to direct the translocation of the growing polypeptide chain across the membrane and into the endoplasmic reticulum for secretion from the cell. This signal peptide may be cleaved from the precursor polypeptide to produce a “mature” polypeptide lacking the signal peptide. The signal peptide may not be cleaved and the entire polypeptide including the signal peptide is secreted from the cell. In an embodiment of the present invention, an NDV HN polypeptide, or fragment or variant thereof, is expressed in microalgae or duckweed from a polynucleotide sequence that is operably linked with a nucleotide sequence encoding a signal peptide that directs secretion of the NDV HN polypeptide, or fragment or variant thereof, into the culture medium. Plant or algae signal

peptides that target protein translocation to the endoplasmic reticulum (for secretion outside of the cell) are known in the art. See, for example, U.S. Patent No. 6,020,169. In the present invention, any plant or algae signal peptide can be used to target the expressed polypeptide to the ER.

[0113] In some embodiments, the signal peptide is the *Arabidopsis thaliana* basic endochitinase signal peptide (amino acids 14-34 of NCBI Protein Accession No. BAA82823), the extensin signal peptide (Stiefel *et al.* (1990) *Plant Cell* 2:785-793), the rice α -amylase signal peptide (amino acids 1-31 of NCBI Protein Accession No. AAA33885; see also GenBank M24286). In another embodiment, the signal peptide corresponds to the signal peptide of a secreted microalgae protein.

[0114] In one embodiment, the signal peptide of the present invention is the NDV HN signal peptide as set forth in SEQ ID NO:13 (encoded by a polynucleotide having the sequence as set forth in SEQ ID NO:12), or SEQ ID NO:21 (encoded by a polynucleotide having the sequence as set forth in SEQ ID NO:27). The NDV HN signal peptide of viral origin showed surprising result in the expression of the NDV protein in microalgae, where it directed the translocation of the polypeptide chain across the membrane and into the endoplasmic reticulum for secretion from the cell.

[0115] Alternatively, a mammalian signal peptide can be used to target the recombinantly produced antigenic NDV polypeptide for secretion from microalgae. It has been demonstrated that plant cells recognize mammalian signal peptides that target the endoplasmic reticulum, and that these signal peptides can direct the secretion of polypeptides not only through the plasma membrane but also through the plant cell wall. See U.S. Patent Nos. 5,202,422 and 5,639,947.

[0116] In one embodiment, the nucleotide sequence encoding the signal peptide is modified for enhanced expression in microalgae, utilizing any modification or combination of modifications disclosed above for the polynucleotide sequence of interest.

[0117] The secreted NDV HN polypeptide, or fragment or variant thereof, can be harvested from the culture medium by any conventional means known in the art, including, but not limited to, chromatography, electrophoresis, dialysis, solvent-solvent extraction, and the like. In so doing, partially or substantially purified antigenic NDV polypeptide, or fragment or variant thereof, can be obtained from the culture medium.

Transformed Microalgae or duckweed

[0118] The present invention provides transformed microalgae or duckweed plant expressing an NDV HN polypeptide, or fragment or variant thereof. The term “microalgae” refers to members of the family *Thraustochytriaceae*. This family currently is divided into four genera: *Schizochytrium*, *Thraustochytrium*, *Labyrinthuloides*, and *Japonochytrium*. Exemplary *Schizochytrium* include, but not limited to, *Schizochytrium aggregatum*, *Schizochytrium limacinum*, *Schizochytrium* sp. (S31) (ATCC 20888), *Schizochytrium* sp. (S8) (ATCC 20889), *Schizochytrium* sp. (LC-RM) (ATCC 18915), *Schizochytrium* sp. (SR21) (ATCC 28209) and deposited *Schizochytrium limacinum* strain IFO 32693 (Honda et Yokochi).

[0119] The term “duckweed” refers to members of the family *Lemnaceae*. This family currently is divided into five genera and 38 species of duckweed as follows: genus *Lemna* (*L. aequinoctialis*, *L. disperma*, *L. ecuadoriensis*, *L. gibba*, *L. japonica*, *L. minor*, *L. miniscula*, *L. obscura*, *L. perpusilla*, *L. tenera*, *L. trisulca*, *L. turionifera*, *L. valdiviana*); genus *Spirodela* (*S. intermedia*, *S. polyrrhiza*, *S. punctata*); genus *Wolffia* (*Wa. angusta*, *Wa. arrhiza*, *Wa. australina*, *Wa. borealis*, *Wa. brasiliensis*, *Wa. columbiana*, *Wa. elongata*, *Wa. globosa*, *Wa. microscopica*, *Wa. neglecta*); genus *Wolffiella* (*Wl. caudata*, *Wl. denticulata*, *Wl. gladiata*, *Wl. hyalina*, *Wl. lingulata*, *Wl. repunda*, *Wl. rotunda*, and *Wl. neotropica*) and genus *Landoltia* (*L. punctata*). *Lemna* species can be classified using the taxonomic scheme described by Landolt (1986) *Biosystematic Investigation on the Family of Duckweeds: The family of Lemnaceae—A Monograph Study* (Geobotanischen Institut ETH, Stiftung Rubel, Zurich).

[0120] As used herein, “plant” includes whole plants, plant organs (*e.g.*, fronds (leaves), stems, roots, *etc.*), seeds, plant cells, and progeny of same. Parts of transgenic plants are to be understood within the scope of the invention to comprise, *e.g.*, plant cells, plant protoplasts, plant cell tissue cultures from which plants can be regenerated, tissues, plant calli, embryos as well as flowers, ovules, stems, fruits, leaves, roots, root tips, nodules, and the like originating in transgenic plants or their progeny previously transformed with a polynucleotide of interest and therefore consisting at least in part of transgenic cells.

[0121] The transformed microalgae or duckweed plants of the invention can be obtained by introducing an expression construct comprising a polynucleotide encoding an NDV HN polypeptide, or fragment or variant thereof, into the microalgae or duckweed plant of interest.

[0122] The term “introducing” in the context of a polynucleotide, for example, an expression construct comprising a polynucleotide encoding an antigenic NDV polypeptide, or fragment or variant thereof, is intended to mean presenting to the microalgae or duckweed

plants the polynucleotide in such a manner that the polynucleotide gains access to the interior of a cell of the microalgae or duckweed. Where more than one polynucleotide is to be introduced, these polynucleotides can be assembled as part of a single nucleotide construct, or as separate nucleotide constructs, and can be located on the same or different transformation vectors. Accordingly, these polynucleotides can be introduced into the microalgae or duckweed host cell of interest in a single transformation event, in separate transformation events, or, for example, as part of a breeding protocol. The compositions and methods of the invention do not depend on a particular method for introducing one or more polynucleotides into microalgae, only that the polynucleotide(s) gains access to the interior of at least one cell of the microalgae or duckweed plants. Methods for introducing polynucleotides into plants or algae are known in the art including, but not limited to, transient transformation methods, stable transformation methods, and virus-mediated methods.

[0123] “Transient transformation” in the context of a polynucleotide such as a polynucleotide encoding an NDV HN polypeptide, or fragment or variant thereof, is intended to mean that a polynucleotide is introduced into the microalgae or duckweed and does not integrate into the genome of the microalgae or duckweed.

[0124] By “stably introducing” or “stably introduced” in the context of a polynucleotide (such as a polynucleotide encoding an NDV HN polypeptide, or fragment or variant thereof) introduced into microalgae or duckweed is intended the introduced polynucleotide is stably incorporated into the microalgae or duckweed genome, and thus the microalgae or duckweed plant is stably transformed with the polynucleotide.

[0125] “Stable transformation” or “stably transformed” is intended to mean that a polynucleotide, for example, a polynucleotide encoding an NDV HN polypeptide, or fragment or variant thereof, introduced into microalgae or duckweed plant integrates into the genome of the microalgae or plant and is capable of being inherited by the progeny thereof, more particularly, by the progeny of multiple successive generations. In some embodiments, successive generations include progeny produced vegetatively (i.e., asexual reproduction), for example, with clonal propagation. In other embodiments, successive generations include progeny produced via sexual reproduction.

[0126] An expression construct comprising a polynucleotide encoding an NDV HN polypeptide, or fragment or variant thereof, can be introduced into microalgae or plant of interest using any transformation protocol known to those of skill in art. Suitable methods of introducing nucleotide sequences into microalgae or plant cells or nodules include

microinjection (Crossway *et al.* (1986) *Biotechniques* 4:320-334), electroporation (Riggs *et al.* (1986) *PNAS USA* 83:5602-5606), *Agrobacterium*-mediated transformation (U.S. Patent Nos. 5,563,055 and 5,981,840), direct gene transfer (Paszkowski *et al.* (1984) *EMBO J.* 3:2717-2722), ballistic particle acceleration (see, *e.g.*, U.S. Patent Nos. 4,945,050; 5,879,918; 5,886,244; and 5,932,782); and Tomes *et al.* (1995) "Direct DNA Transfer into Intact Plant Cells via Microprojectile Bombardment," in *Plant Cell, Tissue, and Organ Culture: Fundamental Methods*, ed. Gamborg and Phillips (Springer-Verlag, Berlin); McCabe *et al.* (1988) *Biotechnology* 6:923-926). The cells that have been transformed may be grown into plants or algae in accordance with conventional ways.

[0127] As noted above, stably transformed microalgae or plants can be obtained by any gene transfer method known in the art, such as one of the gene transfer methods disclosed in U.S. Patent No. 6,040,498 or U.S. Patent Application Publication Nos. 2003/0115640, 2003/0033630 or 2002/0088027. Microalgal or plants can be efficiently transformed with an expression cassette containing a nucleic acid sequence as described herein by any one of a number of methods including *Agrobacterium*-mediated gene transfer, ballistic bombardment or electroporation. The *Agrobacterium* used can be *Agrobacterium tumefaciens* or *Agrobacterium rhizogenes*. Stable microalgae or plant transformants can be isolated by transforming the microalgae or plant cells with both the nucleic acid sequence of interest and a gene that confers resistance to a selection agent, followed by culturing the transformed cells in a medium containing the selection agent. *See*, for example, U.S. Patent No. 6,040,498.

[0128] The stably transformed microalgae or plants utilized in these methods should exhibit normal morphology and be fertile by sexual reproduction and/or able to reproduce vegetatively (*i.e.*, asexual reproduction), for example, with clonal propagation. Preferably, transformed microalgae or plants of the present invention contain a single copy of the transferred nucleic acid comprising a polynucleotide encoding an NDV HN polypeptide, or fragment or variant thereof, and the transferred nucleic acid has no notable rearrangements therein. It is recognized that the transformed microalgae of the invention may contain the transferred nucleic acid present in low copy numbers (*i.e.*, no more than twelve copies, no more than eight copies, no more than five copies, alternatively, no more than three copies, as a further alternative, fewer than three copies of the nucleic acid per transformed cell).

[0129] Transformed plants or algae expressing an NDV HN polypeptide, or fragment or variant thereof, can be cultured under suitable conditions for expressing the NDV HN polypeptide, or fragment or variant thereof. The NDV HN polypeptide, or fragment or variant thereof, can then be harvested from the microalgae, the culture medium, or the

microalgae and the culture medium, and, where desired, purified using any conventional isolation and purification method known in the art, including chromatography, electrophoresis, dialysis, solvent-solvent extraction, and the like. The NDV HN polypeptide, or fragment or variant thereof, can then be formulated as a vaccine for therapeutic applications, as described elsewhere herein.

Methods of Preparing an NDV Polypeptide

[0130] As described fully herein, in an embodiment, a method of producing a recombinant NDV HN polypeptide comprises: (a) culturing microalgal or duckweed plants within a microalgal or duckweed culture medium, wherein the microalgal or duckweed plants are stably transformed to express the NDV polypeptide, and wherein the NDV polypeptide is expressed from a nucleotide sequence comprising a coding sequence for said recombinant NDV polypeptide and an operably linked coding sequence for a signal peptide that directs secretion of the NDV polypeptide into the culture medium; and (b) collecting the NDV polypeptide from said culture medium. The term collecting includes but is not limited to harvesting from the culture medium or purifying.

[0131] After production of the recombinant polypeptide in microalgae or plants, any method available in the art may be used for protein purification. The various steps include freeing the protein from the nonprotein or algae or plant material, followed by the purification of the protein of interest from other proteins. The recombinant protein may be a secreted protein that is isolated from the culture medium following its production by the cell and may comprise a signal peptide. Said signal peptide may be cleaved following secretion, to produce a mature protein product. Depending on the vector and host system used for production, resultant recombinant NDV polypeptides of the present invention may either remain within the recombinant cell or be secreted into the fermentation medium or be secreted into a space between two cellular membranes; or be retained on the outer surface of a cell membrane. Initial steps in the purification process include centrifugation, filtration or a combination thereof. After the initial centrifugation at low speed, the low speed supernatant may be used for pharmaceutical composition or vaccine preparation. The low speed supernatant may undergo further purification using various method described below. Proteins secreted within the extracellular space of tissues can be obtained using vacuum or centrifugal extraction. Minimal processing could also involve preparation of crude products. Other methods include maceration and extraction in order to permit the direct use of the extract.

[0132] Recombinant proteins produced by the method of the present invention may be purified using a variety of standard protein purification techniques, such as, but not limited

to, centrifugation, filtration, affinity chromatography, ion exchange chromatography, electrophoresis, hydrophobic interaction chromatography, gel filtration chromatography, reverse phase chromatography, concanavalin A chromatography, chromatofocusing and differential solubilization. Methods to purify the protein of interest may exploit differences in protein size, physio-chemical properties, and binding affinity. Such methods include chromatography, including procainamide affinity, size exclusion, high pressure liquid, reversed-phase, and anion-exchange chromatography, affinity tags, etc. In particular, immobilized Ni-ion affinity chromatography can be used to purify the expressed protein. See, Favacho *et al.* (2006) Protein expression and purification 46:196-203. See also, Zhou *et al.* (2007) The Protein J 26:29-37; Wang *et al.* (2006) Vaccine 15:2176-2185; and WO/2009/076778. Protectants may be used in the purification process such as osmotica, antioxidants, phenolic oxidation inhibitors, protease inhibitors, and the like.

Methods of Use and Article of Manufacture

[0133] The present invention includes the following method embodiments. In an embodiment, a method of vaccinating an animal comprising administering a composition comprising NDV antigenic polypeptide(s) or fragment or variant thereof and a pharmaceutical or veterinarily acceptable carrier, excipient, or vehicle to an animal is disclosed. In one aspect of this embodiment, the animal is an avian, an equine, a canine, a feline or a porcine.

[0134] In yet another embodiment, the vaccine or composition may be administered to one-day-old or older chickens.

[0135] In one embodiment of the invention, a prime-boost regimen can be employed, which is comprised of at least one primary administration and at least one booster administration using at least one common polypeptide, antigen, epitope or immunogen. Typically the immunological composition or vaccine used in primary administration is different in nature from those used as a booster. However, it is noted that the same composition can be used as the primary administration and the booster administration. This administration protocol is called “prime-boost”.

[0136] In the present invention a recombinant viral vector is used to express an NDV coding sequence or fragments thereof encoding an antigenic NDV polypeptide or fragment or variant thereof. Specifically, the viral vector can express an NDV sequence, more specifically an NDV HN gene or fragment thereof that encodes an antigenic polypeptide. Viral vector contemplated herein includes, but not limited to, poxvirus [e.g., vaccinia virus or

attenuated vaccinia virus, avipox virus or attenuated avipox virus (e.g., canarypox, fowlpox, dovepox, pigeonpox, quailpox, ALVAC, TROVAC; see e.g., US 5,505,941, US 5,494,8070), raccoonpox virus, swinepox virus, etc.], adenovirus (e.g., human adenovirus, canine adenovirus), herpesvirus (e.g. canine herpesvirus, herpesvirus of turkey, Marek's disease virus, infectious laryngotracheitis virus, feline herpesvirus, laryngotracheitis virus (ILTV), bovine herpesvirus, swine herpesvirus), baculovirus, retrovirus, etc. In another embodiment, the avipox expression vector may be a canarypox vector, such as, ALVAC. In yet another embodiment, the avipox expression vector may be a fowlpox vector, such as, TROVAC. The NDV polypeptide, antigen, epitope or immunogen may be an NDV HN. For example, the TROVAC vector comprising the NDV HN or F may be vectors as described in US 7,144,578 and US 2008/0188640, the ILTV vector comprising the NDV antigens including HN and F may be vectors as described in US 6,306,400 and US 6,153,199. The NDV polypeptide or antigen of the invention to be expressed in a viral vector is inserted under the control of a specific poxvirus promoter, e.g., the vaccinia promoter 7.5 kDa (Cochran et al., 1985), the vaccinia promoter 13L (Riviere et al., 1992), the vaccinia promoter HA (Shida, 1986), the cowpox promoter ATI (Funahashi et al., 1988), the vaccinia promoter H6 (Taylor et al., 1988b; Guo et al., 1989; Perkus et al., 1989), *inter alia*.

[0137] In another aspect of the prime-boost protocol or regime of the invention, a composition comprising an NDV antigen of the invention is administered followed by the administration of a recombinant viral vector or a plasmid vector that contains and expresses an NDV antigen and/or variants or fragments thereof *in vivo*. Likewise, a prime-boost protocol may comprise the administration of a recombinant viral vector or a plasmid vector followed by the administration of a recombinant NDV antigen of the invention. It is further noted that both the primary and the secondary administrations may comprise the recombinant NDV antigen of the invention. Thus, the recombinant NDV antigen of the invention may be administered in any order with a viral vector or alternatively may be used alone as both the primary and secondary compositions.

[0138] In yet another aspect of the prime-boost protocol of the invention, a composition comprising an NDV antigen of the invention is administered followed by the administration of an inactivated viral composition or vaccine comprising the NDV antigen. Likewise, a prime-boost protocol may comprise the administration of an inactivated viral composition or vaccine followed by the administration of a recombinant NDV antigen of the invention. It is further noted that both the primary and the secondary administrations may comprise the recombinant antigenic polypeptide of the invention. The antigenic polypeptides of the

invention may be administered in any order with an inactivated viral composition or vaccine or alternatively may be used alone as both the primary and secondary compositions.

[0139] A prime-boost regimen comprises at least one prime-administration and at least one boost administration using at least one common polypeptide and/or variants or fragments thereof. The vaccine used in prime-administration may be different in nature from those used as a later booster vaccine. The prime-administration may comprise one or more administrations. Similarly, the boost administration may comprise one or more administrations.

[0140] The dose volume of compositions for target species that are mammals, e.g., the dose volume of avian compositions, based on viral vectors, e.g., non-poxvirus-viral-vector-based compositions, is generally between about 0.1 to about 2.0 ml, between about 0.1 to about 1.0 ml, and between about 0.5 ml to about 1.0 ml.

[0141] The compositions comprising the recombinant antigenic polypeptides of the invention used in the prime-boost protocols are contained in a pharmaceutically or veterinary acceptable vehicle, diluent or excipient. The protocols of the invention protect the animal from NDV and/or prevent disease progression in an infected animal.

[0142] The various administrations are preferably carried out 1 to 6 weeks apart. According to one embodiment, an annual booster is also envisioned. The animals are at least one-day-old at the time of the first administration.

[0143] The efficacy of the vaccines may be tested about 2 to 4 weeks after the last immunization by challenging animals, such as avian, with a virulent strain of NDV. Both homologous and heterologous strains are used for challenge to test the efficacy of the vaccine. The animal may be challenged by spray, intra-nasally, intra-ocularly, intra-tracheally, and/or orally. The challenge viral may be about 10^{5-8} EID₅₀ in a volume depending upon the route of administration. For example, if the administration is by spray, a virus suspension is aerosolized to generate about 1 to 100 μ m droplets, if the administration is intra-nasal, intra-tracheal or oral, the volume of the challenge virus is about 0.5 ml, 1-2 ml, and 5-10 ml, respectively. Animals may be observed daily for 14 days following challenge for clinical signs, for example, dehydration and pasty vents. In addition, the groups of animals may be euthanized and evaluated for pathological findings of pulmonary and pleural hemorrhage, tracheitis, bronchitis, bronchiolitis, and bronchopneumonia. Oropharyngeal swabs may be collected from all animals post challenge for virus isolation. The presence or absence of viral antigens in respiratory tissues may be evaluated by quantitative real time reverse transcriptase polymerase chain reaction (qRRT-PCR). Blood samples may be

collected before and post-challenge and may be analyzed for the presence of NDV-specific antibody.

[0144] It should be understood by one of skill in the art that the disclosure herein is provided by way of example and the present invention is not limited thereto. From the disclosure herein and the knowledge in the art, the skilled artisan can determine the number of administrations, the administration route, and the doses to be used for each injection protocol, without any undue experimentation.

[0145] The present invention contemplates at least one administration to an animal of an efficient amount of the therapeutic composition made according to the invention. The animal may be male, female, pregnant female and newborn. This administration may be via various routes including, but not limited to, intramuscular (IM), intradermal (ID) or subcutaneous (SC) injection or via intranasal or oral administration. The therapeutic composition according to the invention can also be administered by a needleless apparatus (as, for example with a Pigjet, Dermojet, Biojector, Avijet (Merial, GA, USA), Vctjet or Vitajet apparatus (Bioject, Oregon, USA)). Another approach to administering plasmid compositions is to use electroporation (see, e.g. Tollefsen et al., 2002; Tollefsen et al., 2003; Babiuk et al., 2002; PCT Application No. WO99/01158). In another embodiment, the therapeutic composition is delivered to the animal by gene gun or gold particle bombardment.

[0146] In one embodiment, the subject matter disclosed herein provides a vaccination regime and detection method for differentiation between infected and vaccinated animals (DIVA).

[0147] A strategy that allows “differentiation of infected from vaccinated animals” (DIVA), has been put forward as a possible solution for the eventual eradication of virus without involving mass culling of birds and the consequent economic damage, especially in developing countries (Food and Agriculture Organization of the United (FAO) (2004). FAO, OIE & WHO Technical consultation on the Control of NDV. Animal health special report). This strategy has the benefits of vaccination (less virus in the environment) with the ability to identify infected flocks which still allows the implementation of other control measures, including stamping out. At the flock level, a simple approach is to regularly monitor sentinel birds left unvaccinated in each vaccinated flock, but this may cause some management problems, particularly in identifying the sentinels in large flocks. As an alternative, testing for field exposure may be performed on the vaccinated birds. Alternatively the use of vaccines that contains only NDV HN subunit (protein) would allow classical AGID and NP-or matrix-based ELISAs to be used to detect infection in vaccinated birds.

[0148] It is disclosed herein that the use of the vaccine or composition of the present invention allows the detection of NDV infection in a vaccinated animal using available diagnosis test aiming to detect antibody response against NDV proteins other than HA such as agar gel immunodiffusion or NP-based ELISA. It is disclosed herein that the use of the vaccine or composition of the present invention allows the detection of the infection in animals by differentiating between infected and vaccinated animals (DIVA). A method is disclosed herein for diagnosing the infection of NDV in an animal using NP-based immunogenic detection method, such as, NP-based ELISA. In one embodiment, the subject matter disclosed herein is directed to a method of diagnosing NDV infection in an animal, comprising: a) contacting a solid substrate comprising a nucleoprotein (NP) with a sample obtained from the animal; b) contacting the solid substrate with a monoclonal antibody (MAb) against the NP; and c) detecting binding of the MAb to the sample captured by the NP on the solid substrate, wherein the percentage inhibition of test sample relative to the negative control indicates that the subject is infected with NDV, thereby diagnosing NDV infection in the subject.

[0149] Another embodiment of the invention is a kit for performing a method of eliciting or inducing an immunological or protective response against NDV in an animal comprising a recombinant NDV HN immunological composition or vaccine and instructions for performing the method of delivery in an effective amount for eliciting an immune response in the animal.

[0150] In an embodiment, the subject matter disclosed herein is directed to a kit for performing a method of eliciting or inducing an immune response which may comprise any one of the recombinant NDV immunological compositions or vaccines, or inactivated NDV immunological compositions or vaccines, recombinant NDV viral compositions or vaccines, and instructions for performing the method.

[0151] Another embodiment of the invention is a kit for performing a method of inducing an immunological or protective response against NDV in an animal comprising a composition or vaccine comprising an NDV antigen of the invention and a recombinant NDV viral immunological composition or vaccine, and instructions for performing the method of delivery in an effective amount for eliciting an immune response in the animal.

[0152] Another embodiment of the invention is a kit for performing a method of inducing an immunological or protective response against NDV in an animal comprising a composition or vaccine comprising an NDV antigen of the invention and an inactivated NDV


immunological composition or vaccine, and instructions for performing the method of delivery in an effective amount for eliciting an immune response in the animal.

[0153] Yet another aspect of the present invention relates to a kit for prime-boost vaccination according to the present invention as described above. The kit may comprise at least two vials: a first vial containing a vaccine or composition for the prime-vaccination according to the present invention, and a second vial containing a vaccine or composition for the boost-vaccination according to the present invention. The kit may advantageously contain additional first or second vials for additional prime-vaccinations or additional boost-vaccinations.

[0154] In one embodiment, the invention provides for the administration of a therapeutically effective amount of a vaccine or composition for the delivery and expression of an NDV HN antigen or epitope in a target cell. Determination of the therapeutically effective amount is routine experimentation for one of ordinary skill in the art. In one embodiment, the vaccine or composition comprises a recombinant NDV HN polypeptide, antigen or epitope and a pharmaceutically or veterinarily acceptable carrier, vehicle or excipient. In another embodiment, the pharmaceutically or veterinarily acceptable carrier, vehicle or excipient facilitates transfection or infection and/or improves preservation of the vector or protein.

[0155] The pharmaceutically or veterinarily acceptable carriers or vehicles or excipients are well known to the one skilled in the art. For example, a pharmaceutically or veterinarily acceptable carrier or vehicle or excipient can be a 0.9% NaCl (e.g., saline) solution or a phosphate buffer. Other pharmaceutically or veterinarily acceptable carrier or vehicle or excipients that can be used for methods of this invention include, but are not limited to, poly-(L-glutamate) or polyvinylpyrrolidone. The pharmaceutically or veterinarily acceptable carrier or vehicle or excipients may be any compound or combination of compounds facilitating the administration of the vector or recombinant proteins; advantageously, the carrier, vehicle or excipient may facilitate transfection and/or improve preservation of the vector or protein. Doses and dose volumes are herein discussed in the general description and can also be determined by the skilled artisan from this disclosure read in conjunction with the knowledge in the art, without any undue experimentation.

[0156] The cationic lipids containing a quaternary ammonium salt which are, but not exclusively suitable for plasmids, those having the following formula:



[0157] in which R1 is a saturated or unsaturated straight-chain aliphatic radical having 12 to 18 carbon atoms, R2 is another aliphatic radical containing 2 or 3 carbon atoms and X is an amine or hydroxyl group, e.g. the DMRIE. In another embodiment the cationic lipid can be associated with a neutral lipid, e.g. the DOPE.

[0158] Among these cationic lipids, preference is given to DMRIE (N-(2-hydroxyethyl)-N,N-dimethyl-2,3-bis(tetradecyloxy)-1-propane ammonium; WO96/34109), advantageously associated with a neutral lipid, advantageously DOPE (dioleoyl-phosphatidyl-ethanol amine; Behr, 1994), to form DMRIE-DOPE.

[0159] When DOPE is present, the DMRIE:DOPE molar ratio is advantageously about 95: about 5 to about 5: about 95, more advantageously about 1: about 1, e.g., 1:1.

[0160] In another embodiment, pharmaceutically or veterinarily acceptable carrier, excipient, vehicle, or adjuvant may be a water-in-oil emulsion. Examples of suitable water-in-oil emulsions include oil-based water-in-oil vaccinal emulsions which are stable and fluid at 4°C containing: from 6 to 50 v/v % of an antigen-containing aqueous phase, preferably from 12 to 25 v/v %, from 50 to 94 v/v % of an oil phase containing in total or in part a non-metabolizable oil (e.g., mineral oil such as paraffin oil) and/or metabolizable oil (e.g., vegetable oil, or fatty acid, polyol or alcohol esters), from 0.2 to 20 p/v % of surfactants, preferably from 3 to 8 p/v %, the latter being in total or in part, or in a mixture either polyglycerol esters, said polyglycerol esters being preferably polyglycerol (poly)ricinoleates, or polyoxyethylene ricin oils or else hydrogenated polyoxyethylene ricin oils. Examples of surfactants that may be used in a water-in-oil emulsion include ethoxylated sorbitan esters (e.g., polyoxyethylene (20) sorbitan monooleate (TWEEN 80®), available from AppliChem, Inc., Cheshire, CT) and sorbitan esters (e.g., sorbitan monooleate (SPAN 80®), available from Sigma Aldrich, St. Louis, MO). In addition, with respect to a water-in-oil emulsion, see also US 6,919,084. The water-in-oil emulsion may comprise 75% oil phase containing mineral oil and 4% SPAN 80® and 25% aqueous phase containing 0.4% TWEEN 80®. In some embodiments, the antigen-containing aqueous phase comprises a saline solution comprising one or more buffering agents. An example of a suitable buffering solution is phosphate buffered saline. In one embodiment, the water-in-oil emulsion may be a water/oil/water (W/O/W) triple emulsion (U.S. 6,358,500). The WOW triple emulsion may

51440-197

comprise 60% oil phase containing mineral oil and 6% SPAN 80® and 40% aqueous phase containing 1.6% TWEEN 80®. Examples of other suitable emulsions are described in U.S. 7,371,395.

[0161] The immunological compositions and vaccines according to the invention may comprise or consist essentially of one or more pharmaceutically or veterinarily acceptable carriers, excipients, vehicles, or adjuvants. Suitable carriers or adjuvants for use in the practice of the present invention are (1) polymers of acrylic or methacrylic acid, maleic anhydride and alkenyl derivative polymers, (2) immunostimulating sequences (ISS), such as oligodeoxyribonucleotide sequences having one or more non-methylated CpG units (Klinman et al., 1996; WO98/16247), (3) an oil in water emulsion, such as the SPT emulsion described on page 147 of "Vaccine Design, The Subunit and Adjuvant Approach" published by M. Powell, M. Newman, Plenum Press 1995, and the emulsion MF59 described on page 183 of the same work, (4) cation lipids containing a quaternary ammonium salt, e.g., DDA (5) cytokines, (6) aluminum hydroxide or aluminum phosphate, (7) saponin or (8) other adjuvants discussed in any document cited and incorporated by reference into the instant application, or (9) any combinations or mixtures thereof.

[0162] The oil in water emulsion (3), which is especially appropriate for viral vectors, can be based on: light liquid paraffin oil (European pharmacopoeia type), isoprenoid oil such as squalane, squalene, oil resulting from the oligomerization of alkenes, e.g. isobutene or decene, esters of acids or alcohols having a straight-chain alkyl group, such as vegetable oils, ethyl oleate, propylene glycol, di(caprylate/caprate), glycerol tri(caprylate/caprate) and propylene glycol dioleate, or esters of branched, fatty alcohols or acids, especially isostearic acid esters.

[0163] The oil is used in combination with emulsifiers to form an emulsion. The emulsifiers may be nonionic surfactants, such as: esters of on the one hand sorbitan, mannide (e.g. anhydromannitol oleate), glycerol, polyglycerol or propylene glycol and on the other hand oleic, isostearic, ricinoleic or hydroxystearic acids, said esters being optionally ethoxylated, or polyoxypropylene-polyoxyethylene copolymer blocks, such as PluronicTM, e.g., L121.


[0164] Among the type (1) adjuvant polymers, preference is given to polymers of crosslinked acrylic or methacrylic acid, especially crosslinked by polyalkenyl ethers of sugars or polyalcohols. These compounds are known under the name carbomer (Pharmeuropa, vol. 8, no. 2, June 1996). One skilled in the art can also refer to U.S. 2,909,462, which provides such acrylic polymers crosslinked by a polyhydroxyl compound having at least three

51440-197

hydroxyl groups, preferably no more than eight such groups, the hydrogen atoms of at least three hydroxyl groups being replaced by unsaturated, aliphatic radicals having at least two carbon atoms. The preferred radicals are those containing 2 to 4 carbon atoms, e.g. vinyls, allyls and other ethylenically unsaturated groups. The unsaturated radicals can also contain other substituents, such as methyl. Products sold under the name Carbopol (BF Goodrich, Ohio, USA) are especially suitable. They are crosslinked by allyl saccharose or by allyl pentaerythritol. Among them, reference is made to Carbopol 974P, 934P and 971P.

[0165] As to the maleic anhydride-alkenyl derivative copolymers, preference is given to EMA (Monsanto), which are straight-chain or crosslinked ethylene-maleic anhydride copolymers and they are, for example, crosslinked by divinyl ether. Reference is also made to J. Fields et al., 1960.

[0166] With regard to structure, the acrylic or methacrylic acid polymers and EMA are preferably formed by basic units having the following formula:



in which:

- R1 and R2, which can be the same or different, represent H or CH3
- x = 0 or 1, preferably x = 1
- y = 1 or 2, with x + y = 2.

For EMA, x = 0 and y = 2 and for carbomers x = y = 1.

[0167] These polymers are soluble in water or physiological salt solution (20 g/l NaCl) and the pH can be adjusted to 7.3 to 7.4, e.g., by soda (NaOH), to provide the adjuvant solution in which the expression vector(s) can be incorporated. The polymer concentration in the final immunological or vaccine composition can range between about 0.01 to about 1.5% w/v, about 0.05 to about 1% w/v, and about 0.1 to about 0.4% w/v.

[0168] The cytokine or cytokines (5) can be in protein form in the immunological or vaccine composition, or can be co-expressed in the host with the immunogen or immunogens or epitope(s) thereof. Preference is given to the co-expression of the cytokine or cytokines, either by the same vector as that expressing the immunogen or immunogens or epitope(s) thereof, or by a separate vector thereof.

[0169] The invention comprehends preparing such combination compositions; for instance by admixing the active components, advantageously together and with an adjuvant, carrier, cytokine, and/or diluent.

[0170] Cytokines that may be used in the present invention include, but are not limited to, granulocyte colony stimulating factor (G-CSF), granulocyte/macrophage colony stimulating factor (GM-CSF), interferon α (IFN α), interferon β (IFN β), interferon γ (IFN γ), interleukin-1 α (IL-1 α), interleukin-1 β (IL-1 β), interleukin-2 (IL-2), interleukin-3 (IL-3), interleukin-4 (IL-4), interleukin-5 (IL-5), interleukin-6 (IL-6), interleukin-7 (IL-7), interleukin-8 (IL-8), interleukin-9 (IL-9), interleukin-10 (IL-10), interleukin-11 (IL-11), interleukin-12 (IL-12), tumor necrosis factor α (TNF α), tumor necrosis factor β (TNF β), and transforming growth factor β (TGF β). It is understood that cytokines can be co-administered and/or sequentially administered with the immunological or vaccine composition of the present invention. Thus, for instance, the vaccine of the instant invention can also contain an exogenous nucleic acid molecule that expresses *in vivo* a suitable cytokine, e.g., a cytokine matched to this host to be vaccinated or in which an immunological response is to be elicited (for instance, an avian cytokine for preparations to be administered to avians).

[0171] The invention will now be further described by way of the following non-limiting examples.

EXAMPLES

[0172] Without further elaboration, it is believed that one skilled in the art can, using the preceding descriptions, practice the present invention to its fullest extent. The following detailed examples are to be construed as merely illustrative, and not limitations of the preceding disclosure in any way whatsoever. Those skilled in the art will promptly recognize appropriate variations from the procedures both as to reactants and as to reaction conditions and techniques.

[0173] Construction of DNA inserts, plasmids and recombinant microalgal or plant vectors was carried out using the standard molecular biology techniques described by J. Sambrook *et al.* (Molecular Cloning: A Laboratory Manual, 2nd Edition, Cold Spring Harbor Laboratory, Cold Spring Harbor, New York, 1989).

Example 1 Construction of vectors for the NDV HN gene and transformation

[0174] The vector pAB0018 (ATCC deposit no. PTA9616) was digested with *Bam*HI and *Nde*I resulting in two fragments of 838 bp and 9879 bp. The larger fragment was fractionated by standard electrophoretic techniques in an agar gel, and purified using commercial DNA purification kits. This 9879 bp fragment was ligated to a codon-optimized NDV HN gene (SEQ ID NO:1) which had also been previously digested with *Bam*HI and *Nde*I. The ligation was then used to transform commercially supplied strains of competent *E. coli* DH5- α cells (Invitrogen, Carlsbad, CA, USA) using the manufacturer's protocols. These plasmids were then screened by restriction digests or PCR to confirm that the ligation generated the expected plasmid structures. One such plasmid vector resulting from this procedure was verified by Sanger sequencing and designated pCL0081. The specific nucleic acid sequence of NDV HN gene has been optimized for expression in *Schizochytrium* sp. Additionally, the vector pCL0081 contained a selection marker cassette conferring resistance to *Schizochytrium* transformants grown in the presence of sulfometuron methy, a promoter from the *Schizochytrium* elongation factor-1 gene (EF1) to drive expression of the HN transgene, and following the HN transgene, and the OrfC terminator (also known as the PFA3 terminator).

[0175] *Schizochytrium* sp. (ATCC 20888) was used as a host for transformation with the vector pCL0081 using electroporation method. Cells were grown in M50-20 media on a shaker at 200 rpm for 48 hrs at 29°C. The cells were diluted at 1:100 into fresh media and grown overnight. The cells were centrifuged and resuspended in 1 M mannitol, 10mM CaCl₂ (pH 5.5) to a final concentration of 2 OD₆₀₀ units. 5 mL of cells were mixed with 0.25 mg/mL Protease XIV (Sigma Chemical) and incubated on a shaker for 4 hrs. The cells were washed twice with 10% ice cold glycerol and resuspended in 500 uL of cold 10% glycerol. 90 uL was aliquoted into a prechilled 0.2 cm gap electro-cuvettes (Biorad 165-2086). 10 ul of DNA (1-5 ug) was added to the cuvette and mixed gently and held on ice. Cells were electroporated at 200 ohms (resistance), 25 uF, 250V (0.1 cm gap) 500V (0.2 cm gap). 0.5mL of media was added immediately to the cuvette. The cells were then transferred to 4.5mL of M50-20 media and incubated for 2-3 hrs at 100 rpm on a shaker. The cells were centrifuged and resuspended in 0.5 mL of media and plated onto 2-5 M2B plates with appropriate selection (if needed) and incubated at 29°C.

Example 2 HA analysis of Algae Transformants

[0176] Cryostocks of transgenic strains of *Schizochytrium* (transformed with pCL0081) were grown in M50-20 (described in US 2008/0022422) to confluency, then propagated in

50mL baffled shake flasks at 27°C, 200rpm for 48 hours in a medium containing (per liter) 13.62g Na₂SO₄, 0.72g K₂SO₄, 0.56g KCl, 2.27g MgSO₄·7H₂O, 3g (NH₄)₂SO₄, 0.19g CaCl₂·2H₂O, 3g MSG monohydrate, 21.4g MES, and 0.4g KH₂PO₄. The volume was brought to 900mL with deionized H₂O and the pH was adjusted to 6 before autoclaving for 35min. Filter-sterilized glucose (50g/L), vitamins (2mL/L) and trace metals (2mL/L) were then added to the medium and the volume was adjusted to one liter. The vitamin solution contained 0.16g/L vitamin B12, 9.75g/L thiamine, 3.33g/L Ca-pantothenate. The trace metal solution (pH 2.5) contained 1.00g/L citric acid, 5.15g/L FeSO₄·7H₂O, 1.55g/L MnCl₂·4H₂O, 1.55g/L ZnSO₄·7H₂O, 0.02g/L CoCl₂·6H₂O, 0.02g/L Na₂MoO₄·2H₂O, 1.035g/L CuSO₄·5H₂O, 1.035g/L NiSO₄·6H₂O. All reagents were available commercially.

[0177] *Schizochytrium* cultures were transferred to 50mL conical tubes and centrifuged at 3000g for 15min. This low-speed supernatant was used, as is, for hemagglutination activity assay. A portion of the low-speed supernatant was further centrifuged at 100,000g for one hour. The resulting pellet, insoluble fraction containing the HN protein, was resuspended in phosphate buffer saline (PBS) and used for peptide sequence analysis as well as glycosylation analysis.

[0178] The expression of the HN protein by *Schizochytrium* was first evaluated by an activity assay. The functional HN protein displays an hemagglutination activity which was readily detected by a standard hemagglutination activity assay. Briefly, 50uL of doubling dilutions of low speed supernatant in PBS were prepared in a 96-well microtiter plate. Equal volume of an approximate 1% solution of turkey red blood cells (Fitzgerald Industries, Acton, MA, USA) in PBS was then added to each well followed by incubation at room temperature for 30min. The degree of agglutination was then analyzed visually. The hemagglutination activity unit (HAU) is defined as the highest dilution of low-speed supernatant that causes visible hemagglutination in the well. Typical activity was found to be in the order of 512 HAU in transgenic strain “CL0081-23” (Fig. 3B). PBS or the wild-type strain of *Schizochytrium sp.* ATCC 20888, grown and prepared in the same manner as the transgenic strains, was used as a negative control and did not show any hemagglutination activity. An NDV Hemagglutinin (HA) recombinant protein was used as a positive control. Sample titer was scored at the highest dilution before the defined button was observed. HA activity was detected in raw supernatant (Figure 3A). HAU in concentrated supernatant sample is 3200 HAU/50ul. The hemagglutination activity was found to be stable through multiple rounds of freeze/thaw.

Example 3 Expression Analysis of Algae Transformants

[0179] The expression of the HN protein was also verified by immunoblot analysis following standard immunoblotting procedure. The proteins were separated by sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) on a 4-12% bis-tris gel (Invitrogen). The proteins were then stained with Coomassie blue (SimplyBlue Safe Stain, Invitrogen) or transferred onto polyvinylidene fluoride membrane and probed for the presence of HN protein with anti-NDV antiserum from chicken in 1:1000 dilution (Charles River laboratories, Wilmington, MA, USA) followed by anti-chicken secondary antibody coupled to alkaline phosphatase in 1:5000 dilution (AP-AffiniPure Goat Anti-Chicken #103-055-155, Jackson ImmunoResearch Laboratories, Inc., West Grove, PA, USA). Membrane was then treated with 5-bromo-4-chloro-3-indoyl-phosphate/nitroblue tetrazolium solution (BCIP/NBT) according to the manufacturer's instructions (KPL, Gaithersburg, MD). An example is presented in Fig. 4 for the transgenic strain "CL0081-23". Coomassie blue-stained gels and corresponding anti-NDV immunoblots are presented in panels B and C. The recombinant HN protein was detected in the low-speed supernatant (panel B) and in the insoluble fraction (panel C). The negative control (-Ctrl) was the wild-type strain of *Schizochytrium sp.* ATCC 20888 or the transgenic strain "AB0018".

Example 4 Glycosylation Analysis

[0180] The presence of glycans on the HN protein was first evaluated by enzymatic treatment. The insoluble fraction of the transgenic strain "CL0081-23" was resuspended in PBS and digested with EndoH or PNGase F according to manufacturer's instructions (New England Biolabs, Ipswich, MA, USA). Removal of glycans was then identified by the expected shift in mobility when separating the proteins on 12% SDS-PAGE stained with Coomassie blue, periodic acid, or immunoblotted with anti-NDV antiserum (FIG 5, panel A). The negative control (-Ctrl) of immunoblotting was the transgenic strain "AB0018". The negative control for the enzymatic treatment was the transgenic strain "CL0081-23" incubated without enzymes (non-treated NT). Second, the glycosylation profile of the HN protein produced in *Schizochytrium* was analyzed by matrix-assisted laser-desorption ionization time-of-flight mass spectrometry and NanoSpray ionization-Linear Ion trap Mass spectrometry (Complex Carbohydrate Research Center, Georgia). Coomassie blue-stained gel slices of the proteins of interest were cut into smaller pieces (~1 mm³) and destained alternately with 40mM Ammonium bicarbonate (AmBic) and 100% acetonitrile until the color turned clear. Destained gel was reswelled in 10 mM DTT in 40mM AmBic at 55°C for

51440-197

1 hr. The DTT solution was exchanged with 55mM Iodoacetamide (IAM) and incubated in the dark for 45 min. Incubation was followed by washing alternately with 40mM AmBic and 100% acetonitrile twice. Dehydrated gel was reswelled with trypsin solution (trypsin in 40 mM Ambic) on ice for 45 min initially, and protein digestion was carried out at 37°C overnight. The supernatant was transferred into another tube. Peptides and the glycopeptides were extracted from the gel in series with 20% acetonitrile in 5% formic acid, 50% acetonitrile in 5% formic acid and then 80% acetonitrile in 5% formic acid. The sample solutions were dried and combined into one tube. Extracted tryptic digest was passed through a C18 sep-pak cartridge and washed with 5% acetic acid to remove contaminants (salts, SDS, etc.). Peptides and glycopeptides were eluted in series with 20% iso-propanol in 5% acetic acid, 40% iso-propanol in 5% acetic acid and 100% iso-propanol and dried in a speed vacuum concentrator. The dried samples were combined and then reconstituted with 50 mM sodium phosphate buffer (pH 7.5) and heated at 100°C for 5 min to inactivate trypsin. The tryptic digest was incubated with PNGase F at 37°C overnight to release N-glycans. After digestion, the sample was passed through a C18 sep-pak cartridge and the carbohydrate fraction was eluted with 5% acetic acid and dried by lyophilization. Released N-linked oligosaccharides were permethylated based on the method of Anumula and Taylor (Anumula and Taylor, 1992) and profiled by mass spectrometry. Mass spectrometric analysis was performed following the method developed at the Complex Carbohydrates Research Center (Aoki K, Perlman M, Lim JM, Cantu R, Wells L, Tiemeyer M. J Biol Chem. 2007 Mar 23;282(12):9127-42.). Mass analysis was determined by using NSI-LTQ/MS_n. Briefly, permethylated glycans were dissolved in 1mM NaOH in 50% methanol and infused directly into the instrument (LTQ, Thermo Finnigan) at a constant flow rate of 0.4 µL/min. The MS analysis was performed in the positive ion mode. For total ion mapping, automated MS/MS analysis (at 35 collision energy), m/z range from 500 to 2000 was scanned in successive 2.8 mass unit windows that overlapped the preceding window by 2 mass units. Total ion mapping was performed to examine the presence of fragment ions indicative of glycans. All MS/MS data from m/z 500 through m/z 2000 were taken and then the raw data were analyzed manually. The chromatogram and table of species obtained by NSI-total ion mapping are shown in Figure 5 (panels B and C). This chromatogram was processed by the scan filter, neutral loss of m/z 139, which is the one of characteristic neutral loss of high-mannose type glycans. Total ion mapping revealed that this sample contains a series of high-mannose type glycans with long mannose chain.

51440-197

Example 5 Peptide Analysis of NDV HN

[0181] The insoluble fraction was separated by SDS-PAGE and stained with Coomassie blue or transferred to PVDF and immunoblotted with anti-NDV antiserum from chicken, as described above. The band corresponding to the cross-reaction in immunoblot was excised from the coomassie stained gel and submitted for peptide sequence analysis. The procedure consisted washing/destaining the bands of interest in 50% ethanol, 5% acetic acid. The gel pieces were then dehydrated in acetonitrile, dried in a Speed-vacTM, and digested with trypsin by adding 5 μ L of 10ng/ μ L trypsin in 50mM ammonium bicarbonate and incubating overnight digestion at room temperature. The peptides that were formed were extracted from the polyacrylamide in two aliquots of 30 μ L 50% acetonitrile with 5% formic acid. These extracts were combined and evaporated to <10 μ L in Speed-vacTM and then resuspended in 1% acetic acid to make up a final volume of approximately 30 μ L for LC-MS analysis. The LC-MS system was a Finnigan LTQ linear ion trap mass spectrometer system. The HPLC column was a self-packed 9 cm x 75 μ m id Phenomenex Jupiter C18 reversed-phase capillary chromatography column. Then μ L volumes of the extract were injected and the peptides eluted from the column by an acetonitrile/0.1% formic acid gradient at a flow rate of 0.25 μ L/min were introduced into the source of the mass spectrometer on-line. The microelectrospray ion source was operated at 2.5kV. The digest was analyzed using a selective reaction (SRM) experiments in which the mass spectrometer fragments a series of m/z ratios over the entire course of the LC experiment. The fragmentation pattern of the peptides of interest was then used to produce chromatograms. The peak areas for each peptide was determined and normalized to an internal standard. The internal standards used in this analysis are proteins that have an unchanging abundance between the samples being studied. The final comparison between the two systems is determined by comparing the normalized peak ratios for each protein. The collision induced dissociation spectra were then searched against the ncbi database. The HN protein was identified by a total of 32 peptides covering 68% of the protein sequence. The results with the specific peptides that were sequenced are shown in Fig. 11.

Example 6 Vaccination of Chickens

[0182] Challenge studies were conducted in specific pathogen free (SPF) chickens vaccinated at 3 to 4 weeks of age with *Schizochytrium* expressed NDV HN protein in an adjuvant. Twelve chickens were assigned to each vaccine group. A Group vaccinated with *Schizochytrium* wild type material in the same adjuvant was included as a negative control

group. Three groups of chickens were tested with one shot scheme at three dosage levels (100 HAU, 1000 HAU, and 10000 HAU). The water-in-oil emulsions of the *Schizochytrium* culture medium was given by the intramuscular route in the leg (0.5 ml per site x 2). On day 27, blood samples were collected for hemagglutination inhibition test, and chickens were then challenged intramuscularly with Newcastle Disease Virus GB Texas strain at $10^{4.0}$ EID₅₀ per chicken (Figure 12). The chickens were observed daily to ensure health status of the chickens being challenged. After challenge, the chickens were observed daily for fourteen days for severe clinical signs of NDV, such as but not limited to, extreme nervousness, respiratory distress, nervous signs or death. The mortality data shown in Figure 12 indicate that vaccination with plant derived NDV HN elicits increased protection of 33% at a dose level of 100 HAU, and increased protection of 100% at dose levels of 1000 HAU and 9333 HAU over control.

Example 7 Expression, characterization, immunogenicity and efficacy of NDV HN protein produced in duckweed

[0183] *Lemna minor* protein expression system was used to express NDV HN polypeptide (SEQ ID NO:17, NDV strain YZCQ/Liaoning/08). The *L. minor* optimized HN gene (SEQ ID NO:22 and 23) was cloned into a modified *A. tumefaciens* binary vector (Gasdaska, J., et al., Bioprocessing J. 3, 50–56, 2003). Several vector constructs were made. The constructs contain Super Promoter, 5' leader from *Lemna gibba* RBCS SSU1, and the Nopaline synthase (Nos) terminator. Construct MerH01 contains codon-optimized NDV HN gene with its native signal sequence (signal anchor as shown in the plasmid maps). Construct MerH02 contains codon-optimized NDV HN gene with its native signal sequence and KDEL ER retention sequence. Construct MerH03 contains codon-optimized NDV HN gene (encoding mature HN protein) with the native NDV HN signal sequence replaced with alpha amylase signal sequence. Construct MerH04 contains codon-optimized NDV HN gene with its native signal sequence replaced with alpha amylase signal sequence, and KDEL ER retention sequence. The plasmid maps of the four constructs are shown in Figure 7c. The constructs were transformed to *A. tumefaciens* C58Z707 (Hepburn, A.G. et al., J. Gen. Microbiol. 131, 2961–2969, 1985). Using the *A. tumefaciens* C58Z707 transformed with plant transformation vector constructs, transgenic plants representing individual clonal lines were generated from rapidly growing *L. minor* nodules as described in Yamamoto, Y. et al., In Vitro Cell. Dev. Biol. 37, 349–353 (2001).

-51440-197

[0184] After the transgenic lines are generated, they are screened for expression of NDV HN in the media and the tissue. The plants are grown for two weeks in small research vessels and the resulting media and tissue are collected for analysis. For the tissue analysis, frozen tissue is homogenized, centrifuged and the supernatant is removed for standard hemagglutination assay. The highest lines from the initial screening are being scaled up to provide approximately 1 kg of biomass for further characterization, such as hemagglutination assay, hemagglutination inhibition assay (HI), SDS-PAGE, Western Blot, and immunolocalization.

[0185] Crude plant extract is prepared from transgenic *Lemna* line for evaluation of immunogenicity and efficacy in specific pathogen free (SPF) chickens at 3-4 weeks of age. Twelve chickens are assigned to each vaccine group vaccinated with the composition comprising the recombinant NDV HN polypeptide and an adjuvant. A group vaccinated with *Lemna* wild type material in the same adjuvant is included as a negative control. Other groups of chickens are tested with one shot scheme at different dosage levels. On day 21, blood samples are collected for hemagglutination inhibition test, and chickens are then challenged with different Newcastle Disease Virus strains. After the challenge, the chickens are observed daily for fourteen days for severe clinical signs of NDV, such as but not limited to, extreme nervousness, respiratory distress, nervous signs or death. The composition containing the recombinant NDV HN polypeptide shows efficacy in treating, protecting, and preventing NDV infection and disease.

[0186] All documents cited or referenced in the application cited documents, and all documents cited or referenced herein ("herein cited documents"), and all documents cited or referenced in herein cited documents, together with any manufacturer's instructions, descriptions, product specifications, and product sheets for any products mentioned herein may be employed in the practice of the invention.

[0187] Having thus described in detail preferred embodiments of the present invention, it is to be understood that the invention defined by the above paragraphs is not to be limited to particular details set forth in the above description as many apparent variations thereof are possible without departing from the spirit or scope of the present invention.

SEQUENCE LISTING IN ELECTRONIC FORM

In accordance with Section 111(1) of the Patent Rules, this description contains a sequence listing in electronic form in ASCII text format (file: 51440-197 Seq 21-JUN-12 v1.txt).

A copy of the sequence listing in electronic form is available from the Canadian Intellectual Property Office.

The sequences in the sequence listing in electronic form are reproduced in the following table.

SEQUENCE TABLE

<110> Merial Limited
 Guo, Xuan
 Troupe, Karolyn
 Feilmeier, Bradley
 Pritchard, Joyce
 Cruz-Coy, Julio

<120> Recombinant NDV antigen and uses thereof

<130> 51440-197

<140> CA national phase of PCT/US2010/062209
 <141> 2010-12-28

<150> 61/290,297
 <151> 2009-12-28

<160> 28

<170> PatentIn version 3.5

<210> 1
 <211> 1716
 <212> DNA
 <213> artificial sequence

<220>
 <223> NDV HN codon-optimized DNA

<400> 1

atggacggtg	tcgtctcccg	cgtggctctc	gagaacgagg	agcgtgaggc	caagaacacc	60
tggcgccttg	tctttcgtgt	cgccgtctct	tccttatttg	tcatgacctt	cgccatctcc	120
gtcgcgcgcc	tcgtctacag	catggagggt	agcaccceca	acgatctcgc	cggaatctcg	180
actgttatct	cccgcgccga	ggaccgcgtc	acctccctcc	tcaactccaa	ccaggatgtc	240
gttgatcgcg	tctacaagca	ggtcgcctct	gagtccctct	tcgcctctct	taacaccgag	300
agcatcatta	tgaacgccat	tacctccctc	agctaccaga	ttaacggcgc	cgccaactcg	360
tccgggtcgc	gcgcceccgt	ccatgacctt	gattacatcg	gcggcgctcg	caaggagctc	420
atcgtcgacg	acactagcga	tgccacgtcc	ttctacccta	gcgcctacca	ggagcacctc	480
aacttcatcc	ctgccccac	taccggctcc	ggctgcaccc	gcattcccoag	cttcgacatg	540

tccgccactc	actactgcta	cacccataac	gtcatccttt	cgggttgccg	cgaccactcc	600
cacagccacc	agtacctcgc	cctcggagtt	cttcgtacgt	ccgccaccgg	ccgcgtcttt	660
ttttccaccc	tccgcagcat	caacctcgac	gatacccaga	accgcaagag	ctgctcggtc	720
tcgccacccc	cgctcggctg	cgacatgctc	tgtccaagg	tcaccgagac	ggaggaggag	780
gattacaagt	ccgttacccc	cacttcgatg	gtccacggcc	gccttggttt	cgacggccag	840
taccacgaga	aggacctcga	cgtcaccggt	ctctttaagg	actgggttgc	caactacccc	900
ggcgtcggcg	gcggtccctt	catcgatgac	cgcgctcggg	ttcctgtcta	cgggtggtctc	960
aagcctaaca	gccccctcga	taccgcccag	gagggtaagt	acgtgatcta	caagcgctac	1020
aacaacacct	gccttgacga	gcaggattac	cagggtccga	tggccaagtc	ctcgtacaag	1080
cccggtcgtt	tccggcggcaa	gcgcgtccag	caggccattc	tctcgatcaa	ggtctcgacc	1140
agcctcggag	aggaccccgt	gtcaccggtt	ccccctaaca	ccgtcaccct	tatgggcggc	1200
gagggccgca	tcctcaccgt	cgggtacctcc	cacttcctct	accagcggcg	ctcgagctac	1260
ttttcccttg	cccttcttta	ccccatgact	gttcgcaaca	agactgctac	cctccacagc	1320
ccctacacct	ttaacgcctt	cacgcgcccc	ggaagcgctc	cctgccaggc	gagcgccccg	1380
tgcctaaact	cctgcattac	cggcgctctac	accgaccctt	accctgtcgt	ctttcacccg	1440
aaccataccc	ttcgcggcgt	cttcgggtact	atgcttgata	acgagcaggc	ccgcctcaac	1500
cccgctctcg	ccattttcga	ctacacttcc	cgtctccgta	tcacccgcgt	ctcctccacc	1560
tccaccaagg	ccgcctacac	cacctccacc	tgttttaagg	ttgtcaagac	taacaaggtc	1620
tactgcctct	ccatcgccga	gattagcaac	accctcttcg	gagagtcccg	cattgtcccc	1680
ctgctcgtcg	agatcctcaa	ggaogatcgc	gtttaa			1716

<210> 2

<211> 1716

<212> DNA

<213> artificial sequence

<220>

<223> NDV HN wild type DNA

<400> 2

atggatcgtg	tagttagcag	agtcgtacta	gaaaacgaag	aaagagaagc	aaagaataca	60
tggcgccctg	ttttccgggt	cgcagtccta	tctctaatag	taatgacatt	agctatctct	120
gtagccgccc	tggatatacag	catggagggt	agcacgcoga	acgaccttgc	gggtatatcg	180
acggtgatct	ccagggcaga	ggatagggtt	acatctttac	tcaattcaaa	tcaagatgtg	240
gtagataggg	tatataaaca	ggtggccctt	gagtcgccgc	tggcggttgt	gaatactgag	300
tctataatta	tgaatgcaat	aacttctctt	tcctatcaaa	ttaatggggc	tgcaaatagt	360
agtgggtgtg	gggcacctgt	tcatgaccog	gattatattg	ggggggtagg	taaagagctc	420
atagtagatg	acacgagtga	tgccacttca	ttctatcctt	cagcatatca	agaacacctg	480
aactttatcc	cggcgcccac	cacaggttca	ggctgcactc	ggataccctc	attcgacatg	540
agcgtacccc	actattgtta	tactcacaat	gtgatattat	ctggctgcag	agatcactca	600
cactcacatc	agtatttggt	actagggtgtg	cttcggacat	ctgcaacagg	gaggggtattc	660
ttttctactc	tgcgttccat	caatttagat	gacacccaaa	atcggaagtc	ttgcagtgtg	720
agtgcgaactc	ctttagggttg	tgatatgctg	tgtctaaaag	tcacagagac	tgaggaggag	780
gattataagt	cagttacccc	cacatcaatg	gtgcatggaa	gggttaggggt	tgacggtcag	840
taccatgaga	aggacttaga	cgtcacagtc	ttatttaagg	attgggttgc	aaattacccg	900
ggagtgggag	gagggctctct	tattgacgac	cgtgtatggt	tcccagttta	tggaggggcta	960
aaacccaatt	cacctagcga	cactgcacaa	gaagggaat	atgtaatata	caagcgctat	1020
aataacacat	gccccgatga	acaagattac	caagttcgga	tggctaaatc	ctcgtataag	1080
cctggacggt	ttggtgggaa	gcgcgtacag	caagccatcc	tatctatcaa	agtatcaaca	1140
tctttgggcg	aggacccggg	gctgactgta	ccgccaaata	cagttacact	catggggggcc	1200
gagggcagaa	tcctcacagt	aggaacatct	catttcttgt	accagcgagg	gtcttcatac	1260
ttttctcccg	ccttactata	ccctatgaca	gtgcgcaaca	aaacagccac	tcttcatagt	1320
ccttatacat	ttaatgcgtt	cactcggcgg	ggtagtgtcc	cttgccaggc	atcagcaagg	1380
tgcctaaact	catgtatcac	tggagtctat	actgatccgt	accctgtagt	cttccatagg	1440
aatcacacct	tgcgaggggt	gttcgggaca	atgcttgata	atgaacaagc	aaggctcaat	1500
cccgatatctg	caatatttga	ctacacatct	cgcagtcgca	taacccgggt	aagttcgacc	1560


```

agcaccaagg cagcatacac gacatcgaca tggttttaaag ttgtcaagac taataaagtg 1620
tattgtctta gcattgcaga aatatccaat actctatttg gggaattcag gatcgttcct 1680
ttactgggtcg agattctcaa agatgatagg gtttaa 1716

```

```

<210> 3
<211> 571
<212> PRT
<213> artificial sequence

<220>
<223> NDV HN protein (ABS84265)

```

```

<400> 3
Met Asp Arg Val Val Ser Arg Val Val Leu Glu Asn Glu Glu Arg Glu
1          5          10          15
Ala Lys Asn Thr Trp Arg Leu Val Phe Arg Val Ala Val Leu Ser Leu
          20          25          30
Ile Val Met Thr Leu Ala Ile Ser Val Ala Ala Leu Val Tyr Ser Met
          35          40          45
Glu Ala Ser Thr Pro Asn Asp Leu Ala Gly Ile Ser Thr Val Ile Ser
          50          55          60
Arg Ala Glu Asp Arg Val Thr Ser Leu Leu Asn Ser Asn Gln Asp Val
65          70          75          80
Val Asp Arg Val Tyr Lys Gln Val Ala Leu Glu Ser Pro Leu Ala Leu
          85          90          95
Leu Asn Thr Glu Ser Ile Ile Met Asn Ala Ile Thr Ser Leu Ser Tyr
          100         105         110
Gln Ile Asn Gly Ala Ala Asn Ser Ser Gly Cys Gly Ala Pro Val His
          115         120         125
Asp Pro Asp Tyr Ile Gly Gly Val Gly Lys Glu Leu Ile Val Asp Asp
130         135         140
Thr Ser Asp Ala Thr Ser Phe Tyr Pro Ser Ala Tyr Gln Glu His Leu
145         150         155         160
Asn Phe Ile Pro Ala Pro Thr Thr Gly Ser Gly Cys Thr Arg Ile Pro
          165         170         175
Ser Phe Asp Met Ser Ala Thr His Tyr Cys Tyr Thr His Asn Val Ile
          180         185         190
Leu Ser Gly Cys Arg Asp His Ser His Ser His Gln Tyr Leu Ala Leu
          195         200         205
Gly Val Leu Arg Thr Ser Ala Thr Gly Arg Val Phe Phe Ser Thr Leu
210         215         220
Arg Ser Ile Asn Leu Asp Asp Thr Gln Asn Arg Lys Ser Cys Ser Val
225         230         235         240
Ser Ala Thr Pro Leu Gly Cys Asp Met Leu Cys Ser Lys Val Thr Glu
          245         250         255
Thr Glu Glu Glu Asp Tyr Lys Ser Val Thr Pro Thr Ser Met Val His
          260         265         270
Gly Arg Leu Gly Phe Asp Gly Gln Tyr His Glu Lys Asp Leu Asp Val
          275         280         285
Thr Val Leu Phe Lys Asp Trp Val Ala Asn Tyr Pro Gly Val Gly Gly
290         295         300
Gly Ser Leu Ile Asp Asp Arg Val Trp Phe Pro Val Tyr Gly Gly Leu
305         310         315         320
Lys Pro Asn Ser Pro Ser Asp Thr Ala Gln Glu Gly Lys Tyr Val Ile
          325         330         335

```

Tyr Lys Arg Tyr Asn Asn Thr Cys Pro Asp Glu Gln Asp Tyr Gln Val
 340 345 350
 Arg Met Ala Lys Ser Ser Tyr Lys Pro Gly Arg Phe Gly Gly Lys Arg
 355 360 365
 Val Gln Gln Ala Ile Leu Ser Ile Lys Val Ser Thr Ser Leu Gly Glu
 370 375 380
 Asp Pro Val Leu Thr Val Pro Pro Asn Thr Val Thr Leu Met Gly Ala
 385 390 395 400
 Glu Gly Arg Ile Leu Thr Val Gly Thr Ser His Phe Leu Tyr Gln Arg
 405 410 415
 Gly Ser Ser Tyr Phe Ser Pro Ala Leu Leu Tyr Pro Met Thr Val Arg
 420 425 430
 Asn Lys Thr Ala Thr Leu His Ser Pro Tyr Thr Phe Asn Ala Phe Thr
 435 440 445
 Arg Pro Gly Ser Val Pro Cys Gln Ala Ser Ala Arg Cys Pro Asn Ser
 450 455 460
 Cys Ile Thr Gly Val Tyr Thr Asp Pro Tyr Pro Val Val Phe His Arg
 465 470 475 480
 Asn His Thr Leu Arg Gly Val Phe Gly Thr Met Leu Asp Asn Glu Gln
 485 490 495
 Ala Arg Leu Asn Pro Val Ser Ala Ile Phe Asp Tyr Thr Ser Arg Ser
 500 505 510
 Arg Ile Thr Arg Val Ser Ser Thr Ser Thr Lys Ala Ala Tyr Thr Thr
 515 520 525
 Ser Thr Cys Phe Lys Val Val Lys Thr Asn Lys Val Tyr Cys Leu Ser
 530 535 540
 Ile Ala Glu Ile Ser Asn Thr Leu Phe Gly Glu Phe Arg Ile Val Pro
 545 550 555 560
 Leu Leu Val Glu Ile Leu Lys Asp Asp Arg Val
 565 570

<210> 4
 <211> 1915
 <212> DNA
 <213> artificial sequence

<220>
 <223> NDV HN DNA (M21409)

<400> 4
 gtcctcagtc atggaccgcg cagttagcca agttgcgtta gagaatgatg aaagagagggc 60
 aaaaaataca tggcgcttga tattccggat tgcaatctta ctcttaacag tagtgacctt 120
 agctacatct gtagcctccc ttgtatatag catgggggct agcacaccta gcgaccttgt 180
 aggcataccg accaggattt ccagggcaga agaaaagatt acatctgcac ttggttccaa 240
 tcaagatgta gtagatagga tatataagca agtggccctt gagtctccgt tggcattggt 300
 aaacactgag actacaatta tgaacgcaat aacatctctc tcttatcaga ttaatggagc 360
 tgcgaacaac agcgggtggg gggcacctat ccatgaccca gattttatcg gggggatagg 420
 caaagaactc attgtagatg atgctagtga tgtcacatca ttctatccct ctgcatttca 480
 agaacatcat aattttatcc cggcgcctac tacaggatca ggttgcattc ggataccttc 540
 atttgacatg agtgcctacc attactgcta cactcataat ataatatcgt ctggatgcag 600
 agatcactca cactcatatc agtatttagc acttggtgtg ctccggactt ctgcaacagg 660
 gaggatatte ttttctactc tgcgttccat caatctggat gacaccaga atcggaagtc 720
 ttgcagltgt agtgcaactc ccttaggttg tgatatgctg tgctcgaaag tcacggagac 780
 agaggaagaa gattataact cagctgtccc tacgctgatg gtacatggga ggtaggggtt 840
 cgacggccaa taccacgaaa aggacctaga cgtcacaaca ttatttgagg actgggtggc 900
 caactaccca ggagtagggg gtggatcttt tattgacagc cgcgtatggt tctcagtcta 960

```

cggagggctg aaacccaatt caccagtgta cactgtacag gaagagaaat atgtaataata 1020
caagcgatac aatgacacat gccagatga gcaagactac cagatccgaa tggccaagtc 1080
ttcgtataag cccgggcggt ttggtgggaa acgcatacag caggctatct tatctatcaa 1140
ggtgtcaaca tctttgggcg aagacccagt actgactgta ccgccaaca cagtcacact 1200
catggggggc gaaggcagaa ttctcacagt agggacatct catttcttgt atcagcgagg 1260
gtcatcatac ttctctcccg cgttattata tcctatgaca gtcagcaaca aaacagccac 1320
tcttcatagt cctatacat tcaatgcctt cactcggcca ggtagtatcc cttgccaggc 1380
ttcagcaaga tgccccaact cgtgtgttac tggagtctat acagatccat atcccctaata 1440
cttctatagg aaccacacct tgcgaggggt attcgggaca atgcttgatg gtgaacaagc 1500
aagacttaat cctgcgtctg cagtattcga tagcacatcc cgcagtcgca taacccgagt 1560
gagttcaagc agcaccaaag cagcatacac aacatcaact tgttttaaag ttgtcaagac 1620
caataagacc tattgtctca gcattgctga aatatctaata actctcttcg gagaattcag 1680
aatcgtcccg ttactagttg agatcctcaa aaatgatggg gttagagaag ccaggtctgg 1740
ttagttgagt caactatgaa agagctggaa agatggcatt gtatcaccta tcttcgcgca 1800
caccaagaat caaactgaat gccggtgcga gctcgaattc catgtcgcca gttgaccaca 1860
atcagccagt gctcatgcga tcagatcaag tcttgtcaat agtcctcga ttaag 1915

```

<210> 5

<211> 577

<212> PRT

<213> artificial sequence

<220>

<223> NDV HN protein (P12553)

<400> 5

```

Met Asp Arg Ala Val Ser Gln Val Ala Leu Glu Asn Asp Glu Arg Glu
1          5          10          15
Ala Lys Asn Thr Trp Arg Leu Ile Phe Arg Ile Ala Ile Leu Leu Leu
          20          25          30
Thr Val Val Thr Leu Ala Thr Ser Val Ala Ser Leu Val Tyr Ser Met
          35          40          45
Gly Ala Ser Thr Pro Ser Asp Leu Val Gly Ile Pro Thr Arg Ile Ser
          50          55          60
Arg Ala Glu Glu Lys Ile Thr Ser Ala Leu Gly Ser Asn Gln Asp Val
65          70          75          80
Val Asp Arg Ile Tyr Lys Gln Val Ala Leu Glu Ser Pro Leu Ala Leu
          85          90          95
Leu Asn Thr Glu Thr Thr Ile Met Asn Ala Ile Thr Ser Leu Ser Tyr
          100          105          110
Gln Ile Asn Gly Ala Ala Asn Asn Ser Gly Trp Gly Ala Pro Ile His
          115          120          125
Asp Pro Asp Phe Ile Gly Gly Ile Gly Lys Glu Leu Ile Val Asp Asp
          130          135          140
Ala Ser Asp Val Thr Ser Phe Tyr Pro Ser Ala Phe Gln Glu His His
          145          150          155          160
Asn Phe Ile Pro Ala Pro Thr Thr Gly Ser Gly Cys Ile Arg Ile Pro
          165          170          175
Ser Phe Asp Met Ser Ala Thr His Tyr Cys Tyr Thr His Asn Ile Ile
          180          185          190
Ser Ser Gly Cys Arg Asp His Ser His Ser Tyr Gln Tyr Leu Ala Leu
          195          200          205
Gly Val Leu Arg Thr Ser Ala Thr Gly Arg Ile Phe Phe Ser Thr Leu
          210          215          220
Arg Ser Ile Asn Leu Asp Asp Thr Gln Asn Arg Lys Ser Cys Ser Val
          225          230          235          240

```


Ser Ala Thr Pro Leu Gly Cys Asp Met Leu Cys Ser Lys Val Thr Glu
 245 250 255
 Thr Glu Glu Glu Asp Tyr Asn Ser Ala Val Pro Thr Leu Met Val His
 260 265 270
 Gly Arg Leu Gly Phe Asp Gly Gln Tyr His Glu Lys Asp Leu Asp Val
 275 280 285
 Thr Thr Leu Phe Glu Asp Trp Val Ala Asn Tyr Pro Gly Val Gly Gly
 290 295 300
 Gly Ser Phe Ile Asp Ser Arg Val Trp Phe Ser Val Tyr Gly Gly Leu
 305 310 315 320
 Lys Pro Asn Ser Pro Ser Asp Thr Val Gln Glu Glu Lys Tyr Val Ile
 325 330 335
 Tyr Lys Arg Tyr Asn Asp Thr Cys Pro Asp Glu Gln Asp Tyr Gln Ile
 340 345 350
 Arg Met Ala Lys Ser Ser Tyr Lys Pro Gly Arg Phe Gly Gly Lys Arg
 355 360 365
 Ile Gln Gln Ala Ile Leu Ser Ile Lys Val Ser Thr Ser Leu Gly Glu
 370 375 380
 Asp Pro Val Leu Thr Val Pro Pro Asn Thr Val Thr Leu Met Gly Ala
 385 390 395 400
 Glu Gly Arg Ile Leu Thr Val Gly Thr Ser His Phe Leu Tyr Gln Arg
 405 410 415
 Gly Ser Ser Tyr Phe Ser Pro Ala Leu Leu Tyr Pro Met Thr Val Ser
 420 425 430
 Asn Lys Thr Ala Thr Leu His Ser Pro Tyr Thr Phe Asn Ala Phe Thr
 435 440 445
 Arg Pro Gly Ser Ile Pro Cys Gln Ala Ser Ala Arg Cys Pro Asn Ser
 450 455 460
 Cys Val Thr Gly Val Tyr Thr Asp Pro Tyr Pro Leu Ile Phe Tyr Arg
 465 470 475 480
 Asn His Thr Leu Arg Gly Val Phe Gly Thr Met Leu Asp Gly Glu Gln
 485 490 495
 Ala Arg Leu Asn Pro Ala Ser Ala Val Phe Asp Ser Thr Ser Arg Ser
 500 505 510
 Arg Ile Thr Arg Val Ser Ser Ser Ser Thr Lys Ala Ala Tyr Thr Thr
 515 520 525
 Ser Thr Cys Phe Lys Val Val Lys Thr Asn Lys Thr Tyr Cys Leu Ser
 530 535 540
 Ile Ala Glu Ile Ser Asn Thr Leu Phe Gly Glu Phe Arg Ile Val Pro
 545 550 555 560
 Leu Leu Val Glu Ile Leu Lys Asn Asp Gly Val Arg Glu Ala Arg Ser
 565 570 575
 Gly

<210> 6
 <211> 2002
 <212> DNA
 <213> artificial sequence

<220>
 <223> NDV HN DNA (M24709)

<400> 6
 acgggtagaa cggtaagaga ggccgcccct caattgcgag ccaggcttca caacctcogt 60
 tctaccgctt caccgacaac agtcctcaat catggaccgc gccgttagcc aagttgcgtt 120
 agagaatgat gaaagagagg caaaaaatac atggcgcttg atattccgga ttgcaatctt 180

```

attcttaaca gtagtgacct tggctatata tgtagcctcc cttttatata gcatgggggc 240
tagcacacct agcgatcttg taggcatacc gactaggatt tccagggcag aagaaaagat 300
tacatctaca cttgggtcca atcaagatgt agtagatagg atataaagc aagtggccct 360
tgagtctccg ttggcattgt taaaaactga gaccacaatt atgaacgcaa taacatctct 420
ctcttatcag attaatggag ctgcaaacaa cagcgggttg ggggcaccta tccatgacct 480
agattatata ggggggatag gcaaagaact cattgtagat gatgctagt atgtcacatc 540
attctatccc tctgcatttc aagaacatct gaattttatc ccggcgctta ctacaggatc 600
aggttgcact cgaataccct catttgacat gagtgctacc cattactgct acaccataa 660
tgtaatatgg tctggatgca gagatcactc acattcatat cagtatttag cacttgggtg 720
gctccggaca tctgcaacag ggagggtatt cttttctact ctgcgttcca tcaacctgga 780
cgacacccaa aatcggaagt cttgcagtgt gagtgcaact cccctgggtt gtgatatgct 840
gtgctcgaaa gtcacggaga cagaggaaga agattataac tcagctgtcc ctacgcggat 900
ggcacatggg aggttagggg tcgacggcca ataccacgaa aaggacctag atgtcacaac 960
attattcggg gactgggttg ccaactaccc aggagtaggg ggtggatctt ttattgacgg 1020
ccgcgtatgg ttctcagtct acggagggtc gaaacccaat tcacccagtg acactgtaca 1080
ggaagggaaa tatgtgatat acaagcgata caatgacaca tgcccagatg agcaagacta 1140
ccagattcga atggccaagt ctctgtataa gcctggacgg tttggtggga aacgcattca 1200
gcaggtatc ttatctatca aggtgtcaac atccttaggc gaagaccgg tactgactgt 1260
accgccaac acagtcacac tcatgggggc cgaaggcaga attctcacag tagggacatc 1320
tcatttcttg tatcaacgag ggtcatcata cttctctccc gcgttattat atcctatgac 1380
agtcagcaac aaaacagcca ctcttcatag tccttataca ttcaatgcct tcaactcgcc 1440
aggtagtatc ccttgccagg ctctcagcaag atgccccaac ccgtgtgltta ctggagtcta 1500
tacagatcca tatccctaa tcttctatag aaaccacacc ttgcgagggg tattcgggac 1560
aatgcttgat ggtgtacaag caagacttaa tcctacgtct gcagtattcg atagcacatc 1620
ccgcagtcgc ataactcgag tgagttcaag cagcaccaaa gcagcataca caacatcaac 1680
ttgtttttaa gtggtcaaga ccaataagac ctattgtctc agcattgctg aaatatctaa 1740
tactctcttc ggagaattca gaatcgctcc gttactagtt gagatcctca aagatgacgg 1800
ggttagagaa gccaggctct gctagttgag tcaattataa aggagttgga aagatggcat 1860
tgtatcacct atcttctgcg acatcaagaa tcaaaccgaa tgccggcgcg tgctcgaatt 1920
ccatgttgcc agttgaccac aatcagccag tgctcatgcg atcagattaa gccttgtcaa 1980
tagtctcttg attaagaaaa aa 2002

```

<210> 7

<211> 577

<212> PRT

<213> artificial sequence

<220>

<223> NDV HN protein (AAA46659)

<400> 7

```

Met Asp Arg Ala Val Ser Gln Val Ala Leu Glu Asn Asp Glu Arg Glu
1          5          10          15
Ala Lys Asn Thr Trp Arg Leu Ile Phe Arg Ile Ala Ile Leu Phe Leu
20          25          30
Thr Val Val Thr Leu Ala Ile Ser Val Ala Ser Leu Leu Tyr Ser Met
35          40          45
Gly Ala Ser Thr Pro Ser Asp Leu Val Gly Ile Pro Thr Arg Ile Ser
50          55          60
Arg Ala Glu Glu Lys Ile Thr Ser Thr Leu Gly Ser Asn Gln Asp Val
65          70          75          80
Val Asp Arg Ile Tyr Lys Gln Val Ala Leu Glu Ser Pro Leu Ala Leu
85          90          95
Leu Lys Thr Glu Thr Thr Ile Met Asn Ala Ile Thr Ser Leu Ser Tyr
100         105         110

```

Gln	Ile	Asn	Gly	Ala	Ala	Asn	Asn	Ser	Gly	Trp	Gly	Ala	Pro	Ile	His	115	120	125
Asp	Pro	Asp	Tyr	Ile	Gly	Gly	Ile	Gly	Lys	Glu	Leu	Ile	Val	Asp	Asp	130	135	140
Ala	Ser	Asp	Val	Thr	Ser	Phe	Tyr	Pro	Ser	Ala	Phe	Gln	Glu	His	Leu	145	150	155
Asn	Phe	Ile	Pro	Ala	Pro	Thr	Thr	Gly	Ser	Gly	Cys	Thr	Arg	Ile	Pro	165	170	175
Ser	Phe	Asp	Met	Ser	Ala	Thr	His	Tyr	Cys	Tyr	Thr	His	Asn	Val	Ile	180	185	190
Leu	Ser	Gly	Cys	Arg	Asp	His	Ser	His	Ser	Tyr	Gln	Tyr	Leu	Ala	Leu	195	200	205
Gly	Val	Leu	Arg	Thr	Ser	Ala	Thr	Gly	Arg	Val	Phe	Phe	Ser	Thr	Leu	210	215	220
Arg	Ser	Ile	Asn	Leu	Asp	Asp	Thr	Gln	Asn	Arg	Lys	Ser	Cys	Ser	Val	225	230	235
Ser	Ala	Thr	Pro	Leu	Gly	Cys	Asp	Met	Leu	Cys	Ser	Lys	Val	Thr	Glu	245	250	255
Thr	Glu	Glu	Glu	Asp	Tyr	Asn	Ser	Ala	Val	Pro	Thr	Arg	Met	Ala	His	260	265	270
Gly	Arg	Leu	Gly	Phe	Asp	Gly	Gln	Tyr	His	Glu	Lys	Asp	Leu	Asp	Val	275	280	285
Thr	Thr	Leu	Phe	Gly	Asp	Trp	Val	Ala	Asn	Tyr	Pro	Gly	Val	Gly	Gly	290	295	300
Gly	Ser	Phe	Ile	Asp	Gly	Arg	Val	Trp	Phe	Ser	Val	Tyr	Gly	Gly	Leu	305	310	315
Lys	Pro	Asn	Ser	Pro	Ser	Asp	Thr	Val	Gln	Glu	Gly	Lys	Tyr	Val	Ile	325	330	335
Tyr	Lys	Arg	Tyr	Asn	Asp	Thr	Cys	Pro	Asp	Glu	Gln	Asp	Tyr	Gln	Ile	340	345	350
Arg	Met	Ala	Lys	Ser	Ser	Tyr	Lys	Pro	Gly	Arg	Phe	Gly	Gly	Lys	Arg	355	360	365
Ile	Gln	Gln	Ala	Ile	Leu	Ser	Ile	Lys	Val	Ser	Thr	Ser	Leu	Gly	Glu	370	375	380
Asp	Pro	Val	Leu	Thr	Val	Pro	Pro	Asn	Thr	Val	Thr	Leu	Met	Gly	Ala	385	390	395
Glu	Gly	Arg	Ile	Leu	Thr	Val	Gly	Thr	Ser	His	Phe	Leu	Tyr	Gln	Arg	405	410	415
Gly	Ser	Ser	Tyr	Phe	Ser	Pro	Ala	Leu	Leu	Tyr	Pro	Met	Thr	Val	Ser	420	425	430
Asn	Lys	Thr	Ala	Thr	Leu	His	Ser	Pro	Tyr	Thr	Phe	Asn	Ala	Phe	Thr	435	440	445
Arg	Pro	Gly	Ser	Ile	Pro	Cys	Gln	Ala	Ser	Ala	Arg	Cys	Pro	Asn	Pro	450	455	460
Cys	Val	Thr	Gly	Val	Tyr	Thr	Asp	Pro	Tyr	Pro	Leu	Ile	Phe	Tyr	Arg	465	470	475
Asn	His	Thr	Leu	Arg	Gly	Val	Phe	Gly	Thr	Met	Leu	Asp	Gly	Val	Gln	485	490	495
Ala	Arg	Leu	Asn	Pro	Thr	Ser	Ala	Val	Phe	Asp	Ser	Thr	Ser	Arg	Ser	500	505	510
Arg	Ile	Thr	Arg	Val	Ser	Ser	Ser	Ser	Thr	Lys	Ala	Ala	Tyr	Thr	Thr	515	520	525
Ser	Thr	Cys	Phe	Lys	Val	Val	Lys	Thr	Asn	Lys	Thr	Tyr	Cys	Leu	Ser	530	535	540
Ile	Ala	Glu	Ile	Ser	Asn	Thr	Leu	Phe	Gly	Glu	Phe	Arg	Ile	Val	Pro	545	550	555

Leu Leu Val Glu Ile Leu Lys Asp Asp Gly Val Arg Glu Ala Arg Ser
 565 570 575

Gly

<210> 8

<211> 1716

<212> DNA

<213> artificial sequence

<220>

<223> NDV HN protein (AY288999)

<400> 8

atggatcgtg	tagttagcag	agttgtacta	gagaacgaag	aaagagaagc	aaagaatact	60
tggcgccctg	ttttccggat	cgcagtccta	tctctaatag	taatgacatt	agctatctct	120
gtagccgccc	tggtatacag	catggaggct	agcacaccga	acgaccttgc	gggcatatcg	180
acggtgatct	ccagggcaga	ggatagggtt	acatctttac	tcaattcaaa	tcaagatgtg	240
gtagataggg	tatataaaca	ggtggccctt	gagtcctccg	tggcgtttgt	gaatactgag	300
tctataatta	tgaatgcaat	aacttctctt	tctatcaaaa	ttaatggggc	tgcaaatagt	360
agtgggtgtg	gggcacctgt	tcatgacctg	gattatattg	ggggggtagg	taaagagctc	420
atagtagatg	acacaagtga	tgccacttca	ttctatcctt	cagcatatca	agaacacctg	480
aactttatcc	cggcgcccac	cacaggatca	ggctgcactc	ggataccctc	attcgacatg	540
agcgtaccc	actattgtta	tactcacaat	gtgatattat	ctggctgcag	agatcactca	600
cactcacatc	agtatttggc	actagggtgt	cttcggacat	ctgcaacagg	gagggtatte	660
ttttctactc	tgcgttccat	caatttagat	gacacccaaa	atcggaagtc	ttgcagtgtg	720
agtgcaactt	ctttagggtg	tgatatgctg	tgctctaaag	tcacagagac	tgaggaggag	780
gattataagt	cagttacccc	cacatcaatg	gtgcatggaa	ggttagggtt	tgacggtcag	840
taccatgaga	aggacttaga	cgtcacagtc	ttatttaagg	attgggttgc	aaattaccgc	900
ggagtgggag	gagggctctt	tattgacgac	cgtgtatggt	tcccagttta	cggcggggcta	960
aaaccaattt	cgcctagcga	cactgcacaa	gaagggaat	atgtaataata	caagcgctat	1020
aataacacat	gccccgatga	acaagattac	caagttcgga	tggctaagtc	ctcgtataag	1080
cctggacggg	tlgggtgggaa	gcgcgtacag	caagccatcc	tatctatcaa	agtatcaaca	1140
tctttgggcg	aggacccggg	gctgactgta	ccgccaaata	cagttacact	catggggggcc	1200
gaaggcagaa	tcctcacagt	aggaacatct	catttcttgt	accagcgagg	gtcttcatac	1260
ttttctcctg	ccttactata	ccctatgaca	gtgcgcaaca	aaacagccac	tcttcatagt	1320
ccttatacat	ttaatgcgtt	cactcggcca	ggtagtgtcc	cttgccaggc	atcagcaagg	1380
tgccttaact	catgtatcac	tggagtctat	actgatccgt	accctgtagt	cttccatagg	1440
aatcacacct	tgcgaggggt	gttcgggaca	atgcttgata	atgaacaagc	aaggctcaat	1500
cccgtatctg	caatatttga	ctacacatct	cgcagtcgca	taaccgggtg	aagttcgatc	1560
agcaccaagg	cagcatacac	gacatcgaca	tgttttaaag	ttgtcaagac	caataaagtg	1620
tattgtctta	gcattgcaga	aatatccaat	actctatatt	gggaattcag	gatcgttcct	1680
ttactgggtc	agattctcaa	ggatgatagg	gttttaa			1716

<210> 9

<211> 571

<212> PRT

<213> artificial sequence

<220>

<223> NDV HN protein (AAQ54638)

<400> 9

Met Asp Arg Val Val Ser Arg Val Val Leu Glu Asn Glu Glu Arg Glu
 1 5 10 15

Ala	Lys	Asn	Thr	Trp	Arg	Leu	Val	Phe	Arg	Ile	Ala	Val	Leu	Ser	Leu
			20					25					30		
Ile	Val	Met	Thr	Leu	Ala	Ile	Ser	Val	Ala	Ala	Leu	Val	Tyr	Ser	Met
		35					40					45			
Glu	Ala	Ser	Thr	Pro	Asn	Asp	Leu	Ala	Gly	Ile	Ser	Thr	Val	Ile	Ser
	50					55					60				
Arg	Ala	Glu	Asp	Arg	Val	Thr	Ser	Leu	Leu	Asn	Ser	Asn	Gln	Asp	Val
65					70					75				80	
Val	Asp	Arg	Val	Tyr	Lys	Gln	Val	Ala	Leu	Glu	Ser	Pro	Leu	Ala	Leu
			85					90					95		
Leu	Asn	Thr	Glu	Ser	Ile	Ile	Met	Asn	Ala	Ile	Thr	Ser	Leu	Ser	Tyr
			100					105					110		
Gln	Ile	Asn	Gly	Ala	Ala	Asn	Ser	Ser	Gly	Cys	Gly	Ala	Pro	Val	His
		115					120					125			
Asp	Pro	Asp	Tyr	Ile	Gly	Gly	Val	Gly	Lys	Glu	Leu	Ile	Val	Asp	Asp
	130					135					140				
Thr	Ser	Asp	Ala	Thr	Ser	Phe	Tyr	Pro	Ser	Ala	Tyr	Gln	Glu	His	Leu
145					150					155					160
Asn	Phe	Ile	Pro	Ala	Pro	Thr	Thr	Gly	Ser	Gly	Cys	Thr	Arg	Ile	Pro
			165					170					175		
Ser	Phe	Asp	Met	Ser	Ala	Thr	His	Tyr	Cys	Tyr	Thr	His	Asn	Val	Ile
			180					185					190		
Leu	Ser	Gly	Cys	Arg	Asp	His	Ser	His	Ser	His	Gln	Tyr	Leu	Ala	Leu
		195					200					205			
Gly	Val	Leu	Arg	Thr	Ser	Ala	Thr	Gly	Arg	Val	Phe	Phe	Ser	Thr	Leu
	210					215					220				
Arg	Ser	Ile	Asn	Leu	Asp	Asp	Thr	Gln	Asn	Arg	Lys	Ser	Cys	Ser	Val
225					230					235					240
Ser	Ala	Thr	Ser	Leu	Gly	Cys	Asp	Met	Leu	Cys	Ser	Lys	Val	Thr	Glu
			245					250					255		
Thr	Glu	Glu	Glu	Asp	Tyr	Lys	Ser	Val	Thr	Pro	Thr	Ser	Met	Val	His
			260					265					270		
Gly	Arg	Leu	Gly	Phe	Asp	Gly	Gln	Tyr	His	Glu	Lys	Asp	Leu	Asp	Val
	275					280						285			
Thr	Val	Leu	Phe	Lys	Asp	Trp	Val	Ala	Asn	Tyr	Pro	Gly	Val	Gly	Gly
	290					295					300				
Gly	Ser	Leu	Ile	Asp	Asp	Arg	Val	Trp	Phe	Pro	Val	Tyr	Gly	Gly	Leu
305					310					315					320
Lys	Pro	Asn	Ser	Pro	Ser	Asp	Thr	Ala	Gln	Glu	Gly	Lys	Tyr	Val	Ile
			325					330					335		
Tyr	Lys	Arg	Tyr	Asn	Asn	Thr	Cys	Pro	Asp	Glu	Gln	Asp	Tyr	Gln	Val
			340					345					350		
Arg	Met	Ala	Lys	Ser	Ser	Tyr	Lys	Pro	Gly	Arg	Phe	Gly	Gly	Lys	Arg
		355					360					365			
Val	Gln	Gln	Ala	Ile	Leu	Ser	Ile	Lys	Val	Ser	Thr	Ser	Leu	Gly	Glu
	370					375					380				
Asp	Pro	Val	Leu	Thr	Val	Pro	Pro	Asn	Thr	Val	Thr	Leu	Met	Gly	Ala
385					390					395					400
Glu	Gly	Arg	Ile	Leu	Thr	Val	Gly	Thr	Ser	His	Phe	Leu	Tyr	Gln	Arg
			405					410					415		
Gly	Ser	Ser	Tyr	Phe	Ser	Pro	Ala	Leu	Leu	Tyr	Pro	Met	Thr	Val	Arg
			420					425					430		
Asn	Lys	Thr	Ala	Thr	Leu	His	Ser	Pro	Tyr	Thr	Phe	Asn	Ala	Phe	Thr
		435					440					445			
Arg	Pro	Gly	Ser	Val	Pro	Cys	Gln	Ala	Ser	Ala	Arg	Cys	Pro	Asn	Ser
	450					455						460			

Cys Ile Thr Gly Val Tyr Thr Asp Pro Tyr Pro Val Val Phe His Arg
 465 470 475 480
 Asn His Thr Leu Arg Gly Val Phe Gly Thr Met Leu Asp Asn Glu Gln
 485 490 495
 Ala Arg Leu Asn Pro Val Ser Ala Ile Phe Asp Tyr Thr Ser Arg Ser
 500 505 510
 Arg Ile Thr Arg Val Ser Ser Ile Ser Thr Lys Ala Ala Tyr Thr Thr
 515 520 525
 Ser Thr Cys Phe Lys Val Val Lys Thr Asn Lys Val Tyr Cys Leu Ser
 530 535 540
 Ile Ala Glu Ile Ser Asn Thr Leu Phe Gly Glu Phe Arg Ile Val Pro
 545 550 555 560
 Leu Leu Val Glu Ile Leu Lys Asp Asp Arg Val
 565 570

<210> 10
 <211> 14
 <212> PRT
 <213> artificial sequence

<220>
 <223> NDV HN linear epitope region 1

<400> 10
 Pro Asp Glu Gln Asp Tyr Gln Ile Arg Met Ala Lys Ser Ser
 1 5 10

<210> 11
 <211> 14
 <212> PRT
 <213> artificial sequence

<220>
 <223> NDV HN linear epitope region 2

<400> 11
 Pro Asp Glu Gln Asp Tyr Gln Val Arg Met Ala Lys Ser Ser
 1 5 10

<210> 12
 <211> 78
 <212> DNA
 <213> artificial sequence

<220>
 <223> NDV HN signal sequence

<400> 12
 atggaccgtg tcgtctcccg cgtggctcctc gagaacgagg agcgtgaggc caagaacacc
 tggcgccttg tctttcgt

60
 78

<210> 13
 <211> 26

<212> PRT
 <213> artificial sequence

<220>
 <223> NDV HN signal peptide

<400> 13
 Met Asp Arg Val Val Ser Arg Val Val Leu Glu Asn Glu Glu Arg Glu
 1 5 10 15
 Ala Lys Asn Thr Trp Arg Leu Val Phe Arg
 20 25

<210> 14
 <211> 1638
 <212> DNA
 <213> artificial sequence

<220>
 <223> NDV HN DNA without signal seq

<400> 14
 gtcgccgtcc tctcccttat tgtcatgacc ctgcgccatct ccgtccgccgc cctcgtctac 60
 agcatggagg ctagcacccc caacgatctc gccggaatct cgactgttat ctcccgccgc 120
 gaggaccgcg tcacctccct cctcaactcc aaccaggatg tcgttgatcg cgtctacaag 180
 caggtcgccc tcgagtcccc tctcgccctc cttaacaccg agagcatcat tatgaacgcc 240
 attacctccc tcagctacca gattaacggc gccgccaaact cgtcgggctg cggcgcccc 300
 gtccatgacc ctgattacat cggcgggcgtc ggcaaggagc tcctcgtcga cgacactagc 360
 gatgccacgt ccttctaccc tagcgcctac caggagcacc tcaacttcat ccctgcccc 420
 actaccggt cgggtgcac ccgcattccc agcttcgaca tgtcggccac tcaactactgc 480
 tacaccata acgtcatcct ttccgggttg cgcgaccact cccacagcca ccagtacctc 540
 gccctcggag ttcttcgtac gtccgccacc ggcccggtct tttttccac cctccgcagc 600
 atcaacctcg acgataccca gaaccgcaag agctgctcgg tctccgccac cccgctcggc 660
 tgcgacatgc tctgtcccaa ggtcaccgag acggaggagg aggattacaa gtccgttacc 720
 cccacttcga tgggccacgg ccgccttggc ttcgacggcc agtaccacga gaaggacctc 780
 gacgtcaccc ttctctttaa ggactgggtt gccaaactacc ccggcgctcg cggcggctcc 840
 ctcatcgatg accgcgtctg gtttctgtc tacgggtggtc tcaagcctaa cagccccctc 900
 gataccgccc aggagggtaa gtacgtgatc tacaagcgt acaacaacac ctgccctgac 960
 gagcaggatt accaggtccg catggccaag tctcgtaca agcccggtcg ttccggcggc 1020
 aagcgcgtec agcaggccat tctctcgatc aaggtctcga ccagcctcgg agaggacccc 1080
 gtgtcaccg ttccccctaa caccgtcacc cttatgggcg ccgagggccg catcctcacc 1140
 gtcggtacct cccacttcct ctaccagcgc ggctcgagct acttttcccc tgcccttctt 1200
 taccatga ctgttcgcaa caagactgct accctccaca gccctacac ctttaacgcc 1260
 ttcacgcgcc ccggaagcgt cccctgccag gcgagcgccc gctgccctaa ctccctgcatt 1320
 accggcgctc acaccgaccc ttaccctgtc gtctttcacc gcaaccatac ctttcgcggc 1380
 gtcttcggta ctatgcttga taacgagcag gccgcctca acccggtctc cgccattttc 1440
 gactacactt cccgctcccg tatcaccgc gtctcctcca cctccaccaa ggccgcctac 1500
 accacctcca cctgctttaa gggtgtcaag actaacaagg tctactgcct ctccatcgcc 1560
 gagattagca acacctctt cggagagttc cgcattgtcc ccctgctcgt cgagatcctc 1620
 aaggacgatc gcgtttaa 1638

<210> 15
 <211> 545
 <212> PRT
 <213> artificial sequence

<220>

<223> NDV HN mature protein (without signal peptide)

<400> 15

Val	Ala	Val	Leu	Ser	Leu	Ile	Val	Met	Thr	Leu	Ala	Ile	Ser	Val	Ala
1				5					10					15	
Ala	Leu	Val	Tyr	Ser	Met	Glu	Ala	Ser	Thr	Pro	Asn	Asp	Leu	Ala	Gly
			20					25					30		
Ile	Ser	Thr	Val	Ile	Ser	Arg	Ala	Glu	Asp	Arg	Val	Thr	Ser	Leu	Leu
		35					40					45			
Asn	Ser	Asn	Gln	Asp	Val	Val	Asp	Arg	Val	Tyr	Lys	Gln	Val	Ala	Leu
	50					55					60				
Glu	Ser	Pro	Leu	Ala	Leu	Leu	Asn	Thr	Glu	Ser	Ile	Ile	Met	Asn	Ala
65					70					75				80	
Ile	Thr	Ser	Leu	Ser	Tyr	Gln	Ile	Asn	Gly	Ala	Ala	Asn	Ser	Ser	Gly
			85						90					95	
Cys	Gly	Ala	Pro	Val	His	Asp	Pro	Asp	Tyr	Ile	Gly	Gly	Val	Gly	Lys
			100					105					110		
Glu	Leu	Ile	Val	Asp	Asp	Thr	Ser	Asp	Ala	Thr	Ser	Phe	Tyr	Pro	Ser
		115					120					125			
Ala	Tyr	Gln	Glu	His	Leu	Asn	Phe	Ile	Pro	Ala	Pro	Thr	Thr	Gly	Ser
	130					135					140				
Gly	Cys	Thr	Arg	Ile	Pro	Ser	Phe	Asp	Met	Ser	Ala	Thr	His	Tyr	Cys
145					150					155					160
Tyr	Thr	His	Asn	Val	Ile	Leu	Ser	Gly	Cys	Arg	Asp	His	Ser	His	Ser
			165						170					175	
His	Gln	Tyr	Leu	Ala	Leu	Gly	Val	Leu	Arg	Thr	Ser	Ala	Thr	Gly	Arg
			180					185						190	
Val	Phe	Phe	Ser	Thr	Leu	Arg	Ser	Ile	Asn	Leu	Asp	Asp	Thr	Gln	Asn
		195					200				205				
Arg	Lys	Ser	Cys	Ser	Val	Ser	Ala	Thr	Pro	Leu	Gly	Cys	Asp	Met	Leu
	210					215					220				
Cys	Ser	Lys	Val	Thr	Glu	Thr	Glu	Glu	Glu	Asp	Tyr	Lys	Ser	Val	Thr
225					230					235					240
Pro	Thr	Ser	Met	Val	His	Gly	Arg	Leu	Gly	Phe	Asp	Gly	Gln	Tyr	His
			245						250					255	
Glu	Lys	Asp	Leu	Asp	Val	Thr	Val	Leu	Phe	Lys	Asp	Trp	Val	Ala	Asn
			260					265					270		
Tyr	Pro	Gly	Val	Gly	Gly	Gly	Ser	Leu	Ile	Asp	Asp	Arg	Val	Trp	Phe
		275					280					285			
Pro	Val	Tyr	Gly	Gly	Leu	Lys	Pro	Asn	Ser	Pro	Ser	Asp	Thr	Ala	Gln
	290					295					300				
Glu	Gly	Lys	Tyr	Val	Ile	Tyr	Lys	Arg	Tyr	Asn	Asn	Thr	Cys	Pro	Asp
305					310					315					320
Glu	Gln	Asp	Tyr	Gln	Val	Arg	Met	Ala	Lys	Ser	Ser	Tyr	Lys	Pro	Gly
			325						330					335	
Arg	Phe	Gly	Gly	Lys	Arg	Val	Gln	Gln	Ala	Ile	Leu	Ser	Ile	Lys	Val
			340					345						350	
Ser	Thr	Ser	Leu	Gly	Glu	Asp	Pro	Val	Leu	Thr	Val	Pro	Pro	Asn	Thr
		355					360					365			
Val	Thr	Leu	Met	Gly	Ala	Glu	Gly	Arg	Ile	Leu	Thr	Val	Gly	Thr	Ser
		370				375						380			
His	Phe	Leu	Tyr	Gln	Arg	Gly	Ser	Ser	Tyr	Phe	Ser	Pro	Ala	Leu	Leu
385				390						395					400
Tyr	Pro	Met	Thr	Val	Arg	Asn	Lys	Thr	Ala	Thr	Leu	His	Ser	Pro	Tyr
			405						410					415	

Thr Phe Asn Ala Phe Thr Arg Pro Gly Ser Val Pro Cys Gln Ala Ser
 420 425 430
 Ala Arg Cys Pro Asn Ser Cys Ile Thr Gly Val Tyr Thr Asp Pro Tyr
 435 440 445
 Pro Val Val Phe His Arg Asn His Thr Leu Arg Gly Val Phe Gly Thr
 450 455 460
 Met Leu Asp Asn Glu Gln Ala Arg Leu Asn Pro Val Ser Ala Ile Phe
 465 470 475 480
 Asp Tyr Thr Ser Arg Ser Arg Ile Thr Arg Val Ser Ser Thr Ser Thr
 485 490 495
 Lys Ala Ala Tyr Thr Thr Ser Thr Cys Phe Lys Val Val Lys Thr Asn
 500 505 510
 Lys Val Tyr Cys Leu Ser Ile Ala Glu Ile Ser Asn Thr Leu Phe Gly
 515 520 525
 Glu Phe Arg Ile Val Pro Leu Leu Val Glu Ile Leu Lys Asp Asp Arg
 530 535 540
 Val
 545

<210> 16
 <211> 1713
 <212> DNA
 <213> artificial sequence

<220>
 <223> NDV HN DNA (FJ608369)

<400> 16
 atgggacgcg cgggtaacag agtcgcgctg gagaatgagg aaagagaagc aaagaacaca 60
 tggcgccctgg ttttccggat cgcagttctta cttttaatgg taatgactct agctatctcc 120
 gcagctgccc tggcatacag tgcggggggcc agtacgccgc acgacctcgc aggcataatcg 180
 actgtgatct ctaagacaga ggataaggtt acgtctttac tcagttcgag tcaagatgtg 240
 atagatagga tatacaagca ggtggctctt gaatccccac tggcgctact aaacactgaa 300
 tctatgatta tgaatgcaat aacctctctt tcttatcaaa ttaacggggc tgcgaacaat 360
 agcggatgtg gggcgccctgt tcatgaccca gattatateg gggggatagg caaagaactc 420
 atagtggacg acatcagtga tgtcacatca ttttatcctt ctgcataatca agaacacttg 480
 aatttcatcc cggcgccctac tacaggatcc ggttgccact ggataccctc atttgacatg 540
 agcaccaccc attattgtta tactcacaat gtgatactat ccggttgacg agatcactca 600
 cactcacalc aatacttagc acttggtgtg ctteggacat ctgcaacagg gagggatttc 660
 ttttctactc tgcgctccat caatttagat gacacccaaa atcggaagtc ctgcagtgtg 720
 agtgcacccc ctttaggttg tgatatgctg tgctctaagg tcacagggac tgaagaggag 780
 gattacaagt cagttgcccc cacaccaatg gtgcacggaa ggctagggtt tgacgggtcaa 840
 taccatgaga aggacttaga caccacggtc ttatllaaag attggglggc aaatlaccca 900
 ggagtgggag gaggggtcttt tattgacaac cgtgtatggg tcccagttta cggagggttc 960
 aaaccaatt caccacgtga cactgcacaa gaagggaat atgtaataa taagcgccat 1020
 aacaacacat gccccgataa acaagattac caaattcgga tggctaagtc ttcataataa 1080
 cccgggcgat ttggtggaaa gcgcgtacag caagccatct tatccatcaa agtgtcaaca 1140
 tccttgggta aggaccgggt gctgactatt ccacctata caatcacact catgggagcc 1200
 gaaggcagaa tcctcacagt aggacatct cacttcttgt accaacgagg gtcttcatat 1260
 ttctcccctg ccttattata tcccatgaca gtaaataaca aaacggctac actccatagt 1320
 ccttatacgt ttaatgcttt cactcggcca ggtagtggcc cttgccaggc atcagcaaga 1380
 tgccccaact catgcatcac tggagtctat actgatccat atcccttaat ctccatagg 1440
 aatcatactc tacgaggggt cttegggacg atgcttgatg atgaacaagc gagacttaac 1500
 cccgtatctg cagtattcga caacatatcc cgcagtcgtg tcacccgggt gagttcaagc 1560
 agcaccaagg cagcatacac aacatcgaca tgttttaag ttgtcaagac caataaagct 1620

tattgtctta gtattgcaga aatatccaat accctattcg gggaatttag gatcggtccc 1680
 ttattagtgtg agatcctcaa ggatgataga gtt 1713

<210> 17
 <211> 571
 <212> PRT
 <213> artificial sequence

<220>
 <223> NDV HN protein (ACM67348)

<400> 17
 Met Gly Arg Ala Val Asn Arg Val Ala Leu Glu Asn Glu Glu Arg Glu
 1 5 10 15
 Ala Lys Asn Thr Trp Arg Leu Val Phe Arg Ile Ala Val Leu Leu Leu
 20 25 30
 Met Val Met Thr Leu Ala Ile Ser Ala Ala Ala Leu Ala Tyr Ser Ala
 35 40 45
 Gly Ala Ser Thr Pro His Asp Leu Ala Gly Ile Ser Thr Val Ile Ser
 50 55 60
 Lys Thr Glu Asp Lys Val Thr Ser Leu Leu Ser Ser Ser Gln Asp Val
 65 70 75 80
 Ile Asp Arg Ile Tyr Lys Gln Val Ala Leu Glu Ser Pro Leu Ala Leu
 85 90 95
 Leu Asn Thr Glu Ser Met Ile Met Asn Ala Ile Thr Ser Leu Ser Tyr
 100 105 110
 Gln Ile Asn Gly Ala Ala Asn Asn Ser Gly Cys Gly Ala Pro Val His
 115 120 125
 Asp Pro Asp Tyr Ile Gly Gly Ile Gly Lys Glu Leu Ile Val Asp Asp
 130 135 140
 Ile Ser Asp Val Thr Ser Phe Tyr Pro Ser Ala Tyr Gln Glu His Leu
 145 150 155 160
 Asn Phe Ile Pro Ala Pro Thr Thr Gly Ser Gly Cys Thr Arg Ile Pro
 165 170 175
 Ser Phe Asp Met Ser Thr Thr His Tyr Cys Tyr Thr His Asn Val Ile
 180 185 190
 Leu Ser Gly Cys Arg Asp His Ser His Ser His Gln Tyr Leu Ala Leu
 195 200 205
 Gly Val Leu Arg Thr Ser Ala Thr Gly Arg Val Phe Phe Ser Thr Leu
 210 215 220
 Arg Ser Ile Asn Leu Asp Asp Thr Gln Asn Arg Lys Ser Cys Ser Val
 225 230 235 240
 Ser Ala Thr Pro Leu Gly Cys Asp Met Leu Cys Ser Lys Val Thr Gly
 245 250 255
 Thr Glu Glu Glu Asp Tyr Lys Ser Val Ala Pro Thr Pro Met Val His
 260 265 270
 Gly Arg Leu Gly Phe Asp Gly Gln Tyr His Glu Lys Asp Leu Asp Thr
 275 280 285
 Thr Val Leu Phe Lys Asp Trp Val Ala Asn Tyr Pro Gly Val Gly Gly
 290 295 300
 Gly Ser Phe Ile Asp Asn Arg Val Trp Phe Pro Val Tyr Gly Gly Leu
 305 310 315 320
 Lys Pro Asn Ser Pro Ser Asp Thr Ala Gln Glu Gly Lys Tyr Val Ile
 325 330 335
 Tyr Lys Arg His Asn Asn Thr Cys Pro Asp Lys Gln Asp Tyr Gln Ile
 340 345 350

Arg Met Ala Lys Ser Ser Tyr Lys Pro Gly Arg Phe Gly Gly Lys Arg
 355 360 365
 Val Gln Gln Ala Ile Leu Ser Ile Lys Val Ser Thr Ser Leu Gly Lys
 370 375 380
 Asp Pro Val Leu Thr Ile Pro Pro Asn Thr Ile Thr Leu Met Gly Ala
 385 390 395 400
 Glu Gly Arg Ile Leu Thr Val Gly Thr Ser His Phe Leu Tyr Gln Arg
 405 410 415
 Gly Ser Ser Tyr Phe Ser Pro Ala Leu Leu Tyr Pro Met Thr Val Asn
 420 425 430
 Asn Lys Thr Ala Thr Leu His Ser Pro Tyr Thr Phe Asn Ala Phe Thr
 435 440 445
 Arg Pro Gly Ser Ala Pro Cys Gln Ala Ser Ala Arg Cys Pro Asn Ser
 450 455 460
 Cys Ile Thr Gly Val Tyr Thr Asp Pro Tyr Pro Leu Ile Phe His Arg
 465 470 475 480
 Asn His Thr Leu Arg Gly Val Phe Gly Thr Met Leu Asp Asp Glu Gln
 485 490 495
 Ala Arg Leu Asn Pro Val Ser Ala Val Phe Asp Asn Ile Ser Arg Ser
 500 505 510
 Arg Val Thr Arg Val Ser Ser Ser Ser Thr Lys Ala Ala Tyr Thr Thr
 515 520 525
 Ser Thr Cys Phe Lys Val Val Lys Thr Asn Lys Ala Tyr Cys Leu Ser
 530 535 540
 Ile Ala Glu Ile Ser Asn Thr Leu Phe Gly Glu Phe Arg Ile Val Pro
 545 550 555 560
 Leu Leu Val Glu Ile Leu Lys Asp Asp Arg Val
 565 570

<210> 18

<211> 1716

<212> DNA

<213> artificial sequence

<220>

<223> NDV HN DNA (strain ZJ1)

<400> 18

atggaccgcg	cggttaacag	agtcgtgctg	gagaatgagg	aaagagaagc	aaagaacaca	60
tggcgccctgg	ttttccggat	cgcagtctta	cttttaaatgg	taatgactct	agctatctcc	120
gcagctgccc	tggcatacag	tacggggggcc	agtacgccgc	acgacctcgc	aggcatatcg	180
actgtgatct	ccaagacaga	agataagggt	acatctttac	tcagtttgag	tcaagatgtg	240
atagataaga	tatacaagca	ggtggctctt	gaatccccgc	tggcgctact	aaacactgaa	300
tctataatta	tgaatgcaat	aacctctctt	tcttatcaaa	ttaacggggc	tgcgaacaat	360
agcggatgtg	gggcgcctgt	tcatgaccca	gattatatcg	gggggatagg	caaagaactc	420
atagtggacg	acatcagtga	tgtcacatca	ttttatcctt	ctgcatatca	agaacacttg	480
aatttcaccc	cggcgccctac	tacaggatcc	ggttgcactc	ggataccctc	atttgacatg	540
agcaccaccc	attattgtta	tactcacaat	gtgatactat	ccggttgcag	agatcactca	600
cactcacatc	aatacttagc	acttggtgtg	cttcggacat	ctgcaacagg	gagggtatcc	660
ttttctactc	tgcgctccac	caatttagat	gacacccaaa	atcggaagtc	ctgcagtgtg	720
agtgcaaccc	ctttagggtt	tgatatgctg	tgctctaagg	tcacagagac	tgaagaggag	780
gattacaagt	cagttgcccc	cacatcaatg	gtgcacggaa	ggctaggggt	tgacgggtcaa	840
taccatgaga	aggacttaga	caccacggtc	ttattttaagg	attgggtggc	aaattaccca	900
ggagcgggag	gaggggtctt	tattgacgac	cgtgtatgg	tcccagttta	cggagggctc	960
aaacccaatt	caccacgtga	cactgcacaa	gaagggaat	atgtaataata	caagcgccat	1020
aacaacacat	gccctgatga	acaagattac	caaattcgga	tggctaagtc	ttcatataaa	1080

```

ccccggcgat ttgggtggaaa ggcggtacag caagccatcc tatccatcaa agtgtcaaca 1140
tccttgggta aggacccggt gctgactatt ccacctata caatcacact catgggagcc 1200
gaaggcagaa tcctcacagt agggacatct cacttcttgt accaacgagg gtcttcatat 1260
ttctcccctg ccttattata tcccatgaca gtaaataaca aaacggctac actccatagt 1320
ccttatacgt ttaatgcttt cactcggcca ggtagtgtcc cttgccaggc atcagcaaga 1380
tgccccaact catgcatcac tgggggtctat actgatccat atcccttaat cttccatagg 1440
aatcatactc tacgaggggt cttcgggacg atgcttgatg atgaacaagc gagacttaac 1500
cccgatatctg cagtattcga caacatatct cgcagtcgtg tcacccgggt gagttcaagc 1560
agcaccaagg cagcatacac gacatcgaca tgttttaaag ttgtcaagac caataaaact 1620
tattgtctta gtattgcaga aatatccaat accctattcg gggaatttag gatcgttccc 1680
ttattagttg agatcctcaa ggatgataga gtttaa 1716

```

<210> 19

<211> 571

<212> PRT

<213> artificial sequence

<220>

<223> NDV HN protein (AAL18936)

<400> 19

```

Met Asp Arg Ala Val Asn Arg Val Val Leu Glu Asn Glu Glu Arg Glu
1          5          10          15
Ala Lys Asn Thr Trp Arg Leu Val Phe Arg Ile Ala Val Leu Leu Leu
          20          25          30
Met Val Met Thr Leu Ala Ile Ser Ala Ala Ala Leu Ala Tyr Ser Thr
          35          40          45
Gly Ala Ser Thr Pro His Asp Leu Ala Gly Ile Ser Thr Val Ile Ser
          50          55          60
Lys Thr Glu Asp Lys Val Thr Ser Leu Leu Ser Leu Ser Gln Asp Val
65          70          75          80
Ile Asp Lys Ile Tyr Lys Gln Val Ala Leu Glu Ser Pro Leu Ala Leu
          85          90          95
Leu Asn Thr Glu Ser Ile Ile Met Asn Ala Ile Thr Ser Leu Ser Tyr
          100          105          110
Gln Ile Asn Gly Ala Ala Asn Asn Ser Gly Cys Gly Ala Pro Val His
          115          120          125
Asp Pro Asp Tyr Ile Gly Gly Ile Gly Lys Glu Leu Ile Val Asp Asp
130          135          140
Ile Ser Asp Val Thr Ser Phe Tyr Pro Ser Ala Tyr Gln Glu His Leu
145          150          155          160
Asn Phe Ile Pro Ala Pro Thr Thr Gly Ser Gly Cys Thr Arg Ile Pro
          165          170          175
Ser Phe Asp Met Ser Thr Thr His Tyr Cys Tyr Thr His Asn Val Ile
          180          185          190
Leu Ser Gly Cys Arg Asp His Ser His Ser His Gln Tyr Leu Ala Leu
          195          200          205
Gly Val Leu Arg Thr Ser Ala Thr Gly Arg Val Phe Phe Ser Thr Leu
210          215          220
Arg Ser Thr Asn Leu Asp Asp Thr Gln Asn Arg Lys Ser Cys Ser Val
225          230          235          240
Ser Ala Thr Pro Leu Gly Cys Asp Met Leu Cys Ser Lys Val Thr Glu
          245          250          255
Thr Glu Glu Glu Asp Tyr Lys Ser Val Ala Pro Thr Ser Met Val His
260          265          270

```


Gly Arg Leu Gly Phe Asp Gly Gln Tyr His Glu Lys Asp Leu Asp Thr
 275 280 285
 Thr Val Leu Phe Lys Asp Trp Val Ala Asn Tyr Pro Gly Ala Gly Gly
 290 295 300
 Gly Ser Phe Ile Asp Asp Arg Val Trp Phe Pro Val Tyr Gly Gly Leu
 305 310 315 320
 Lys Pro Asn Ser Pro Ser Asp Thr Ala Gln Glu Gly Lys Tyr Val Ile
 325 330 335
 Tyr Lys Arg His Asn Asn Thr Cys Pro Asp Glu Gln Asp Tyr Gln Ile
 340 345 350
 Arg Met Ala Lys Ser Ser Tyr Lys Pro Gly Arg Phe Gly Gly Lys Arg
 355 360 365
 Val Gln Gln Ala Ile Leu Ser Ile Lys Val Ser Thr Ser Leu Gly Lys
 370 375 380
 Asp Pro Val Leu Thr Ile Pro Pro Asn Thr Ile Thr Leu Met Gly Ala
 385 390 395 400
 Glu Gly Arg Ile Leu Thr Val Gly Thr Ser His Phe Leu Tyr Gln Arg
 405 410 415
 Gly Ser Ser Tyr Phe Ser Pro Ala Leu Leu Tyr Pro Met Thr Val Asn
 420 425 430
 Asn Lys Thr Ala Thr Leu His Ser Pro Tyr Thr Phe Asn Ala Phe Thr
 435 440 445
 Arg Pro Gly Ser Val Pro Cys Gln Ala Ser Ala Arg Cys Pro Asn Ser
 450 455 460
 Cys Ile Thr Gly Val Tyr Thr Asp Pro Tyr Pro Leu Ile Phe His Arg
 465 470 475 480
 Asn His Thr Leu Arg Gly Val Phe Gly Thr Met Leu Asp Asp Glu Gln
 485 490 495
 Ala Arg Leu Asn Pro Val Ser Ala Val Phe Asp Asn Ile Ser Arg Ser
 500 505 510
 Arg Val Thr Arg Val Ser Ser Ser Ser Thr Lys Ala Ala Tyr Thr Thr
 515 520 525
 Ser Thr Cys Phe Lys Val Val Lys Thr Asn Lys Thr Tyr Cys Leu Ser
 530 535 540
 Ile Ala Glu Ile Ser Asn Thr Leu Phe Gly Glu Phe Arg Ile Val Pro
 545 550 555 560
 Leu Leu Val Glu Ile Leu Lys Asp Asp Arg Val
 565 570

<210> 20

<211> 525

<212> PRT

<213> artificial sequence

<220>

<223> NDV HN mature protein sequence (without signal pepetide of ACM67348)

<400> 20

Ser Ala Gly Ala Ser Thr Pro His Asp Leu Ala Gly Ile Ser Thr Val
 1 5 10 15
 Ile Ser Lys Thr Glu Asp Lys Val Thr Ser Leu Leu Ser Ser Ser Gln
 20 25 30
 Asp Val Ile Asp Arg Ile Tyr Lys Gln Val Ala Leu Glu Ser Pro Leu
 35 40 45

Ala	Leu	Leu	Asn	Thr	Glu	Ser	Met	Ile	Met	Asn	Ala	Ile	Thr	Ser	Leu
50						55				60					
Ser	Tyr	Gln	Ile	Asn	Gly	Ala	Ala	Asn	Asn	Ser	Gly	Cys	Gly	Ala	Pro
65				70					75						80
Val	His	Asp	Pro	Asp	Tyr	Ile	Gly	Gly	Ile	Gly	Lys	Glu	Leu	Ile	Val
				85					90					95	
Asp	Asp	Ile	Ser	Asp	Val	Thr	Ser	Phe	Tyr	Pro	Ser	Ala	Tyr	Gln	Glu
			100					105					110		
His	Leu	Asn	Phe	Ile	Pro	Ala	Pro	Thr	Thr	Gly	Ser	Gly	Cys	Thr	Arg
		115					120					125			
Ile	Pro	Ser	Phe	Asp	Met	Ser	Thr	Thr	His	Tyr	Cys	Tyr	Thr	His	Asn
130					135					140					
Val	Ile	Leu	Ser	Gly	Cys	Arg	Asp	His	Ser	His	Ser	His	Gln	Tyr	Leu
145					150					155					160
Ala	Leu	Gly	Val	Leu	Arg	Thr	Ser	Ala	Thr	Gly	Arg	Val	Phe	Phe	Ser
				165					170					175	
Thr	Leu	Arg	Ser	Ile	Asn	Leu	Asp	Asp	Thr	Gln	Asn	Arg	Lys	Ser	Cys
			180					185					190		
Ser	Val	Ser	Ala	Thr	Pro	Leu	Gly	Cys	Asp	Met	Leu	Cys	Ser	Lys	Val
		195					200					205			
Thr	Gly	Thr	Glu	Glu	Glu	Asp	Tyr	Lys	Ser	Val	Ala	Pro	Thr	Pro	Met
210					215						220				
Val	His	Gly	Arg	Leu	Gly	Phe	Asp	Gly	Gln	Tyr	His	Glu	Lys	Asp	Leu
225					230					235					240
Asp	Thr	Thr	Val	Leu	Phe	Lys	Asp	Trp	Val	Ala	Asn	Tyr	Pro	Gly	Val
			245						250					255	
Gly	Gly	Gly	Ser	Phe	Ile	Asp	Asn	Arg	Val	Trp	Phe	Pro	Val	Tyr	Gly
			260					265					270		
Gly	Leu	Lys	Pro	Asn	Ser	Pro	Ser	Asp	Thr	Ala	Gln	Glu	Gly	Lys	Tyr
		275					280					285			
Val	Ile	Tyr	Lys	Arg	His	Asn	Asn	Thr	Cys	Pro	Asp	Lys	Gln	Asp	Tyr
290						295					300				
Gln	Ile	Arg	Met	Ala	Lys	Ser	Ser	Tyr	Lys	Pro	Gly	Arg	Phe	Gly	Gly
305					310					315					320
Lys	Arg	Val	Gln	Gln	Ala	Ile	Leu	Ser	Ile	Lys	Val	Ser	Thr	Ser	Leu
			325						330					335	
Gly	Lys	Asp	Pro	Val	Leu	Thr	Ile	Pro	Pro	Asn	Thr	Ile	Thr	Leu	Met
			340					345					350		
Gly	Ala	Glu	Gly	Arg	Ile	Leu	Thr	Val	Gly	Thr	Ser	His	Phe	Leu	Tyr
		355					360					365			
Gln	Arg	Gly	Ser	Ser	Tyr	Phe	Ser	Pro	Ala	Leu	Leu	Tyr	Pro	Met	Thr
370						375					380				
Val	Asn	Asn	Lys	Thr	Ala	Thr	Leu	His	Ser	Pro	Tyr	Thr	Phe	Asn	Ala
385					390					395					400
Phe	Thr	Arg	Pro	Gly	Ser	Ala	Pro	Cys	Gln	Ala	Ser	Ala	Arg	Cys	Pro
			405						410					415	
Asn	Ser	Cys	Ile	Thr	Gly	Val	Tyr	Thr	Asp	Pro	Tyr	Pro	Leu	Ile	Phe
			420					425					430		
His	Arg	Asn	His	Thr	Leu	Arg	Gly	Val	Phe	Gly	Thr	Met	Leu	Asp	Asp
		435					440					445			
Glu	Gln	Ala	Arg	Leu	Asn	Pro	Val	Ser	Ala	Val	Phe	Asp	Asn	Ile	Ser
		450				455					460				
Arg	Ser	Arg	Val	Thr	Arg	Val	Ser	Ser	Ser	Ser	Thr	Lys	Ala	Ala	Tyr
465					470					475					480
Thr	Thr	Ser	Thr	Cys	Phe	Lys	Val	Val	Lys	Thr	Asn	Lys	Ala	Tyr	Cys
			485						490					495	

Leu Ser Ile Ala Glu Ile Ser Asn Thr Leu Phe Gly Glu Phe Arg Ile
 500 505 510
 Val Pro Leu Leu Val Glu Ile Leu Lys Asp Asp Arg Val
 515 520 525

<210> 21
 <211> 46
 <212> PRT
 <213> artificial sequence

<220>
 <223> NDV HN signal peptide (of ACM67348)

<400> 21
 Met Gly Arg Ala Val Asn Arg Val Ala Leu Glu Asn Glu Glu Arg Glu
 1 5 10 15
 Ala Lys Asn Thr Trp Arg Leu Val Phe Arg Ile Ala Val Leu Leu Leu
 20 25 30
 Met Val Met Thr Leu Ala Ile Ser Ala Ala Ala Leu Ala Tyr
 35 40 45

<210> 22
 <211> 1713
 <212> DNA
 <213> artificial sequence

<220>
 <223> NDV HN codon-optimized (duckweed-preferred) DNA (for ACM67348)

<400> 22
 atgggcccggg ccgtcaaccg cgtggcggtg gagaacgagg agcggggaggc caagaacacc 60
 tggaggctcg tgttcgcgat cgccgtgctc ctgctcatgg tcatgaccct ggcgatctcg 120
 gccgcggccc tggcctactc cgccggtgcg agcacccegc acgacctggc cgggatcagc 180
 accgtcatct cgaagaccga ggacaagggtg acgtccctgc tcagctcgtc ccaggacggt 240
 atcgaccgca tctacaagca agtcgccttg gagagccctc tggccctgct caacacggag 300
 agcatgatca tgaacgcgat cacctccctg agctaccaga tcaacggggc cgcgaacaat 360
 tccgggtgcg gcgccccgt gcacgaccct gactacatcg gcgggatcgg caaggaactc 420
 atcgttgacg acatcagcga cgtgacgtcg ttctacccct ccgcctacca ggagcacctc 480
 aacttcatec ccgccccgac cacggggagc ggctgcaccc ggatcccgtc cttecgacatg 540
 tccaccacgc actattgcta caccacaaac gtgatcctgt cgggggtgccg cgaccacagc 600
 cactcgcacc agtacctggc gctgggcgtc ctcaggacct ccgcgaccgg ccgcgtgttc 660
 ttctccactc tccgtccat caacctggac gatacgcaga accgcaagtc ctgcagcgtg 720
 tccgccacgc ccctcggtg cgacatgctc tgctccaagg tgaccggcac cgaggaggag 780
 gactacaagt ccgtggcccc caccocgatg gtgcacgggc ggctcggctt cgatggtcag 840
 taccacgaga aggacctgga cacgaccgtg ctcttcaagg actgggtggc gaactacccc 900
 ggtgtggggg gcggtagctt catcgacaac agagtctggt tccccgtgta cgggggcctg 960
 aagcccaact cccctccga cacggcccag gaggggaagt acgtcatcta caagcggcac 1020
 aacaacacct gcccggaaca gcaggactat cagatccgga tggccaaaag ctctacaag 1080
 cccggccgct tcgggggcaa gagagtccag caggcgatcc tctccatcaa ggtgagcacg 1140
 agcctcggca aggaccgggt cctgaccatc cccccgaaca ccataccct catgggcgcc 1200
 gaggggagaa tctcactgt cggcacctcc cacttcctgt accagcgggg cagctcgtac 1260
 ttcagcccgg cgtcctgta cccgatgacc gtcaacaaca agaccgccac gctgcaactc 1320
 ccctacacct tcaacgcctt caccgcgcc gccagcggcc cgtgccaggc ctccgccgcg 1380
 tgcccgaaact cgtgcatcac cgggggtctac accgacctt acccgtgat cttccaccgc 1440
 aaccacacgc tcaggggggt gttcgggacc atgctcgacg acgagcaggc tcgcctgaac 1500


```

cccgtcagcg ccgtcttcga caacatctcc cgcagccgcg tcaagagagt ctctcgtcc 1560
tcgacgaagg ccgcgtacac cacgtccacc tgcttcaagg tggttaagac caacaaagcc 1620
taactgcctct ccacgctga gatctccaac accctcttcg gcgagttccg gatcgtgccc 1680
ctcttggtgg agatcctgaa ggacgaccgc gtg 1713

```

<210> 23
 <211> 1575
 <212> DNA
 <213> artificial sequence

<220>
 <223> NDV HN codon-optimized (duckweed) encoding mature protein
 (ACM67348)

```

<400> 23
tcgcgcggtg cgagcacccc gcacgacctg gccgggatca gcaccgtcat ctggaagacc 60
gaggacaagg tgacgtccct gctcagctcg tcccaggacg ttatcgaccg catctacaag 120
caagtcgcct tggagagccc tctggccctg ctcaacacgg agagcatgat catgaacgcg 180
atcacctccc tgagctacca gatcaacggg gccgcgaaca attccgggtg cggcgcccc 240
gtgcacgacc ctgactacat cggcgggatc ggcaaggaa tcacgttga cgacateagc 300
gacgtgacgt cgttctaccc ctccgcctac caggagcacc tcaacttcac ccccgccccg 360
accacgggga gcggtgcac ccgatcccc tccttcgaca tgtccaccac gcaactattgc 420
tacaccaca acgtgatect gtcggggtgc cgcgaccaca gccactcgca ccagtaacctg 480
gcgctgggcg tcctcaggac ctccgcgacc gccgcggtgt tcttctccac tctccgctcc 540
atcaacctgg acgatacgca gaaccgcaag tcctgcagcg tgcccgccac gccctcggc 600
tgcgacatgc tctgctccaa ggtgaccggc accgaggagg aggactacaa gtccgtggcc 660
cccacccgga tgggtgcacgg gcggtcggc ttcgatggtc agtaccacga gaaggacctg 720
gacacgaccg tgctcttcaa ggactgggtg gcgaactacc ccggtgtggg gggcggtagc 780
ttcatcgaca acagagtctg gttccccgtg tacggggggc tgaagcccaa ctccccctcc 840
gacacggccc aggaggggaa gtacgtcatc tacaagcggc acaacaacac ctgcccgac 900
aagcaggact atcagatccg gatggccaaa agctcctaca agcccgccg ctccgggggc 960
aagagagtcc agcaggcgat cctctccatc aaggtgagca cgagcctcgg caaggaccog 1020
gtcctgacca tcccccgaa caccatcacc ctcatgggcg ccgaggggag aatcctcact 1080
gtcggcacct cccacttcct gtaccagcgg gccagctcgt acttcagccc ggcgctcctg 1140
taccgatga ccgtcaacaa caagaccgcc acgctgcact cgcctacac cttcaacgcc 1200
ttacccgcc ccggcagcgc cccgtgccag gcctccgcc gctgccgaa ctcgtgcac 1260
accggggtct acaccgaccc ttaccgctg atcttccacc gcaaccacac gctcaggggg 1320
gtgttcggga coatgctga cgacgagcag gctcgcctga acccgtcag cgcgctctc 1380
gacaacatct cccgcagccg cgtcacgaga gtctcctcgt cctcgacgaa ggcgcgtac 1440
accacgtcca cctgcttcaa ggtggttaag accaacaag cctactgcct ctccatcgt 1500
gagatctcca acacctctt cggcgagttc cggatcgtgc cctcttggt ggagatcctg 1560
aaggacgacc gcgtg 1575

```

<210> 24
 <211> 4
 <212> PRT
 <213> artificial sequence

<220>
 <223> ER retention seq

<400> 24
 Lys Asp Glu Leu
 1

<210> 25
 <211> 93
 <212> DNA
 <213> artificial sequence

 <220>
 <223> alpha amylase signal seq

 <400> 25
 atgcagggtcc tgaacacgat ggtcaacaag cacttcctct cctgtccgt cctcatcgtc 60
 ctctcgggc tgagcagcaa cctcaccgcc ggc 93

<210> 26
 <211> 31
 <212> PRT
 <213> artificial sequence

 <220>
 <223> alpha amylase signal peptide

<400> 26
 Met Gln Val Leu Asn Thr Met Val Asn Lys His Phe Leu Ser Leu Ser
 1 5 10 15
 Val Leu Ile Val Leu Leu Gly Leu Ser Ser Asn Leu Thr Ala Gly
 20 25 30

<210> 27
 <211> 138
 <212> DNA
 <213> artificial sequence

<220>
 <223> NDV HN signal sequence codon-optimized (duckweed)

<400> 27
 atgggccggg cgtcaaccg cgtggcggtg gagaacgagg agcgggaggg caagaacacc 60
 tggaggctcg tgttcgcgat cgccgtgctc ctgctcatgg tcatgaccct ggcgatctcg 120
 gccgcggccc tggcctac 138

<210> 28
 <211> 14
 <212> PRT
 <213> artificial sequence

<220>
 <223> NDV HN linear epitope region 3

<400> 28
 Pro Asp Lys Gln Asp Tyr Gln Ile Arg Met Ala Lys Ser Ser
 1 5 10

CLAIMS:

1. *Schizochytrium* culture stably transformed with a gene for expressing an NDV HN polypeptide or antigen comprising an amino acid sequence as set forth in SEQ ID NO: 3, 5, 7, 9, 15, 17, 19, or 20.
2. A method of producing an NDV HN polypeptide or antigen, comprising:
(a) culturing a *Schizochytrium* culture within a *Schizochytrium* culture medium, wherein the *Schizochytrium* culture is stably transformed to express the NDV HN polypeptide, and wherein the NDV HN polypeptide is expressed from a nucleotide sequence comprising a coding sequence for the NDV HN polypeptide and an operably linked coding sequence for a signal peptide that directs secretion of the polypeptide into said culture medium and the NDV HN polypeptide or antigen comprises an amino acid sequence as set forth in SEQ ID NO: 3, 5, 7, 9, 15, 17, 19, or 20; and (b) collecting the NDV HN polypeptide or antigen from the culture medium.
3. The method of claim 2, wherein the signal peptide has a sequence as set forth in SEQ ID NO: 13, or 21.
4. A plasmid comprising a DNA fragment encoding a signal peptide having a sequence as set forth in SEQ ID NO: 13, or 21 wherein the DNA fragment is operably linked to a polynucleotide encoding an NDV HN polypeptide or antigen comprising an amino acid sequence as set forth in SEQ ID NO: 3, 5, 7, 9, 15, 17, 19, or 20, wherein the plasmid is for *Schizochytrium* transformation.

Figure 1

SEQ ID NO:	Type	Description
1	DNA	NDV HN codon-optimized DNA
2	DNA	NDV HN wild type DNA (EF520717) (gamefowl/US(CA)/212676/2002 strain)
3	Protein	NDV HN protein (ABS84265) (gamefowl/US(CA)/212676/2002 strain)
4	DNA	NDV HN DNA (M21409) (Texas GB strain)
5	Protein	NDV HN protein (P12553) (Texas GB strain)
6	DNA	NDV HN DNA (M24709) (LaSota strain)
7	Protein	NDV HN protein (AAA46659) (LaSota strain)
8	DNA	NDV HN DNA (AY288999) (MEX/96 strain)
9	Protein	NDV HN protein (AAQ54638) (MEX/96 strain)
10	Protein	NDV HN Linear Epitope Region 1
11	Protein	NDV HN Linear Epitope Region 2
12	DNA	NDV HN signal sequence
13	Protein	NDV HN signal peptide (from SEQ ID NO:3, ABS84265)
14	DNA	NDV HN DNA encoding mature protein (without signal sequence, 79bp -1716bp of SEQ ID NO:1) (codon-optimized)
15	Protein	NDV HN mature protein (without signal peptide, 27aa-571aa of SEQ ID NO:3) (EF520717) (gamefowl/US(CA)/212676/2002 strain)
16	DNA	NDV HN DNA (FJ608369) (NDV strain chicken YZCQ/Liaoning/08)
17	Protein	NDV HN protein(ACM67348) (NDV strain chicken YZCQ/Liaoning/08)
18	DNA	NDV HN DNA (NDV strain ZJ1)
19	Protein	NDV HN protein (AAL18936) (NDV strain ZJ1)
20	Protein	NDV HN mature protein (without signal peptide, 47aa-571aa of SEQ ID NO:17, ACM67348)
21	Protein	NDV HN signal peptide (from SEQ ID NO:17, ACM67348)
22	DNA	NDV HN codon-optimized DNA encoding ACM67348
23	DNA	NDV HN codon-optimized DNA encoding mature protein (without signal sequence, 139 bp -1713 bp of SEQ ID NO:22, NDV strain chicken YZCQ/Liaoning/08)
24	Protein	ER retention sequence (KDEL)
25	DNA	alpha amylase signal sequence
26	protein	alpha amylase signal peptide
27	DNA	NDV HN signal sequence, codon-optimized (duckweed- preferred codon optimization) (1-138 bp of SEQ ID NO:22)
28	protein	NDV HN Linear Epitope Region 3

Figure 2a (1/2)

HN Sequences of LaSota, CA/02 and TX/GB strains of NDV. Glycosylation sites are underlined.

NDV HN CA/02 (ABS84265) (SEQ ID NO:3)

```

1  MDRVVSRVVL ENEEREAKNT WRLVFRVAVL SLIVMTLAIS VAALVYSMEA STPNDLAGIS
61 TVISRAEDRV TSLNLSNQDV VDRVYKQVAL ESPLALLNTE SIIMNAITSL SYQINGAANS
121 SGCGAPVHDP DYIGGVGKEL IVDDTSDATS FYPSAYQEHL NFIPAPTTGS GCTRIPSFDM
181 SATHYCYTHN VILSGCRDHS HSHQYLALGV LRSTATGRVF FSTLRSINLD DTQNRKSCSV
241 SATPLGCDML CSKVTETEEE DYKSVTPISM VHGRLGFDGQ YHEKDLDVTV LFKDWVANYP
301 GVGGGSLIDD RVWFPVYGGL KPNSPSDTAQ EGKYVIYKRY NDTCPDEQDY QVRMAKSSYK
361 PGRFGGKRVQ QAILSIVKST SLGEDPVLTV PPNTVTLMGA EGRILTVGTS HFLYQRGSSY
421 FSPALLYPMT VRNKTATLHS PYTFNAFTRP GSVPCQASAR CPNSCITGVY TDPYPVVFHR
481 NHTLRGVFGT MLDNEQARLN PVSAIFDYTS RSRITRVSS STKAAYTTST CFKVVKTNKV
541 YCLSIAEISN TLFGEFRIVP LLVEILKDDR V

```

NDV HN TX/GB (P12553) (SEQ ID NO:5)

```

1  MDRAVSQVAL ENDEREAKNT WRLIFRIAIL LLTVVTLATS VASLVYSMGA STPSDLVGIP
61 TRISRAEEKI TSALGSNQDV VDRIYKQVAL ESPLALLNTE TTIMNAITSL SYQINGAANN
121 SGWGAPIHDP DFIGGIGKEL IVDDASDVTS FYPSAFQEH NFIPAPTTGS GCIRIPSFDM
181 SATHYCYTHN IISGCRDHS HSYQYLALGV LRSTATGRIF FSTLRSINLD DTQNRKSCSV
241 SATPLGCDML CSKVTETEEE DYN SAVPTLM VHGRLGFDGQ YHEKDLDVTT LFEDWVANYP
301 GVGGGSFIDS RVWFSVYGGL KPNSPSDTVQ EEKYVIYKRY NDTCPDEQDY QIRMAKSSYK
361 PGRFGGKRIQ QAILSIVKST SLGEDPVLTV PPNTVTLMGA EGRILTVGTS HFLYQRGSSY
421 FSPALLYPMT VSNKTATLHS PYTFNAFTRP GSIPCQASAR CPNSCVTGVY TDPYPLIFYR
481 NHTLRGVFGT MLDGEQARLN PASAVFDSTS RSRITRVSS STKAAYTTST CFKVVKNKT
541 YCLSIAEISN TLFGEFRIVP LLVEILKNDG VREARSG

```

NDV HN LaSota (AAA46659) (SEQ ID NO:7)

```

MDRAVSQVAL ENDEREAKNT WRLIFRIAIL FLTVVTLAIS VASLLYSMGA STPSDLVGIP 60
TRISRAEEKI TSLGNSQDV VDRIYKQVAL ESPLALLKTE TTIMNAITSL SYQINGAANN 120
SGWGAPIHDP DYIGGIGKEL IVDDASDVTS FYPSAFQEHL NFIPAPTTGS GCTRIPSFDM 180
SATHYCYTHN VILSGCRDHS HSYQYLALGV LRSTATGRVF FSTLRSINLD DTQNRKSCSV 240
SATPLGCDML CSKVTETEEE DYN SAVPTRM AHGR LGFDGQ YHEKDLDVTT LFGDWVANYP 300
GVGGGSFIDG RVWFSVYGGL KPNSPSDTVQ EGKYVIYKRY NDTCPDEQDY QIRMAKSSYK 360
PGRFGGKRIQ QAILSIVKST SLGEDPVLTV PPNTVTLMGA EGRILTVGTS HFLYQRGSSY 420
FSPALLYPMT VSNKTATLHS PYTFNAFTRP GSIPCQASAR CPNPCVTGVY TDPYPLIFYR 480
NHTLRGVFGT MLDGVQARLN PTS AVFDSTS RSRITRVSS STKAAYTTST CFKVVKNKT 540
YCLSIAEISN TLFGEFRIVP LLVEILKDDG VREARSG 577

```


Figure 3

Figure 3A




Figure 3B


Hemagglutination activity:

Figure 4


Secretion of HN protein by transgenic *Schizochytrium* - immunoblot analysis

Figure 5 (1/2)





Figure 5 (2/2)

B**NSI-Total Ion Mapping of permethylated N-glycans****C**

Proposed Structure	Mass [M+Na]	Charge State [z]	23
Hex ₅ HexNAC ₂	1579 802	1 2	100
Hex ₆ HexNAC ₂	1783 903	1 2	100
Hex ₇ HexNAC ₂	1987 1005	1 2	100
Hex ₈ HexNAC ₂	1106	2	100
Hex ₉ HexNAC ₂	1210	2	100
Hex ₁₀ HexNAC ₂	1312	2	100

Figure 6a (1/2)

	1	50
NDV HN ABS84265 (CA2002)	(1)	MDRVVERVLENEEREAKNTWRLLVFRVAVLSLIVMTLALISVAILVYSMEA
NDV HN MEX96 (AAQ54638)	(1)	MDRVVERVLENEEREAKNTWRLLVFRVAVLSLIVMTLALISVAILVYSMEA
NDV HN LaSota (AAA46659)	(1)	MDRVVSOVALENDEREAKNTWRLLVFRVAVLSLIVMTLALISVAILVYSMEA
NDV HN Texas (P12553)	(1)	MDRVVSOVALENDEREAKNTWRLLVFRVAVLSLIVMTLALISVAILVYSMEA
NDV HN Liaoning (ACM67348)	(1)	MGRVVRVLENEEREAKNTWRLLVFRVAVLSLIVMTLALISVAILVYSMEA
NDV HN ZJ1 (AAL18936)	(1)	MGRVVRVLENEEREAKNTWRLLVFRVAVLSLIVMTLALISVAILVYSMEA
	51	100
NDV HN ABS84265 (CA2002)	(51)	STPNDLACISTVISHAEEDVTSLENSQDVVDRIYKQVALESPLALLITE
NDV HN MEX96 (AAQ54638)	(51)	STPNDLACISTVISHAEEDVTSLENSQDVVDRIYKQVALESPLALLITE
NDV HN LaSota (AAA46659)	(51)	STPSDLVGIPTRISKAEKKTSTLGEMQDVVDRIYKQVALESPLALLITE
NDV HN Texas (P12553)	(51)	STPSDLVGIPTRISKAEKKTSTLGEMQDVVDRIYKQVALESPLALLITE
NDV HN Liaoning (ACM67348)	(51)	STPHDLACISTVISHAEEDVTSLENSQDVVDRIYKQVALESPLALLITE
NDV HN ZJ1 (AAL18936)	(51)	STPHDLACISTVISHAEEDVTSLENSQDVVDRIYKQVALESPLALLITE
	101	150
NDV HN ABS84265 (CA2002)	(101)	ETIMNAITSLSYQINGAANSSCGAPVHDPDYIGGVGKELIVDDTSDATE
NDV HN MEX96 (AAQ54638)	(101)	ETIMNAITSLSYQINGAANSSCGAPVHDPDYIGGVGKELIVDDTSDATE
NDV HN LaSota (AAA46659)	(101)	ETIMNAITSLSYQINGAANSSCGAPVHDPDYIGGVGKELIVDDTSDATE
NDV HN Texas (P12553)	(101)	ETIMNAITSLSYQINGAANSSCGAPVHDPDYIGGVGKELIVDDTSDATE
NDV HN Liaoning (ACM67348)	(101)	ETIMNAITSLSYQINGAANSSCGAPVHDPDYIGGVGKELIVDDTSDATE
NDV HN ZJ1 (AAL18936)	(101)	ETIMNAITSLSYQINGAANSSCGAPVHDPDYIGGVGKELIVDDTSDATE
	151	200
NDV HN ABS84265 (CA2002)	(151)	FYPSTQEHENFIPAPTTGSGCTRIPSFDMSTHYCYTHNVILSGCRDHS
NDV HN MEX96 (AAQ54638)	(151)	FYPSTQEHENFIPAPTTGSGCTRIPSFDMSTHYCYTHNVILSGCRDHS
NDV HN LaSota (AAA46659)	(151)	FYPSTQEHENFIPAPTTGSGCTRIPSFDMSTHYCYTHNVILSGCRDHS
NDV HN Texas (P12553)	(151)	FYPSTQEHENFIPAPTTGSGCTRIPSFDMSTHYCYTHNVILSGCRDHS
NDV HN Liaoning (ACM67348)	(151)	FYPSTQEHENFIPAPTTGSGCTRIPSFDMSTHYCYTHNVILSGCRDHS
NDV HN ZJ1 (AAL18936)	(151)	FYPSTQEHENFIPAPTTGSGCTRIPSFDMSTHYCYTHNVILSGCRDHS
	201	250
NDV HN ABS84265 (CA2002)	(201)	HSHQYLALGVLRTSATGRVFFSTLRSINLDDTQNRKSCSVSATPLGCDML
NDV HN MEX96 (AAQ54638)	(201)	HSHQYLALGVLRTSATGRVFFSTLRSINLDDTQNRKSCSVSATPLGCDML
NDV HN LaSota (AAA46659)	(201)	HSHQYLALGVLRTSATGRVFFSTLRSINLDDTQNRKSCSVSATPLGCDML
NDV HN Texas (P12553)	(201)	HSHQYLALGVLRTSATGRVFFSTLRSINLDDTQNRKSCSVSATPLGCDML
NDV HN Liaoning (ACM67348)	(201)	HSHQYLALGVLRTSATGRVFFSTLRSINLDDTQNRKSCSVSATPLGCDML
NDV HN ZJ1 (AAL18936)	(201)	HSHQYLALGVLRTSATGRVFFSTLRSINLDDTQNRKSCSVSATPLGCDML
	251	300
NDV HN ABS84265 (CA2002)	(251)	CSKVTETEEEDYKSYTPTSMYGRGLGFDGQYHEKDLDVTLFEDWVANYF
NDV HN MEX96 (AAQ54638)	(251)	CSKVTETEEEDYKSYTPTSMYGRGLGFDGQYHEKDLDVTLFEDWVANYF
NDV HN LaSota (AAA46659)	(251)	CSKVTETEEEDYKSYTPTSMYGRGLGFDGQYHEKDLDVTLFEDWVANYF
NDV HN Texas (P12553)	(251)	CSKVTETEEEDYKSYTPTSMYGRGLGFDGQYHEKDLDVTLFEDWVANYF
NDV HN Liaoning (ACM67348)	(251)	CSKVTETEEEDYKSYTPTSMYGRGLGFDGQYHEKDLDVTLFEDWVANYF
NDV HN ZJ1 (AAL18936)	(251)	CSKVTETEEEDYKSYTPTSMYGRGLGFDGQYHEKDLDVTLFEDWVANYF
	301	350
NDV HN ABS84265 (CA2002)	(301)	GVGGGSLIDRVWFFVYGGGLKPNPSPSDTAQEGKYVIYKRNNTCPDEQDY
NDV HN MEX96 (AAQ54638)	(301)	GVGGGSLIDRVWFFVYGGGLKPNPSPSDTAQEGKYVIYKRNNTCPDEQDY
NDV HN LaSota (AAA46659)	(301)	GVGGGSLIDRVWFFVYGGGLKPNPSPSDTVQEGKYVIYKRNNTCPDEQDY
NDV HN Texas (P12553)	(301)	GVGGGSLIDRVWFFVYGGGLKPNPSPSDTVQEGKYVIYKRNNTCPDEQDY
NDV HN Liaoning (ACM67348)	(301)	GVGGGSLIDRVWFFVYGGGLKPNPSPSDTAQEGKYVIYKRNNTCPDEQDY
NDV HN ZJ1 (AAL18936)	(301)	GVGGGSLIDRVWFFVYGGGLKPNPSPSDTAQEGKYVIYKRNNTCPDEQDY
	351	400
NDV HN ABS84265 (CA2002)	(351)	QIRMAKSSYKPGKPGCKPVQQAISIKVSTSLGKDPVLTIPPNTVILMGA
NDV HN MEX96 (AAQ54638)	(351)	QIRMAKSSYKPGKPGCKPVQQAISIKVSTSLGKDPVLTIPPNTVILMGA
NDV HN LaSota (AAA46659)	(351)	QIRMAKSSYKPGKPGCKPVQQAISIKVSTSLGKDPVLTIPPNTVILMGA
NDV HN Texas (P12553)	(351)	QIRMAKSSYKPGKPGCKPVQQAISIKVSTSLGKDPVLTIPPNTVILMGA
NDV HN Liaoning (ACM67348)	(351)	QIRMAKSSYKPGKPGCKPVQQAISIKVSTSLGKDPVLTIPPNTVILMGA
NDV HN ZJ1 (AAL18936)	(351)	QIRMAKSSYKPGKPGCKPVQQAISIKVSTSLGKDPVLTIPPNTVILMGA

Figure 6a (2/2)

		401	450
NDV HN ABS84265 (CA2002)	(401)	EGRIITVGTSHFLYQRCSSYPSPALLYPMTVRNKTATLSPYTFNAFTRP	
NDV HN MEX96 (AAQ54638)	(401)	EGRIITVGTSHFLYQRCSSYPSPALLYPMTVRNKTATLSPYTFNAFTRP	
NDV HN LaSota (AAA46659)	(401)	EGRIITVGTSHFLYQRCSSYPSPALLYPMTVSNKTATLSPYTFNAFTRP	
NDV HN Texas (P12553)	(401)	EGRIITVGTSHFLYQRCSSYPSPALLYPMTVSNKTATLSPYTFNAFTRP	
NDV HN Liaoning (ACM67348)	(401)	EGRIITVGTSHFLYQRCSSYPSPALLYPMTVNNKTATLSPYTFNAFTRP	
NDV HN ZJ1 (AAL18936)	(401)	EGRIITVGTSHFLYQRCSSYPSPALLYPMTVNNKTATLSPYTFNAFTRP	
		451	500
NDV HN ABS84265 (CA2002)	(451)	GSVPCQASARCPNSCTGVTDPYPVYFERNHTLRGVFGTMDNEQARLN	
NDV HN MEX96 (AAQ54638)	(451)	GSVPCQASARCPNSCTGVTDPYPVYFERNHTLRGVFGTMDNEQARLN	
NDV HN LaSota (AAA46659)	(451)	GSVPCQASARCPNCPVTCVYTDYPYPLIFERNHTLRGVFGTMDLGVQARLN	
NDV HN Texas (P12553)	(451)	GSVPCQASARCPNCPVTCVYTDYPYPLIFERNHTLRGVFGTMDLGVQARLN	
NDV HN Liaoning (ACM67348)	(451)	GSAPCQASARCPNSCTGVTDPYPYPLIFERNHTLRGVFGTMDLDEQARLN	
NDV HN ZJ1 (AAL18936)	(451)	GSVPCQASARCPNSCTGVTDPYPYPLIFERNHTLRGVFGTMDLDEQARLN	
		501	550
NDV HN ABS84265 (CA2002)	(501)	PVSALFDYTSRSRITRVSSISTKAAYTTSTCFKVVETNKVYCLSIASISN	
NDV HN MEX96 (AAQ54638)	(501)	PVSALFDYTSRSRITRVSSISTKAAYTTSTCFKVVETNKVYCLSIASISN	
NDV HN LaSota (AAA46659)	(501)	PTSAYFDSTSRSPITRVSSISTKAAYTTSTCFKVVETNKVYCLSIASISN	
NDV HN Texas (P12553)	(501)	PASAYFDSTSRSPITRVSSISTKAAYTTSTCFKVVETNKVYCLSIASISN	
NDV HN Liaoning (ACM67348)	(501)	PVSAYFDNISRSRITRVSSISTKAAYTTSTCFKVVETNKVYCLSIASISN	
NDV HN ZJ1 (AAL18936)	(501)	PVSAYFDNISRSRITRVSSISTKAAYTTSTCFKVVETNKVYCLSIASISN	
		551	577
NDV HN ABS84265 (CA2002)	(551)	TLFGEFRIVPLLVEILKDDV-----	
NDV HN MEX96 (AAQ54638)	(551)	TLFGEFRIVPLLVEILKDDV-----	
NDV HN LaSota (AAA46659)	(551)	TLFGEFRIVPLLVEILKDDGVREARSG	
NDV HN Texas (P12553)	(551)	TLFGEFRIVPLLVEILKDDGVREARSG	
NDV HN Liaoning (ACM67348)	(551)	TLFGEFRIVPLLVEILKDDV-----	
NDV HN ZJ1 (AAL18936)	(551)	TLFGEFRIVPLLVEILKDDV-----	

NDV HN ABS84265 (CA2002): SEQ ID NO:3
 NDV HN MEX96 (AAQ54638): SEQ ID NO:9
 NDV HN LaSota (AAA46659): SEQ ID NO:7
 NDV HN Texas (P12553): SEQ ID NO:5
 NDV HN Liaoning (ACM67348): SEQ ID NO:17
 NDV HN ZJ1 (AAL18936): SEQ ID NO:19

Sequence identity percentage:

SEQ ID NO:	9	3	7	5	17	19
9	100	99	89	88	92	92
3		100	89	88	92	92
7			100	97	88	87
5				100	87	87
17					100	97
19						100

Vector NTI 11.0 (PC) software package (Invitrogen, 1600 Faraday Ave., Carlsbad, CA).

Figure 6b (1/2)

		1		50
SEQ ID NO:20	(1)	-----SAGASTPHDLAGISTVIS	KTEDK	VTSL SS
SEQ ID NO:15	(1)	VAVLSLIVMTLAISVAALVYSMEASTPN	DLAGISTVISRAEDR	VTSL INS
		51		100
SEQ ID NO:20	(31)	SQDVLDRIYKQVALESPLALLNTES	MIMNAITSLSYQINGAAN	NSGCCAP
SEQ ID NO:15	(51)	NQDVLDRIYKQVALESPLALLNTES	IIMNAITSLSYQINGAAN	SSGCCAP
		101		150
SEQ ID NO:20	(81)	VHDPDYIGGIGKELIVDDISDVTSFYPSAYQ	EHLNFIPAPTTGSGCTRI	
SEQ ID NO:15	(101)	VHDPDYIGGVGKELIVDDTSDATSFYPSAYQ	EHLNFIPAPTTGSGCTRI	
		151		200
SEQ ID NO:20	(131)	SFDMSTTHYCYTHNVILSGCRDRSESHQY	LALGVLRTSATGRVFFST LSRS	
SEQ ID NO:15	(151)	SFDMSATTHYCYTHNVILSGCRDRSESHQY	LALGVLRTSATGRVFFST LSRS	
		201		250
SEQ ID NO:20	(181)	INLDDTQNRKSCSVSATFLGCDMLCSKVT	GTEEDYKSVAPT PMVHGRLG	
SEQ ID NO:15	(201)	INLDDTQNRKSCSVSATFLGCDMLCSKVT	ETEEEDYKSVTPT SMVHGRLG	
		251		300
SEQ ID NO:20	(231)	FDGQYHEKDLDITVLFKDWVANYPGVGGGS	FIDNRVWFVPVYGGLKPN SPS	
SEQ ID NO:15	(251)	FDGQYHEKDLDITVLFKDWVANYPGVGGGS	LIDDRVWFVPVYGGLKPN SPS	
		301		350
SEQ ID NO:20	(281)	DTAQEGKYVIYKRHNNTCPDKQDYQ	IPMAKSSYKPGKFGGKRVQQA ILSI	
SEQ ID NO:15	(301)	DTAQEGKYVIYKRHNNTCPDEQDYQ	IPMAKSSYKPGKFGGKRVQQA ILSI	
		351		400
SEQ ID NO:20	(331)	KVSTSLGKDPVLTIPNTITLMGAEGRI	LTVGTS HFLYQRGSSYFSPALL	
SEQ ID NO:15	(351)	KVSTSLGEDPVLTIPNTITLMGAEGRI	LTVGTS HFLYQRGSSYFSPALL	
		401		450
SEQ ID NO:20	(381)	YPMTVNNKTATLHSPYTFNAFTRPGSA	PCQASARCPNSCITGVYTD PYP	
SEQ ID NO:15	(401)	YPMTVRNKTATLHSPYTFNAFTRPGSV	PCQASARCPNSCITGVYTD PYP	
		451		500
SEQ ID NO:20	(431)	IFHRNHTLRGVFGTMLDDEQARLN	FPVSAVFDNISRSRV TRVSSSTKAAY	
SEQ ID NO:15	(451)	IFHRNHTLRGVFGTMLDNEQARLN	FPVSAIFDYTSRSRI TRVSSSTKAAY	
		501		546
SEQ ID NO:20	(481)	TTSTCFKVVKTNKAYCLSLAEISNTLF	G EFRIVPLLVEILKDDR	-
SEQ ID NO:15	(501)	TTSTCFKVVKTNKVYCLSLAEISNTLF	G EFRIVPLLVEILKDDR	-

The protein identity percentage between SEQ ID NO:15 and SEQ ID NO:20 is 93%.

Figure 7a (1/6)

	1	50
NDV HN (FJ608369)	(1)	-----
NDV HN (ZJ1 strain)	(1)	-----
NDV HN LaSota (M24709)	(1)	ACGGGTAGAACGGTAAGAGAGGCCGCCCTCAATTGCGAGCCAGGCTTCA
NDV HN texas (M21409)	(1)	-----
NDV HN CA02 (EF520717)	(1)	-----
NDV HN MEX (AY288999)	(1)	-----
	51	100
NDV HN (FJ608369)	(1)	-----ATGGGAGCG
NDV HN (ZJ1 strain)	(1)	-----ATGGAGCGG
NDV HN LaSota (M24709)	(51)	CAACCTCCGTTCTACCGCTTCACCGACAACAGTCCTCAATCATGGAACCG
NDV HN texas (M21409)	(1)	-----GTCCTCAGTCATGGAACCG
NDV HN CA02 (EF520717)	(1)	-----ATGCATCGT
NDV HN MEX (AY288999)	(1)	-----ATGCATCGT
	101	150
NDV HN (FJ608369)	(10)	GGGCTTAACAGAGTCGCCCTGAGCAATGAGGAAAGAGAGGCAAAAGAACAC
NDV HN (ZJ1 strain)	(10)	GGGCTTAACAGAGTCGCCCTGAGCAATGAGGAAAGAGAGGCAAAAGAACAC
NDV HN LaSota (M24709)	(101)	GGCCTTAGCCCAAGTTCCGTTAGAGAAATGATGAAGAGAGGCAAAAGAACAC
NDV HN texas (M21409)	(20)	GGCCTTAGCCCAAGTTCCGTTAGAGAAATGATGAAGAGAGGCAAAAGAACAC
NDV HN CA02 (EF520717)	(10)	GTAGTTAGCCCAAGTTCCGTTAGAGAAACCAAGAAAGAGAGGCAAAAGAACAC
NDV HN MEX (AY288999)	(10)	GTAGTTAGCCCAAGTTCCGTTAGAGAAACCAAGAAAGAGAGGCAAAAGAACAC
	151	200
NDV HN (FJ608369)	(60)	ATGGGCGCTGCTTTTCCGGATGCGAGTCCTTACTTTTAATGCTAATGACTC
NDV HN (ZJ1 strain)	(60)	ATGGGCGCTGCTTTTCCGGATGCGAGTCCTTACTTTTAATGCTAATGACTC
NDV HN LaSota (M24709)	(151)	ATGGGCGCTTGAATATTCGGGATTCGAATCTTACTCTTAACAGTAGTGAACCT
NDV HN texas (M21409)	(70)	ATGGGCGCTTGAATATTCGGGATTCGAATCTTACTCTTAACAGTAGTGAACCT
NDV HN CA02 (EF520717)	(60)	ATGGGCGCTGCTTTTCCGGATGCGAGTCCTTACTCTTAATGCTAATGACTC
NDV HN MEX (AY288999)	(60)	TTGGGCGCTGCTTTTCCGGATGCGAGTCCTTACTCTTAATGCTAATGACTC
	201	250
NDV HN (FJ608369)	(110)	TAGCTATCTCTCCGAGCTGCGCTGCGATAGAGTGCGGGGGCCAGTACGCGG
NDV HN (ZJ1 strain)	(110)	TAGCTATCTCTCCGAGCTGCGCTGCGATAGAGTGCGGGGGCCAGTACGCGG
NDV HN LaSota (M24709)	(201)	TGGCTATATCTTACGCTCCCTTTTATATAGCATGGGGGCTAGCAACCT
NDV HN texas (M21409)	(120)	TAGCTATATCTTACGCTCCCTTTTATATAGCATGGGGGCTAGCAACCT
NDV HN CA02 (EF520717)	(110)	TAGCTATCTCTTACGCGCGCTGCTATAGAGCATGGAGGCTAGCAACCT
NDV HN MEX (AY288999)	(110)	TAGCTATCTCTTACGCGCGCTGCTATAGAGCATGGAGGCTAGCAACCT
	251	300
NDV HN (FJ608369)	(160)	CAGGAGCTCGGAGGCATATCGAGCTGTGATCTCTAGACAGAGGCTAAGCT
NDV HN (ZJ1 strain)	(160)	CAGGAGCTCGGAGGCATATCGAGCTGTGATCTCTAGACAGAGGCTAAGCT
NDV HN LaSota (M24709)	(251)	AGCGATCTTTGAGGATATCGAGCTTAGGATTTGAGGAGGAGAGAAAGAT
NDV HN texas (M21409)	(170)	AGCGAGCTTGTAGGATATCGAGCTTAGGATTTGAGGAGGAGAGAAAGAT
NDV HN CA02 (EF520717)	(160)	AAGGAGCTTGGGATATATCGAGCTGTGATCTCTAGGAGGAGGCTAAGCT
NDV HN MEX (AY288999)	(160)	AAGGAGCTTGGGATATATCGAGCTGTGATCTCTAGGAGGAGGCTAAGCT
	301	350
NDV HN (FJ608369)	(210)	TACGTCTTTACTCAGTTGAGTCAAGATGTGATAGATAGCATATACAAAC
NDV HN (ZJ1 strain)	(210)	TACGTCTTTACTCAGTTGAGTCAAGATGTGATAGATAGCATATACAAAC
NDV HN LaSota (M24709)	(301)	TACATCTACACTTGCTTCCATCAAGATGTAGTAGATAGCATATATAGCC
NDV HN texas (M21409)	(220)	TACATCTGCACCTTGCTTCCATCAAGATGTAGTAGATAGCATATATAGCC
NDV HN CA02 (EF520717)	(210)	TACGTCTTTACTCAGTTCAATCAAGATGTGATAGATAGCATATATAGCC
NDV HN MEX (AY288999)	(210)	TACGTCTTTACTCAGTTCAATCAAGATGTGATAGATAGCATATATAGCC
	351	400
NDV HN (FJ608369)	(260)	AGGTGGCTCTTGAATCCCGAGTGGGCTACTAAGACTGAATCTATGATT
NDV HN (ZJ1 strain)	(260)	AGGTGGCTCTTGAATCCCGAGTGGGCTACTAAGACTGAATCTATGATT
NDV HN LaSota (M24709)	(351)	AAGTGGGCTTGAATCTCCCTTGGCAATCTTAAAGACTGAGAACCAATT
NDV HN texas (M21409)	(270)	AAGTGGGCTTGAATCTCCCTTGGCAATCTTAAAGACTGAGAACCAATT
NDV HN CA02 (EF520717)	(260)	AGGTGGGCTTGAATCCCGAGTGGGCTTCTTGAATAGTGAATCTATGATT
NDV HN MEX (AY288999)	(260)	AGGTGGGCTTGAATCCCGAGTGGGCTTCTTGAATAGTGAATCTATGATT

Figure 7a (2/6)

NDV HN (FJ608369)	(310)	ATGAATGCCAATAA	401	CTCTCTTCTTATCA	450	AGGGGCTGGGAA
NDV HN (ZJ1 strain)	(310)	ATGAATGCCAATAA		CTCTCTTCTTATCA		AGGGGCTGGGAA
NDV HN LaSota (M24709)	(401)	ATGAACGCCAATAA		CTCTCTTCTTATCA		AGGGGCTGGGAA
NDV HN texas (M21409)	(320)	ATGAACGCCAATAA		CTCTCTTCTTATCA		AGGGGCTGGGAA
NDV HN CA02 (EF520717)	(310)	ATGAATGCCAATAA		CTCTCTTCTTATCA		AGGGGCTGGGAA
NDV HN MEX (AY288999)	(310)	ATGAATGCCAATAA		CTCTCTTCTTATCA		AGGGGCTGGGAA
NDV HN (FJ608369)	(360)	TAGCGGATCTGGGGG	451	CGCTCTTCATGACCC	500	AGATTATATCGGGGG
NDV HN (ZJ1 strain)	(360)	TAGCGGATCTGGGGG		CGCTCTTCATGACCC		AGATTATATCGGGGG
NDV HN LaSota (M24709)	(451)	CAGCGGCTCGGGGGG		AGCTATCCATGACCC		AGATTATATCGGGGG
NDV HN texas (M21409)	(370)	CAGCGGCTCGGGGGG		AGCTATCCATGACCC		AGATTATATCGGGGG
NDV HN CA02 (EF520717)	(360)	TAGTGGCTCTGGGGG		AGCTCTTCATGACCC		AGATTATATCGGGGG
NDV HN MEX (AY288999)	(360)	TAGTGGCTCTGGGGG		AGCTCTTCATGACCC		AGATTATATCGGGGG
NDV HN (FJ608369)	(410)	GCAAGAGACTCATAT	501	CTGGACCAATCAGT	550	GCATTCATTTTATCC
NDV HN (ZJ1 strain)	(410)	GCAAGAGACTCATAT		CTGGACCAATCAGT		GCATTCATTTTATCC
NDV HN LaSota (M24709)	(501)	GCAAGAGACTCATAT		CTGGACCAATCAGT		GCATTCATTTTATCC
NDV HN texas (M21409)	(420)	GCAAGAGACTCATAT		CTGGACCAATCAGT		GCATTCATTTTATCC
NDV HN CA02 (EF520717)	(410)	GTAAGAGACTCATAT		CTGGACCAATCAGT		GCATTCATTTTATCC
NDV HN MEX (AY288999)	(410)	GTAAGAGACTCATAT		CTGGACCAATCAGT		GCATTCATTTTATCC
NDV HN (FJ608369)	(460)	TCCTGCATATCAAGA	551	CACTTGAATTCATCC	600	CGCGCGCGCTACT
NDV HN (ZJ1 strain)	(460)	TCCTGCATATCAAGA		CACTTGAATTCATCC		CGCGCGCGCTACT
NDV HN LaSota (M24709)	(551)	TCCTGCATTTCAAGA		CACTTGAATTCATCC		CGCGCGCGCTACT
NDV HN texas (M21409)	(470)	TCCTGCATTTCAAGA		CACTTGAATTCATCC		CGCGCGCGCTACT
NDV HN CA02 (EF520717)	(460)	TCACCATATCAAGA		CACTTGAATTCATCC		CGCGCGCGCGCCAC
NDV HN MEX (AY288999)	(460)	TCACCATATCAAGA		CACTTGAATTCATCC		CGCGCGCGCGCCAC
NDV HN (FJ608369)	(510)	CGCTTGCACCTCCG	601	ATACCTTCATTCGAC	650	ATACCATTTATCTT
NDV HN (ZJ1 strain)	(510)	CGCTTGCACCTCCG		ATACCTTCATTCGAC		ATACCATTTATCTT
NDV HN LaSota (M24709)	(601)	AGGTTGCACCTCCG		ATACCTTCATTCGAC		ATACCATTTATCTT
NDV HN texas (M21409)	(520)	AGGTTGCACCTCCG		ATACCTTCATTCGAC		ATACCATTTATCTT
NDV HN CA02 (EF520717)	(510)	AGGCTGCACCTCCG		ATACCTTCATTCGAC		ATACCATTTATCTT
NDV HN MEX (AY288999)	(510)	AGGCTGCACCTCCG		ATACCTTCATTCGAC		ATACCATTTATCTT
NDV HN (FJ608369)	(560)	ATACTCACAATGTG	651	ATATCCGTTTCAGAG	700	ATCACTCACACTCAG
NDV HN (ZJ1 strain)	(560)	ATACTCACAATGTG		ATATCCGTTTCAGAG		ATCACTCACACTCAG
NDV HN LaSota (M24709)	(651)	ACACCCATANTGT		ATATCCGTTTCAGAG		ATCACTCACACTCAG
NDV HN texas (M21409)	(570)	ACACTCATAATATA		ATATCCGTTTCAGAG		ATCACTCACACTCAG
NDV HN CA02 (EF520717)	(560)	ATACTCACAATGTG		ATATCCGTTTCAGAG		ATCACTCACACTCAG
NDV HN MEX (AY288999)	(560)	ATACTCACAATGTG		ATATCCGTTTCAGAG		ATCACTCACACTCAG
NDV HN (FJ608369)	(610)	CAATACTTAGCACT	701	TGGTGTGCTTCGG	750	ACACAGGGAGGAT
NDV HN (ZJ1 strain)	(610)	CAATACTTAGCACT		TGGTGTGCTTCGG		ACACAGGGAGGAT
NDV HN LaSota (M24709)	(701)	CAGTATTTAGCACT		TGGTGTGCTTCGG		ACACAGGGAGGAT
NDV HN texas (M21409)	(620)	CAGTATTTAGCACT		TGGTGTGCTTCGG		ACACAGGGAGGAT
NDV HN CA02 (EF520717)	(610)	CAGTATTTAGCACT		TGGTGTGCTTCGG		ACACAGGGAGGAT
NDV HN MEX (AY288999)	(610)	CAGTATTTAGCACT		TGGTGTGCTTCGG		ACACAGGGAGGAT
NDV HN (FJ608369)	(660)	CTTTTCTACTCTGG	751	CTCCATCAATTTAG	800	ATGACACCCAAAT
NDV HN (ZJ1 strain)	(660)	CTTTTCTACTCTGG		CTCCATCAATTTAG		ATGACACCCAAAT
NDV HN LaSota (M24709)	(751)	CTTTTCTACTCTGG		CTCCATCAATTTAG		ATGACACCCAAAT
NDV HN texas (M21409)	(670)	CTTTTCTACTCTGG		CTCCATCAATTTAG		ATGACACCCAAAT
NDV HN CA02 (EF520717)	(660)	CTTTTCTACTCTGG		CTCCATCAATTTAG		ATGACACCCAAAT
NDV HN MEX (AY288999)	(660)	CTTTTCTACTCTGG		CTCCATCAATTTAG		ATGACACCCAAAT

Figure 7a (3/6)

		801	850
NDV HN (FJ608369)	(710)	CCATGAGTGTGAGTGCACACCCCTTATAGGTTGTGATATGCTGTGCTCTAAG	
NDV HN (ZJ1 strain)	(710)	CCATGAGTGTGAGTGCACACCCCTTATAGGTTGTGATATGCTGTGCTCTAAG	
NDV HN LaSota (M24709)	(801)	CCATGAGTGTGAGTGCACACCCCTGCGTTGTGATATGCTGTGCTCGAAG	
NDV HN texas (M21409)	(720)	CCATGAGTGTGAGTGCACACCCCTTATAGGTTGTGATATGCTGTGCTCGAAG	
NDV HN CA02 (EF520717)	(710)	CCATGAGTGTGAGTGCACACCCCTTATAGGTTGTGATATGCTGTGCTCTAAG	
NDV HN MEX (AY288999)	(710)	CCATGAGTGTGAGTGCACACCTTATAGGTTGTGATATGCTGTGCTCTAAG	
		851	900
NDV HN (FJ608369)	(760)	GTCACAGGGACTGCAAGAGCAGGATTACAACTCAGTTGCCCCACATCCAAAT	
NDV HN (ZJ1 strain)	(760)	GTCACAGGGACTGCAAGAGCAGGATTACAACTCAGTTGCCCCACATCCAAAT	
NDV HN LaSota (M24709)	(851)	GTCACAGGGAGACAGAGGAGAGAGATTATAACTCAGCTCTCCCTACGCGGAT	
NDV HN texas (M21409)	(770)	GTCACAGGAGACAGAGGAGAGAGATTATAACTCAGCTCTCCCTACGCTGAT	
NDV HN CA02 (EF520717)	(760)	GTCACAGGAGACTGAGAGAGCAGGATTATAACTCAGTTACCCCAATCCAAAT	
NDV HN MEX (AY288999)	(760)	GTCACAGGAGACTGAGAGAGCAGGATTATAACTCAGTTACCCCAATCCAAAT	
		901	950
NDV HN (FJ608369)	(810)	GGTGCACGGAGAGGCTAGGGTTTGACGGTCAATACCATGAGGAAGGACTTAG	
NDV HN (ZJ1 strain)	(810)	GGTGCACGGAGAGGCTAGGGTTTGACGGTCAATACCATGAGGAAGGACTTAG	
NDV HN LaSota (M24709)	(901)	GGCAGATGGGAGGCTTAGGGTTTCAAGCGCCATACCCAGGAAGGAGCTAG	
NDV HN texas (M21409)	(820)	GGTACATGGGAGGCTTAGGGTTTCAAGCGCCATACCCAGGAAGGAGCTAG	
NDV HN CA02 (EF520717)	(810)	GGTGCATGGAGGCTTAGGGTTTGACGGTCAATACCATGAGGAAGGACTTAG	
NDV HN MEX (AY288999)	(810)	GGTGCATGGAGGCTTAGGGTTTGACGGTCAATACCATGAGGAAGGACTTAG	
		951	1000
NDV HN (FJ608369)	(860)	ACACACCGGTCTTATTATTAAGGATTTGGGTGGCAATTAACCCAGGAGTGGGA	
NDV HN (ZJ1 strain)	(860)	ACACACCGGTCTTATTATTAAGGATTTGGGTGGCAATTAACCCAGGAGTGGGA	
NDV HN LaSota (M24709)	(951)	ATGTCACACACATTATTTCGGGAGCTGGGTGGCAACTACCCAGGAGTGGGA	
NDV HN texas (M21409)	(870)	AGGTACACACATTATTTCGGGAGCTGGGTGGCAACTACCCAGGAGTGGGA	
NDV HN CA02 (EF520717)	(860)	AGGTACACAGTCTTATTATTAAGGATTTGGGTGGCAATTAACCCAGGAGTGGGA	
NDV HN MEX (AY288999)	(860)	AGGTACACAGTCTTATTATTAAGGATTTGGGTGGCAATTAACCCAGGAGTGGGA	
		1001	1050
NDV HN (FJ608369)	(910)	GGAGGCTCTCTTATTATTAAGGATTTGGGTGGCAATTAACCCAGGAGTGGGA	
NDV HN (ZJ1 strain)	(910)	GGAGGCTCTCTTATTATTAAGGATTTGGGTGGCAATTAACCCAGGAGTGGGA	
NDV HN LaSota (M24709)	(1001)	GGTGCATCTCTTATTATTAAGGATTTGGGTGGCAATTAACCCAGGAGTGGGA	
NDV HN texas (M21409)	(920)	GGTGCATCTCTTATTATTAAGGATTTGGGTGGCAATTAACCCAGGAGTGGGA	
NDV HN CA02 (EF520717)	(910)	GGAGGCTCTCTTATTATTAAGGATTTGGGTGGCAATTAACCCAGGAGTGGGA	
NDV HN MEX (AY288999)	(910)	GGAGGCTCTCTTATTATTAAGGATTTGGGTGGCAATTAACCCAGGAGTGGGA	
		1051	1100
NDV HN (FJ608369)	(960)	CAAAACCAATTTCACCCAGTGCACACTGCACAGGAAGCGAATATGTATAT	
NDV HN (ZJ1 strain)	(960)	CAAAACCAATTTCACCCAGTGCACACTGCACAGGAAGCGAATATGTATAT	
NDV HN LaSota (M24709)	(1051)	GAAACCAATTTCACCCAGTGCACACTGCACAGGAAGCGAATATGTATAT	
NDV HN texas (M21409)	(970)	GAAACCAATTTCACCCAGTGCACACTGCACAGGAAGCGAATATGTATAT	
NDV HN CA02 (EF520717)	(960)	AAACCAATTTCACCTAACCAACTGCACAGGAAGCGAATATGTATAT	
NDV HN MEX (AY288999)	(960)	AAACCAATTTCACCTAACCAACTGCACAGGAAGCGAATATGTATAT	
		1101	1150
NDV HN (FJ608369)	(1010)	ATAAGCGGCATTAACACACATGCCCCGATAAACAGATTACCAAGTTCCG	
NDV HN (ZJ1 strain)	(1010)	ACAAGCGGCATTAACACACATGCCCCGATAAACAGATTACCAAGTTCCG	
NDV HN LaSota (M24709)	(1101)	ACAAGCGCATTAACACACATGCCCCGATTAAGCAAGATTACCAAGTTCCG	
NDV HN texas (M21409)	(1020)	ACAAGCGCATTAACACACATGCCCCGATTAAGCAAGATTACCAAGTTCCG	
NDV HN CA02 (EF520717)	(1010)	ACAAGCGGTATTAACACACATGCCCCGATTAACAGATTACCAAGTTCCG	
NDV HN MEX (AY288999)	(1010)	ACAAGCGGTATTAACACACATGCCCCGATTAACAGATTACCAAGTTCCG	
		1151	1200
NDV HN (FJ608369)	(1060)	ATGGCTAAGTCTTCATATAAACCCGGGCAATTTGGTGGAAAGCGCGTACA	
NDV HN (ZJ1 strain)	(1060)	ATGGCTAAGTCTTCATATAAACCCGGGCAATTTGGTGGAAAGCGCGTACA	
NDV HN LaSota (M24709)	(1151)	ATGGCCAAAGTCTTCATATAAACCCGGGCAATTTGGTGGAAAGCGCGTACA	
NDV HN texas (M21409)	(1070)	ATGGCCAAAGTCTTCATATAAACCCGGGCGGTTTGGTGGAAAGCGCGTACA	
NDV HN CA02 (EF520717)	(1060)	ATGGCTAAGTCTTCATATAAACCCGGGCAATTTGGTGGAAAGCGCGTACA	
NDV HN MEX (AY288999)	(1060)	ATGGCTAAGTCTTCATATAAACCCGGGCAATTTGGTGGAAAGCGCGTACA	

Figure 7a (4/6)

		1201	1250
NDV HN (FJ608369)	(1110)	GCAGGCCATCTTATCCATCAAAAGTGTCAACATCCTTGGGTAAAGGACCCGG	
NDV HN (ZJ1 strain)	(1110)	GCAGGCCATCTTATCCATCAAAAGTGTCAACATCCTTGGGTAAAGGACCCGG	
NDV HN LaSota (M24709)	(1201)	GCAGGCTATCTTATCTATCAAGGTGTCAACATCCTTAGGGGAAGACCCGG	
NDV HN texas (M21409)	(1120)	GCAGGCTATCTTATCTATCAAGGTGTCAACATCCTTGGGGAAGACCCAG	
NDV HN CA02 (EF520717)	(1110)	GCAGGCCATCTTATCTATCAAAAGTGTCAACATCCTTGGGGAAGACCCGG	
NDV HN MEX (AY288999)	(1110)	GCAGGCCATCTTATCTATCAAAAGTGTCAACATCCTTGGGGAAGACCCGG	
		1251	1300
NDV HN (FJ608369)	(1160)	TGCTGACTATTCCACCTAATAACAATCACTCATGGGAGCCGAAGGCAGA	
NDV HN (ZJ1 strain)	(1160)	TGCTGACTATTCCACCTAATAACAATCACTCATGGGAGCCGAAGGCAGA	
NDV HN LaSota (M24709)	(1251)	TACTGACTGTACCCGCCAACACAGTCACACTCATGGGAGCCGAAGGCAGA	
NDV HN texas (M21409)	(1170)	TACTGACTGTACCCGCCAACACAGTCACACTCATGGGAGCCGAAGGCAGA	
NDV HN CA02 (EF520717)	(1160)	TGCTGACTGTACCCGCCAACACAGTCACACTCATGGGAGCCGAAGGCAGA	
NDV HN MEX (AY288999)	(1160)	TGCTGACTGTACCCGCCAACACAGTCACACTCATGGGAGCCGAAGGCAGA	
		1301	1350
NDV HN (FJ608369)	(1210)	ATGCTCAGCTAGGGACATCTCCTTCTGTACCAACGAGGGTCTTCATA	
NDV HN (ZJ1 strain)	(1210)	ATGCTCAGCTAGGGACATCTCCTTCTGTACCAACGAGGGTCTTCATA	
NDV HN LaSota (M24709)	(1301)	ATTCTCAGCTAGGGACATCTCCTTCTGTATCAACGAGGGTCTTCATA	
NDV HN texas (M21409)	(1220)	ATTCTCAGCTAGGGACATCTCCTTCTGTATCAACGAGGGTCTTCATA	
NDV HN CA02 (EF520717)	(1210)	ATGCTCAGCTAGGAACATCTCCTTCTGTACCAACGAGGGTCTTCATA	
NDV HN MEX (AY288999)	(1210)	ATGCTCAGCTAGGAACATCTCCTTCTGTACCAACGAGGGTCTTCATA	
		1351	1400
NDV HN (FJ608369)	(1260)	TTTGTCCCTTGGCTTATTATATCCCATGACAGTAATAACAAAACGGCTA	
NDV HN (ZJ1 strain)	(1260)	TTTGTCCCTTGGCTTATTATATCCCATGACAGTAATAACAAAACGGCTA	
NDV HN LaSota (M24709)	(1351)	CTTTGTCCCTTGGCTTATTATATCCCATGACAGTCAGCAACAAAACAGCCA	
NDV HN texas (M21409)	(1270)	CTTTGTCCCTTGGCTTATTATATCCCATGACAGTCAGCAACAAAACAGCCA	
NDV HN CA02 (EF520717)	(1260)	CTTTGTCCCTTGGCTTATTATATCCCATGACAGTCAGCAACAAAACAGCCA	
NDV HN MEX (AY288999)	(1260)	CTTTGTCCCTTGGCTTATTATATCCCATGACAGTCAGCAACAAAACAGCCA	
		1401	1450
NDV HN (FJ608369)	(1310)	CACTCCATAGTCCCTTATACGTTTAAATGCTTTCACCTCGGGCAGGTAGTCC	
NDV HN (ZJ1 strain)	(1310)	CACTCCATAGTCCCTTATACGTTTAAATGCTTTCACCTCGGGCAGGTAGTCC	
NDV HN LaSota (M24709)	(1401)	CTCTTCATAGTCCCTTATACATTCATGCTTTCACCTCGGGCAGGTAGTATC	
NDV HN texas (M21409)	(1320)	CTCTTCATAGTCCCTTATACATTCATGCTTTCACCTCGGGCAGGTAGTATC	
NDV HN CA02 (EF520717)	(1310)	CTCTTCATAGTCCCTTATACATTCATGCTTTCACCTCGGGCAGGTAGTCC	
NDV HN MEX (AY288999)	(1310)	CTCTTCATAGTCCCTTATACATTCATGCTTTCACCTCGGGCAGGTAGTCC	
		1451	1500
NDV HN (FJ608369)	(1360)	CCFTGCCAGGCAATCAGCAAGATGCCCCAAGCTCATGCATCACTGGAGTCTA	
NDV HN (ZJ1 strain)	(1360)	CCFTGCCAGGCAATCAGCAAGATGCCCCAAGCTCATGCATCACTGGAGTCTA	
NDV HN LaSota (M24709)	(1451)	CCFTGCCAGGCTTCAGCAAGATGCCCCAAGCCGTTTGTACTGGAGTCTA	
NDV HN texas (M21409)	(1370)	CCFTGCCAGGCTTCAGCAAGATGCCCCAAGCTGTTTGTACTGGAGTCTA	
NDV HN CA02 (EF520717)	(1360)	CCFTGCCAGGCAATCAGCAAGATGCCCCAAGCTCATGCATCACTGGAGTCTA	
NDV HN MEX (AY288999)	(1360)	CCFTGCCAGGCAATCAGCAAGATGCCCCAAGCTCATGCATCACTGGAGTCTA	
		1501	1550
NDV HN (FJ608369)	(1410)	TACTGATCCATATCCCTTAATCTTCATAGGANTCATACTCTAAGAGGGG	
NDV HN (ZJ1 strain)	(1410)	TACTGATCCATATCCCTTAATCTTCATAGGANTCATACTCTAAGAGGGG	
NDV HN LaSota (M24709)	(1501)	TACAGTCCATATCCCTTAATCTTCATAGAACACACCTTCCAGGGG	
NDV HN texas (M21409)	(1420)	TACAGTCCATATCCCTTAATCTTCATAGAACACACCTTCCAGGGG	
NDV HN CA02 (EF520717)	(1410)	TACTGATCCGTACCTGTAGTCTTCATAGGANTCAGACCTTCCAGGGG	
NDV HN MEX (AY288999)	(1410)	TACTGATCCGTACCTGTAGTCTTCATAGGANTCAGACCTTCCAGGGG	
		1551	1600
NDV HN (FJ608369)	(1460)	TCFTCGGGACGATGCTTGATGATGACAAAGCGAGACTTAACCCCTATCT	
NDV HN (ZJ1 strain)	(1460)	TCFTCGGGACGATGCTTGATGATGACAAAGCGAGACTTAACCCCTATCT	
NDV HN LaSota (M24709)	(1551)	TATTCGGGACATGCTTGATGATGATACAAAGCAGACTTAATCCCTACGCT	
NDV HN texas (M21409)	(1470)	TATTCGGGACATGCTTGATGATGATACAAAGCAGACTTAATCCCTACGCT	
NDV HN CA02 (EF520717)	(1460)	TGFTCGGGACATGCTTGATGATGACAAAGCGAGGCTCAATCCCTATCT	
NDV HN MEX (AY288999)	(1460)	TGFTCGGGACATGCTTGATGATGACAAAGCGAGGCTCAATCCCTATCT	

Figure 7a (5/6)

		1601	1650
NDV HN (FJ608369)	(1510)	GCAGTATTTCGACAAACATATCCCGCAGTGGTGTCAACCGGGTGAGTTCAAG	
NDV HN (ZJ1 strain)	(1510)	GCAGTATTTCGACAAACATATCCCGCAGTGGTGTCAACCGGGTGAGTTCAAG	
NDV HN LaSota (M24709)	(1601)	GCAGTATTTCGATAGCAGATCCCGCAGTGGTCAACTCGAGTTCAAG	
NDV HN texas (M21409)	(1520)	GCAGTATTTCGATAGCAGATCCCGCAGTGGTCAACTCGAGTTCAAG	
NDV HN CA02 (EF520717)	(1510)	GCAATATTTTCACTACAGATCCCGCAGTGGTCAACTCGAGTTCAAG	
NDV HN MEX (AY288999)	(1510)	GCAATATTTTCACTACAGATCCCGCAGTGGTCAACTCGAGTTCAAG	
		1651	1700
NDV HN (FJ608369)	(1560)	CAGCACCAGGCGAGCATAACACAAACATCGACATGTTTTAAAGTTCTCAAGA	
NDV HN (ZJ1 strain)	(1560)	CAGCACCAGGCGAGCATAACACAAACATCGACATGTTTTAAAGTTCTCAAGA	
NDV HN LaSota (M24709)	(1651)	CAGCACCAGGCGAGCATAACACAAACATCGACATGTTTTAAAGTTCTCAAGA	
NDV HN texas (M21409)	(1570)	CAGCACCAGGCGAGCATAACACAAACATCGACATGTTTTAAAGTTCTCAAGA	
NDV HN CA02 (EF520717)	(1560)	CAGCACCAGGCGAGCATAACACAAACATCGACATGTTTTAAAGTTCTCAAGA	
NDV HN MEX (AY288999)	(1560)	CAGCACCAGGCGAGCATAACACAAACATCGACATGTTTTAAAGTTCTCAAGA	
		1701	1750
NDV HN (FJ608369)	(1610)	CCATTAAGGCTTATTGCTCTTACTATTGCGAAGTATCCATACCCCTATTG	
NDV HN (ZJ1 strain)	(1610)	CCATTAAGGCTTATTGCTCTTACTATTGCGAAGTATCCATACCCCTATTG	
NDV HN LaSota (M24709)	(1701)	CCATTAAGGCTTATTGCTCTTACTATTGCGAAGTATCCATACCCCTATTG	
NDV HN texas (M21409)	(1620)	CCATTAAGGCTTATTGCTCTTACTATTGCGAAGTATCCATACCCCTATTG	
NDV HN CA02 (EF520717)	(1610)	CTAATAAGGCTTATTGCTCTTACTATTGCGAAGTATCCATACCCCTATTG	
NDV HN MEX (AY288999)	(1610)	CCATTAAGGCTTATTGCTCTTACTATTGCGAAGTATCCATACCCCTATTG	
		1751	1800
NDV HN (FJ608369)	(1660)	GGGCAATTTCAGGATCGTTCCCTTATTAGTTGAGATGCTCAAGGATGATAG	
NDV HN (ZJ1 strain)	(1660)	GGGCAATTTCAGGATCGTTCCCTTATTAGTTGAGATGCTCAAGGATGATAG	
NDV HN LaSota (M24709)	(1751)	GGGCAATTTCAGGATCGTTCCCTTATTAGTTGAGATGCTCAAGGATGATAG	
NDV HN texas (M21409)	(1670)	GGGCAATTTCAGGATCGTTCCCTTATTAGTTGAGATGCTCAAGGATGATAG	
NDV HN CA02 (EF520717)	(1660)	GGGCAATTTCAGGATCGTTCCCTTATTAGTTGAGATGCTCAAGGATGATAG	
NDV HN MEX (AY288999)	(1660)	GGGCAATTTCAGGATCGTTCCCTTATTAGTTGAGATGCTCAAGGATGATAG	
		1801	1850
NDV HN (FJ608369)	(1710)	AGTTTAA-----	
NDV HN (ZJ1 strain)	(1710)	AGTTTAA-----	
NDV HN LaSota (M24709)	(1801)	GGTTAGAGGAAGCCAGGTCTGGCTAGTTGAGTCAATTATAAAGGAGTTGGA	
NDV HN texas (M21409)	(1720)	GGTTAGAGGAAGCCAGGTCTGGTTAGTTGAGTCAACTATGAAAGAGCTGGA	
NDV HN CA02 (EF520717)	(1710)	GGTTTAA-----	
NDV HN MEX (AY288999)	(1710)	GGTTTAA-----	
		1851	1900
NDV HN (FJ608369)	(1714)	-----	
NDV HN (ZJ1 strain)	(1717)	-----	
NDV HN LaSota (M24709)	(1851)	AAGATGGCATTGTATCACCTATCTTCTGCGACATCAAGAATCAAACCGAA	
NDV HN texas (M21409)	(1770)	AAGATGGCATTGTATCACCTATCTTCCGCGACACCAAGAATCAAACCTGAA	
NDV HN CA02 (EF520717)	(1717)	-----	
NDV HN MEX (AY288999)	(1717)	-----	
		1901	1950
NDV HN (FJ608369)	(1714)	-----	
NDV HN (ZJ1 strain)	(1717)	-----	
NDV HN LaSota (M24709)	(1901)	TGCCGGCGCGTGCTCGAATTCCATGTTGCCAGTTGACCACAATCAGCCAG	
NDV HN texas (M21409)	(1820)	TGCCGGTGCGAGCTCGAATTCCATGTCGCCAGTTGACCACAATCAGCCAG	
NDV HN CA02 (EF520717)	(1717)	-----	
NDV HN MEX (AY288999)	(1717)	-----	
		1951	2000
NDV HN (FJ608369)	(1714)	-----	
NDV HN (ZJ1 strain)	(1717)	-----	
NDV HN LaSota (M24709)	(1951)	TGCTCATGCGATCAGATTAAGCCTTGTCAATAGTCTCTTGATTAAGAAAA	
NDV HN texas (M21409)	(1870)	TGCTCATGCGATCAGATCAAGTCTTGTCAATAGTCCCTCGATTAAG----	
NDV HN CA02 (EF520717)	(1717)	-----	
NDV HN MEX (AY288999)	(1717)	-----	

Figure 7a (6/6)

2001

NDV HN (FJ608369)	(1714)	--
NDV HN (ZJ1 strain)	(1717)	--
NDV HN LaSota (M24709)	(2001)	AA
NDV HN texas (M21409)	(1916)	--
NDV HN CA02 (EF520717)	(1717)	--
NDV HN MEX (AY288999)	(1717)	--

NDV HN CA02 (EF520717):	SEQ ID NO:2
NDV HN MEX (AY288999):	SEQ ID NO:8
NDV HN LaSota (M24709):	SEQ ID NO:6
NDV HN texas (M21409):	SEQ ID NO:4
NDV HN (FJ608369):	SEQ ID NO:16
NDV HN (ZJ1 strain):	SEQ ID NO:18

Sequence identity percentage:

SEQ ID NO:	2	4	6	8	16	18
2	100	83.9%	83.5%	98.9%	87.2%	87.9%
4		100	83.8%	84.2%	82.8%	82.9%
6			100	96.3%	82.1%	82.2%
8				100	87.5%	88.2%
16					100	98.4%
18						100

Vector NTI 11.0 (PC) software package (Invitrogen, 1600 Faraday Ave., Carlsbad, CA).

Figure 7b (1/4)

Alignment of SEQ ID NO:1 and SEQ ID NO:2

		1	50
SEQ ID NO:1	(1)	ATGGACCGTGTCTCTCCCGCGTGGTCCCTCAGAACGAGGAGCGTGAGGC	
SEQ ID NO:2	(1)	ATGGATCTTGTAGTTAGCAGAGTGGTACTAGAAACGAGAAAGAGAGGC	
		51	100
SEQ ID NO:1	(51)	CAAGAACACCTGGGCGCTTGTCTTTTGTGTGGCCTCTCTCCCTTATTG	
SEQ ID NO:2	(51)	AAAGAAATACATGGGCGCTGTTTTCGGGTCGCACTCTATCTCTAATAG	
		101	150
SEQ ID NO:1	(101)	TCATGACCCCTCGCCATCTCCGTCCCGCGCTCTCTACAGCATGGAGGCT	
SEQ ID NO:2	(101)	TAATGACATTAGCTATCTCTAGCCGCGCTGTATACAGCATGGAGGCT	
		151	200
SEQ ID NO:1	(151)	AGCACCCTCAACGATCTCGCCGGANTCTGGACTGTATCTCCCGCGCGCA	
SEQ ID NO:2	(151)	AGCAGCGCGAAGCAGCTTGGCGGTATATGGAGGCTGATCTCCAGGCAGA	
		201	250
SEQ ID NO:1	(201)	GGACCTCTCACTCTCCCTCTCTCACTCCACCGGATCTCGTTGATCGCG	
SEQ ID NO:2	(201)	GGATAGGCTTACATCTTTACTCAATTCAATCAATCTGTGTAGATAGGG	
		251	300
SEQ ID NO:1	(251)	TCTACAGCAGGTCTGGCTCTGGCTCCCTCTCGCCCTCCTTAACACCGAG	
SEQ ID NO:2	(251)	TATATAAACAGGTGGCGCTTGGTGGCTGGCTGGCTGGTGGTGGTGGTGG	
		301	350
SEQ ID NO:1	(301)	AGCATCATTTATGAACGCCATTACCTCCCTCAGCTACAGATTAACGCCGC	
SEQ ID NO:2	(301)	TCTATAAATTAATGAATGAATGAATGAATGAATGAATGAATGAATGAAT	
		351	400
SEQ ID NO:1	(351)	CGCCAACTCGTCCGCTCGCGCGCGCGCGCTCCATGACCTGATTTACATCG	
SEQ ID NO:2	(351)	TCCAAATAGTAGTGGGTCTGGGCACTCTCTCATGACCGGCAATATATTG	
		401	450
SEQ ID NO:1	(401)	CGCGCTCTCGCAAGAGGCTCATCGTCCAGCAGACTAGCATGGCCAGTCC	
SEQ ID NO:2	(401)	GGCGGCTAGGTAAAGAGCTCATAGTAGATGACACGATGATGGCCACTTCA	
		451	500
SEQ ID NO:1	(451)	TTCTACCTAGCGCTTACCAGGAGCACTCAACTTCATCTCTGCGCGCGC	
SEQ ID NO:2	(451)	TTCTATCTCTCAGCATATCAAGAACCTGAGCTTATCTCGCGCGCGCAC	
		501	550
SEQ ID NO:1	(501)	TACCGCTCTCGCTCGCACTCGCATTTCCAGCTTCAGCATCTCCGCCACTC	
SEQ ID NO:2	(501)	CACAGCTTCAAGCTTCAGCTCGCATTTCCAGCTTCAGCATCTCCGCCACTC	
		551	600
SEQ ID NO:1	(551)	ACTACTCTTACAGCCATTAACGTATCTCTTGGCTTGGCTGCGGACCACTCC	
SEQ ID NO:2	(551)	ACTATCTTATTAATCACTATCTGATATTATCTGCTTGGCTGCGGACCACTCC	
		601	650
SEQ ID NO:1	(601)	CACAGCCAGCAGTACCTCGCCCTCGGAGTTCTTCTAGGTCCGCCACCGG	
SEQ ID NO:2	(601)	CACTCACATCACTATTTGGCACTAGGTCTGCTTGGCACTCTGCAACAGG	
		651	700
SEQ ID NO:1	(651)	CCGCTCTCTTTTCTTCCACCTCTCGCAGCATCAACCTCGACGATACCCAG	
SEQ ID NO:2	(651)	GAGGTATCTCTTCTTCTTCTTCTTCTTCTTCTTCTTCTTCTTCTTCTTCT	
		701	750
SEQ ID NO:1	(701)	ACCGCAAGAGCTCTCTCGGTCTCCGCCACCCGCTCGGCTCGGACATGCTC	
SEQ ID NO:2	(701)	ATCGGAAGTCTTTCAGTGTGAGTGAACCTCTTATAGTTGTGATATGCTG	
		751	800
SEQ ID NO:1	(751)	TGCTTCAAGGTCAACCGAGCGAGGAGGAGGAGGAGGAGGAGGAGGAGGAG	
SEQ ID NO:2	(751)	TGCTTCAAGGTCAACCGAGCGAGGAGGAGGAGGAGGAGGAGGAGGAGGAG	
		801	850
SEQ ID NO:1	(801)	CAGTTCGATGCTCCAGCGCCGCTTGGCTTCCAGCGCCAGTACCCAGAGA	
SEQ ID NO:2	(801)	CAGTTCGATGCTCCAGCGCCGCTTGGCTTCCAGCGCCAGTACCCAGAGA	
		851	900
SEQ ID NO:1	(851)	AGGACCTCGAGCTCACTCTCTCTTAAAGGACTGGGTTGGCACTACCCG	
SEQ ID NO:2	(851)	AGGACTTAGAGCTCACTCTCTTAAAGGACTGGGTTGGCACTACCCG	
		901	950
SEQ ID NO:1	(901)	GGCTTCGCGCGCGCTCCCTCATCTGACCGCGCTCTGGTTCTCTCTA	
SEQ ID NO:2	(901)	GGATGGGAGGAGGCTCTCTTATTGACGACCTCTATGGTTCCAGTTTA	
		951	1000
SEQ ID NO:1	(951)	CGGTCTCTCAAGCTTAACAGCCCTCCGATACCGCCAGGAGGCTAAGT	
SEQ ID NO:2	(951)	TGGAGGCTTAAACCAATTCACTAGCGACACTGCAAGAGAGGGAAT	

Figure 7b (2/4)

		1001	1050
SEQ ID NO:1	(1001)	ACGTGATCTACAGGGCTACAACAACACTGGCTTACGAGCAGGATTAC	
SEQ ID NO:2	(1001)	ATGTAATATACAGGGCTATAATAACACATGCCCCGATGAACAAGATTAC	
		1051	1100
SEQ ID NO:1	(1051)	CAGTCCGCATGCGCAAGTCCCTGTACAAGCCCGTCTTTCCGCGGCA	
SEQ ID NO:2	(1051)	CAGTTCGATGGCTAAATCTCTGTATAAGCTGACCGTTTGGTGGGAA	
		1101	1150
SEQ ID NO:1	(1101)	GGCGTCCAGCAGGCCATTCTCTCGATCAAGTCTCGAGCAGCCTCGGAG	
SEQ ID NO:2	(1101)	GGCGGTACAGCAAGCCATCCTATCTATCAAGTATTAACATCTTTGGGCG	
		1151	1200
SEQ ID NO:1	(1151)	AGGACCCCTTGGCTCACCCTTCCCTTAACACCTCACCCTTATGGGCGGC	
SEQ ID NO:2	(1151)	AGGACCCGTTGCTGACTGTACCGCCAAATACAGTTACACTCATGGGCGGC	
		1201	1250
SEQ ID NO:1	(1201)	CAGGCGCCCATCTCTCACCCTCGGTACCTCCACTTCTCTACAGGCGCG	
SEQ ID NO:2	(1201)	CAGGCGCAGATCTCTCAGTAGGAACATCTCTTCTTGTACAGGAGG	
		1251	1300
SEQ ID NO:1	(1251)	CTCGAGCTACTTTTCCCTTCCCTTCTTTACCCCATGACTGTTGGCAACA	
SEQ ID NO:2	(1251)	GTCTTCACTACTTTTCTCCGCTTACTATACCTATGACATTTGGGCAACA	
		1301	1350
SEQ ID NO:1	(1301)	AGATGCTACCTCTCCACAGCCCTACACCTTTAACGCCCTTCAGGCGCCGC	
SEQ ID NO:2	(1301)	AAACAGCCACTCTCTCATAGTCTTATACATTTAATGGGTTCACTCGGCGC	
		1351	1400
SEQ ID NO:1	(1351)	GGAAAGCTGCGCTGCGCAGGCGAGCGCCCGCTGCGCTAACTCTGCATTAC	
SEQ ID NO:2	(1351)	GGTAGTGTGCTTGGCAGGCGATCAGCAAGGTGCGCTAACTCATTTATCAC	
		1401	1450
SEQ ID NO:1	(1401)	CGGCTGTACACCGACCCCTTACCCCTGTCTCTTTTACCCTCAACCATACCC	
SEQ ID NO:2	(1401)	TGGAGTGTATCTGATCGGTACCCCTTACTCTTCCATAGGAATCACACCT	
		1451	1500
SEQ ID NO:1	(1451)	TTGGCGGCTCTCTTGGTACTATGCTTGATAACAGCAGGCCCGCTCAAC	
SEQ ID NO:2	(1451)	TGGCAAGGCTGTGGGAGCAATGCTTGATAATGAAAGCAAGGCTCAAT	
		1501	1550
SEQ ID NO:1	(1501)	CCCGTCTCGGCAATTTTCGACTACACTTCCCGCTCCCGTATCACCGCGCT	
SEQ ID NO:2	(1501)	CCCGTATCTGCAATATTTGACTACACATCTCGGAGTGGCATAAACCGGCT	
		1551	1600
SEQ ID NO:1	(1551)	CTCCCTCACCTCCACCAAGGCCGCTACACCACTCCACCTGCTTTAAGG	
SEQ ID NO:2	(1551)	AAGTTCGAGCCAGCACCAAGGCCAGCATACAGCAATCGACATGTTTAAAG	
		1601	1650
SEQ ID NO:1	(1601)	TTGTCAAGACTAACAAGGTCTACTGCTCTCCTATCCCGAGATTAGCAAC	
SEQ ID NO:2	(1601)	TTGTCAAGACTAATAAGTGTATTGCTTTAGCATTCAGAAATATCCAAAT	
		1651	1700
SEQ ID NO:1	(1651)	ACCTCTTTCGAGAGTTCGCAATTTCTCCCCCTGCTCTCGAGATCTCAA	
SEQ ID NO:2	(1651)	ACTCTAATTTGGGCAATTCAGGATCGTTCTTTTACGCTCGAGATTTCTCAA	
		1701	1716
SEQ ID NO:1	(1701)	GGACGATCCGCTTTAA	
SEQ ID NO:2	(1701)	AGATCATAGGCTTTAA	

Sequence identity percentage between SEQ ID NOs:1 and 2: 72.4%

Figure 7b (3/4)

Alignment of SEQ ID NO:16 and SEQ ID NO:22

		1	50
SEQ ID NO:16	(1)	ATGGCAAGCGGCTTAACAGAGTCGCGCTGGAATTAAGAAAGAGAGC	
SEQ ID NO:22	(1)	ATGGCCCGGCGCTCAACCGCTGCGCTTGGAGAACGAGGAGCGGAGGC	
		51	100
SEQ ID NO:16	(51)	AAAGAACATATGGCGCCTGGTTTTCGGATGGCAATCTTACTTTTAAATGG	
SEQ ID NO:22	(51)	CAAGAACACCTGGAGGCTCGTGTTCGGCATGGCCCTGCTCCTGCTCATGG	
		101	150
SEQ ID NO:16	(101)	TAAAGACTCTAGCTATCTCCGAGCTGCGCTGGCATAAGTGGGGGGCC	
SEQ ID NO:22	(101)	TCATGAGCTTGGCGATCTGGCGCGCGCGCTGGCTACTCCGCGGTGG	
		151	200
SEQ ID NO:16	(151)	AGTACGCGCGAGACCTCGCAGGCATATCGACTTGTGTCTTAAGACAGA	
SEQ ID NO:22	(151)	AGCACCGCGCAGACCTGGCGGGATCAGCACCTCATCTTGAAGACCGA	
		201	250
SEQ ID NO:16	(201)	GGATAAGCTTACGCTTTTACTCAGTTCCAGTCAAGATCTGATAGATAGGA	
SEQ ID NO:22	(201)	GGACAAGCTGAGCTCCCTGCTCAGCTCGTCCAGGACCTTATCAGCCCA	
		251	300
SEQ ID NO:16	(251)	TATACAAACAGGTGGCTCTTGAATCCCCACTGGCGTAACTAAACAATGAA	
SEQ ID NO:22	(251)	TCTACAAACAACTGCGCTTGGAGAGCGCTTGGCGCTGCTCAACAGGAG	
		301	350
SEQ ID NO:16	(301)	TCTATGATTATGAAATGCAATAGCCTCTCTTTCTATCAATTAAGGGGGC	
SEQ ID NO:22	(301)	AGCATGATCATGAACGGATCACTCCCTGAGCTACGAGATCAAGGGGGC	
		351	400
SEQ ID NO:16	(351)	TGGGAACAATAGCGAATGTGGGGCGCTTCTCATGAGCAAGATTATATCG	
SEQ ID NO:22	(351)	CGCGAACAATTCGGGTGCGCGCGCGCGCTGCGACGCGCTTACTACATCG	
		401	450
SEQ ID NO:16	(401)	CGGCAATAGGCAAGAACTCATAGTGAACGACATCAATGATGTCACATCA	
SEQ ID NO:22	(401)	CCGCAATTCGCAAGGAATCATCGTTACGACATCACTGACGTGACGTGG	
		451	500
SEQ ID NO:16	(451)	TTTTATCTTCTGCAATATCAAGAACACTTGAATTTCTTCCCGGGCGCTAC	
SEQ ID NO:22	(451)	TTCTACCGCTTCGCTTACGAGAGCACTCAACTTCATGCGCGCGCGAC	
		501	550
SEQ ID NO:16	(501)	TACAGGATCGGTTGCACTCGGTAACCTCAATTCACATGAGCAACACCC	
SEQ ID NO:22	(501)	CAGGCGGAGCGCTTCACCGCGATCCCGTCTTCACATGTCACCCAGCG	
		551	600
SEQ ID NO:16	(551)	ATTATTCCTTATACTCACAATGTGATACTATCCCTTGGCAAGATCACTCA	
SEQ ID NO:22	(551)	ACTATTCCTACACCCACAACGTGATCCTGTGCGGTGCGCGGACCAAGC	
		601	650
SEQ ID NO:16	(601)	CACTCACATCAATACCTTAGCACTTGGTGTGCTTCGGACATCTGCACAGG	
SEQ ID NO:22	(601)	CACTCGCACTAGTACCTGGCGGTGGCGCTCCCTCAGGACCTCCCGAGCCG	
		651	700
SEQ ID NO:16	(651)	GAGGTAATTCCTTCTACTCTGGCTCCATCAATTTAGATGACACCCAAA	
SEQ ID NO:22	(651)	CCGCTGTCTCTCTCACTCTCCGCTCCATCAACCTGACGATACGCAGA	
		701	750
SEQ ID NO:16	(701)	ATCGGAAGTCTTCACTCTCAGTCCAAACCCCTTFACTTCTGATATGCTG	
SEQ ID NO:22	(701)	ACCGCAAGTCTTCACTCTCAGTCCAAACCCCTTFACTTCTGATATGCTG	
		751	800
SEQ ID NO:16	(751)	TGCTCTAAGGTCACAGGCACTGACAGGAGGATTAAGATCACTTGGCCC	
SEQ ID NO:22	(751)	TGCTCTAAGGTCACAGGCACTGACAGGAGGATTAAGATCACTTGGCCC	
		801	850
SEQ ID NO:16	(801)	CACACCAATGGTGGACGGAAAGGCTAGGGTTTACGGTCAATACCATGAGA	
SEQ ID NO:22	(801)	CACCCCGATGGTGGACGGGCGGCTCGGCTTCGATGCTCAGTACCAAGAGA	
		851	900
SEQ ID NO:16	(851)	AGGACTTACACACCAAGCTCTTATTTAAGGATTTGGTGGCAATTAACCA	
SEQ ID NO:22	(851)	AGGACCTGGACACGACCTGTCTTCAAGGACTGGTGGGGAATTAACCA	

Figure 7b (4/4)

		901		950
SEQ ID NO:16	(901)	GGATTCGGAGAGGTCTTTTATTGACAAACCTTTATGGTTCCCACTTTA		
SEQ ID NO:22	(901)	GGTGTGGGGGGCGGTAGCTTTCATCGACAAACAGATCTGGTTCCCGCTGTA		
		951		1000
SEQ ID NO:16	(951)	CGGAGGGGTCAAACCCCAATTCAACCAAGTGACACTGCAACAAGAGGGAAAT		
SEQ ID NO:22	(951)	CGGGGGCCTGAAGCCCAACTCCCCCTCCGACACGGGCCAGGAGGGGAAGT		
		1001		1050
SEQ ID NO:16	(1001)	ATGTAATATATAAGGGCCATAACACACATGCCCCGATAACAAGATTAC		
SEQ ID NO:22	(1001)	ACGTCATCTACAGGGGCGACACACACCTGCGCGACCAAGCAGGACTAT		
		1051		1100
SEQ ID NO:16	(1051)	CAAAATCGGATGCTAAGTCTTCAATATAACCGGGGGGATTTGGTGGAA		
SEQ ID NO:22	(1051)	CAGATCCGATGGCCAAAGCTCTACAGCCCGCCCTTCGGGGCAA		
		1101		1150
SEQ ID NO:16	(1101)	GCCTTACAGCAAGCACTTATCCATCAAAGTCTCAACATCCTTGGGTA		
SEQ ID NO:22	(1101)	CAAAATCCAGCAGGGGATCTCTCCATCAAAGTGGAGCAAGAGCTCGGCA		
		1151		1200
SEQ ID NO:16	(1151)	AGGACCCCGGTGCTGACTATTCCACCTAATAACAATCAACTTCATGGGAGCC		
SEQ ID NO:22	(1151)	AGGACCCCGGTCTGACCATCCCCCGAACAACATCACTTCATGGGGCGC		
		1201		1250
SEQ ID NO:16	(1201)	GAAGGCAGAAATCCTCACAGTAGGGACATCTCACTTCTTGTACCAACGAGG		
SEQ ID NO:22	(1201)	CAGGGAGAAATCTCACTTCTCGGCACCTCCCACTTCTTGTACAGGGGG		
		1251		1300
SEQ ID NO:16	(1251)	GTCTTCAATATTTCTCCCTGCTTATTATATCCATGACAGTAATAACA		
SEQ ID NO:22	(1251)	CAGCTCGTACTTCAGCCCGGGCGCTCCTGTACCCGATGACCTCAACAACA		
		1301		1350
SEQ ID NO:16	(1301)	AAAGGCTACACTCCATAGTCTTATAAGTTAATGCTTTCACTCGGCGCA		
SEQ ID NO:22	(1301)	AGAACGCCAGGTGCACTCGCCCTACACTTCAACGCCCTTCACCGGCCCC		
		1351		1400
SEQ ID NO:16	(1351)	GGTATGCCCCCTTGGCAGGCATCAAGAAATGCCCCCACTCATGCTCAC		
SEQ ID NO:22	(1351)	GGCAGCGCCCCGTGGCAGGCCTCCGCCCGCTGGCCGAACTCGTGCATCAC		
		1401		1450
SEQ ID NO:16	(1401)	TGGATTCATACTGATCCATATCCCTTAATCTTCCATAAGAAATCATACTC		
SEQ ID NO:22	(1401)	CGGGTCTACACCACCCCTTACCCGCTGATCTTCACCCCAACCACACGC		
		1451		1500
SEQ ID NO:16	(1451)	TACGAGGGGTCTTCCGGACGATGCTTATGATGAACAAGCGAGACTTAAC		
SEQ ID NO:22	(1451)	TCAGGGGGGTGTTCGGGACATGCTCGACGACGAGCAGCTCCCTGAAC		
		1501		1550
SEQ ID NO:16	(1501)	CCCGTATCTGCAATTCGACAACTATCCCGCACTGCTGTCCGCCGGGT		
SEQ ID NO:22	(1501)	CCCGTCAGCGGCCCTCTTCGACAACTATCCCGCACTGCTGTCCGCCGGGT		
		1551		1600
SEQ ID NO:16	(1551)	GAGTCAAGCAGCACCAGGCAGCATAACAACATCGACATGTTTTAAAG		
SEQ ID NO:22	(1551)	CTCCTCGTCTCGACGAGGCCCGGTACACCACGTCACCTGCTTCAAGC		
		1601		1650
SEQ ID NO:16	(1601)	TTGTCAACACCAATAAAGCTTATTGCTTTAGTATTCACAAATATCCAT		
SEQ ID NO:22	(1601)	TGGTTAGAACCAACAAGCCCTACTGCCTCTCCATCCTGAGATCTCCAAC		
		1651		1700
SEQ ID NO:16	(1651)	ACCCATATCGGGGAATTTAGGATCGTTCCCTTATTAATGAGATCTCAN		
SEQ ID NO:22	(1651)	ACCCATCTCGGGGAGTTCCGGATCGTGCCCCCTCTGTTGAGATCTGAA		
		1701		1713
SEQ ID NO:16	(1701)	GGATCATAGATT		
SEQ ID NO:22	(1701)	GGACGACCCCTG		

The identity percentage between SEQ ID NO:16 and SEQ ID NO:22 is 73%.

Figure 7c (1/2)





Figure 7c (2/2)





Figure 8

HN Linear Epitope Region (boxed region)

NDV HN - TX/GB (P12553)	(330)	QSENYVIYER	YNDTCDEQD	YQIRMAKSSY	KPGRFGGKRY	QQAILSIKVS
NDV HN LaSota (AAA46659)	(330)	QEGFYVIYKR	YNDTCDEQD	YQIRMAKSSY	KPGRFGGKRY	QQAILSIKVS
NDV HN CA/02 (ABS84265)	(330)	QEGFYVIYKR	YNDTCDEQD	YQIRMAKSSY	KPGRFGGKRY	QQAILSIKVS
NDV HN MEX/96 (AAQ54638)	(330)	QEGKYVIYNR	YNDTCDEQD	YQIRMAKSSY	KPGRFGGKRY	QQAILSIKVS
NDV HN Liaoning/08 (ACM67348)	(330)	QEGKYVIYFR	YNDTCDEQD	YQIRMAKSSY	KPGRFGGKRY	QQAILSIKVS
NDV HN ZJ1 (AAL18936)	(330)	QEGKYVIYER	YNDTCDEQD	YQIRMAKSSY	KPGRFGGKRY	QQAILSIKVS

The alignment shows the amino acids between position 330 and position 379 of below protein sequences:

- NDV HN - TX/GB (P12553): SEQ ID NO:5
- NDV HN LaSota (AAA46659): SEQ ID NO:7
- NDV HN CA/02(ABS84265): SEQ ID NO:3
- NDV HN MEX/96 (AAQ54638): SEQ ID NO:9
- NDV HN Liaoning/08(ACM67348): SEQ ID NO:17
- NDV HN ZJ1 (AAL18936) SEQ ID NO:19

NDV HN Linear Epitope Region 1 (SEQ ID NO:10): PDEQDYQIRMAKSS

NDV HN Linear Epitope Region 2 (SEQ ID NO:11): PDEQDYQVRMAKSS

NDV HN Linear Epitope Region 3 (SEQ ID NO: 28): PDKQDYQIRMAKSS

Figure 9

Location and Presence of Glycosylation Sites in NDV Strains

Glycosylation Site*	Sequence	Glycosylation Site Presence by Strain		
		LaSota (SEQ ID NO:7)	CA/02 (SEQ ID NO:3)	TX/GB (SEQ ID NO:5)
119	NSS/NNS	X**	X	X
341	NNT/NDT	X	X	X
433	NKT	X	X	X
481	NHT	X	X	X
508				
538	NKT	X	_***	X

*There are six potential sites for glycosylation. The glycosylation site is indicated at the amino acid position of the protein sequence.

** : presence of the glycosylation site

*** : absence of the glycosylation site.

Figure 10

Graphical Feature Map of the NDV HN Protein (SEQ ID NO:3)




Figure 11

Peptide sequence analysis of expressed NDV HN (SEQ ID NO:3) in algae

Species: Newcastle disease virus

Name: Hemagglutinin-neuraminidase


Identified by 32 peptides covering 68% of the protein sequence.

```

1  MDRVVSRVVL ENEEEEAKNT WRLVFRVAVL SLIVMTLAIS VAALVYSMEA STPNDLAGIS TVISRAEDRY TSLINSNQDV
81  VORVYKQVAL ESPLALLNTE SIIMNAITSL SYQINGAANS SGCGAPVHDP DYIGGVGKEL IVDDTSDATS FYPSAYQEHL
161 NFIPAPTTGS GCTRIPSFDM SATHYCYTHN VILSGCRDES HSHQYLALGV LRTSATGRVF FSTLRSINLD DTQNRESCSV
241 SATPLGCDML CSKVTETEE DYKSVTFESM VHGRLGFDGQ YHEKDLDVTV LFKDWVANYP GVGGSLIDD KVWFPVYGGL
321 KPNSPSDTAQ EGKYVIYKRY NNTCPDEQDY QVRMAKSSYK PGRFGGKRVQ QAILSIKVST SLGEDPVLTV PPNTVTLMGA
401 EGRILTVGTS EFLYQRGSSY FSPALLYPMT VRNKTATLES PYTFNATRP GSVPCQASAR CPNSCITGVY TDPYPVVFER
481 NHTLRGVFGT MLDNEQARLN PVSALFDYTS RSRITRVSST STKAAYTST CPKVVKTNKV YCLSIAEISN TLGGEFRIVP
561 LLVEILKDDR V


```


Figure 12



Group	Mortality	Protection (%)
Algae WT	12/12	0
Algae NDV HN 100 HAU	8/12	33
Algae NDV HN 1000 HAU	0/12	100
Algae NDV HN 9333HAU	0/12	100

A



B

Hemagglutination activity:

